🏷

Classifications

Harrison's Part

🔗

Mappings

MONDO

MONDO:0008758 mitochondrial DNA depletion syndrome 4a

MONDO:0008758 is the entity for Alpers-Huttenlocher syndrome, carried under the molecular label mitochondrial DNA depletion syndrome 4a and defined as the cerebrohepatopathy characterized by the triad of progressive developmental regression, intractable seizures, and hepatic failure. The clinical eponym is used as the entry name and preferred_term because that is what the literature and the clinic use.

👪

Inheritance

1

Autosomal recessive HP:0000007

Alpers-Huttenlocher syndrome due to POLG is associated with biallelic pathogenic or likely pathogenic variants, usually inherited from asymptomatic heterozygous parents. Parental testing establishes phase and recurrence risk. If both parents carry one familial pathogenic variant, each pregnancy has a 25% chance of an affected child; severity can differ between siblings. Common POLG polymorphisms and dominant POLG-associated ophthalmoplegia require separate interpretation.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:20138553 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Molecular studies revealed homozygous p.R597W or p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S."

Biallelic genotypes in four selected patients with subsequent valproate-associated liver failure.

PMID:20301791 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"If both parents are known to be heterozygous for a POLG pathogenic variant, each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants and being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial..."

GeneReviews recurrence-risk counseling.

?

Discussions and Knowledge Gaps

4

Which liver-specific mechanisms explain the severe valproate vulnerability of recessive POLG disease?

KNOWLEDGE GAP OPEN alpers-valproate-mediator

Attached to

pathophysiology#Valproate-Associated Hepatocellular Injury

Clinical risk is well established, but the 2010 assays used yeast chimeras and primary muscle cells. Failure to observe extra mtDNA depletion there does not exclude mitochondrial-genome or fatty-acid pathways in liver. Impaired regeneration and an HDAC-mediated explanation were proposed, not directly demonstrated in human hepatocytes. Mechanistic research should use appropriate models without exposing affected children to a contraindicated drug.

Show evidence (2 references)

PMID:21038416 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Human hepatocyte cell lines from patients with POLG variants are not available."

Explicit lineage limitation.

PMID:21038416 SUPPORT DIRECT PRIMARY RESULT In Vitro

"but there was no further decrease in mtDNA content with the addition of 10mM VPA"

Negative result in the tested muscle-cell context.

How should common POLG polymorphisms be interpreted separately from biallelic Alpers-causing variants?

INTERPRETATION OPEN alpers-common-polymorphism-risk

Attached to

genetic#POLG

The 2010 association in selected suspected valproate liver-injury cases used population controls and differs from a recessive molecular diagnosis. A later small monotherapy comparison did not reproduce increased toxicity for Q1236H/E1143G in the absence of other pathogenic variants. Neither study establishes universal heterozygote risk or relaxes the contraindication for established Alpers.

Show evidence (2 references)

PMID:21038416 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Heterozygous genetic variation in POLG was strongly associated with VPA-induced liver toxicity"

Selected association-study conclusion; variant classes and comparator population require separate interpretation.

PMID:30255931 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Transient liver dysfunction was identified in three (n = 33, 9.1%) variant group patients and in one (n = 28, 3.6%) nonvariant group patient (P = 0.62)."

Small available-abstract null comparison, not proof of zero risk.

Does early inhibitory-network dysfunction drive seizures, or does prolonged epilepsy amplify the observed neuronal injury?

KNOWLEDGE GAP OPEN alpers-neural-selectivity

Attached to

pathophysiology#Reduced Cortical Inhibition pathophysiology#Cortical Neuronal Loss

End-stage human tissue shows respiratory-chain protein deficiency and cell loss, but cannot order these events. Both interneuron and pyramidal-cell densities were reduced; respiratory-chain abnormalities were more pronounced in interneurons. Limited sampled regions do not establish occipital exclusivity. Longitudinal, appropriately controlled neural models are needed to separate intrinsic dysfunction from seizure-related injury.

Show evidence (1 reference)

PMID:30021052 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"Although loss of interneurons and pyramidal cells was similar, the magnitude of respiratory chain deficiency was more pronounced in interneurons raising the possibility that the loss of inhibitory neural networks plays a role in the seizure development in these patients."

Authors explicitly frame the causal network mechanism as a possibility.

Why does the A449T knock-in mouse remain much milder than human Alpers and resist the tested valproate challenges?

HUMAN MODEL MISMATCH OPEN alpers-a449t-model-mismatch

Attached to

animal_models#Homozygous Polg A449T knock-in mouse pathophysiology#Valproate-Associated Hepatocellular Injury

The model recapitulates proximal biochemical defects and stress-dependent mtDNA recovery but not the severe human triad, shortened lifespan or tested valproate-associated hepatic damage. Compensatory processes, species biology and allele combinations remain unresolved. The negative mouse drug phenotype cannot establish safety in affected people.

Show evidence (2 references)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"We monitored the PolgA449T/A449T and WT littermates up to 2 years of age, but neither reduction of the lifespan nor the presence of obvious age-related phenotypes was observed."

Explicit long-term mild phenotype.

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Both WT and PolgA449T/A449T did not show any sign of hepatic failure or histological damage."

Explicit negative result after the tested valproate protocols.

⚙

Pathophysiology

16

Biallelic Pathogenic POLG Variation

Biallelic pathogenic POLG variants cause the molecularly defined Alpers phenotype. The combination of alleles and other modifiers influences presentation; a common polymorphism alone is not the initiating lesion modeled here.

POLG hgnc:9179

Downstream

Reduced DNA Polymerase Gamma Function Pathogenic alleles can compromise catalytic performance or protein abundance through allele-specific defects.

Impaired Polymerase Gamma Holoenzyme Assembly A subset of interface variants impairs association with the accessory subunit.

Neurodevelopmental Delay A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Hypotonia A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Failure to Thrive A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Peripheral Neuropathy A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Nystagmus A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Feeding Difficulties A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Dysphagia A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Vomiting A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Headache A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.

Show evidence (1 reference)

PMID:20138553 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Molecular studies revealed homozygous p.R597W or p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S."

Biallelic genotypes in four selected patients with subsequent valproate-associated liver failure.

Reduced DNA Polymerase Gamma Function

Reduced catalytic activity and/or processivity impairs mitochondrial genome maintenance. Recombinant A467T retains residual polymerase activity and relatively preserved exonuclease function; other alleles need not have the same biochemical profile.

DNA-directed DNA polymerase activity GO:0003887 ↓ DECREASED

mitochondrion GO:0005739

Experimental models

Reconstituted human and mouse polymerase gamma assays OTHER Mutant long-template DNA synthesis remained slower despite accessory subunit.

Downstream

Impaired Mitochondrial DNA Replication Reduced polymerase performance compromises synthesis of mitochondrial DNA.

Show evidence (1 reference)

PMID:16024923 SUPPORT DIRECT PRIMARY RESULT In Vitro

"The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in kcat with minimal effect on exonuclease function."

Allele-specific biochemical result.

Impaired Mitochondrial DNA Replication

Impaired synthesis and maintenance of mitochondrial genomes can reduce copy number as tissues develop and genomes turn over. Depletion is tissue- and stage-dependent, so an initially normal muscle assay does not exclude the disorder.

mitochondrial DNA replication GO:0006264

mitochondrion GO:0005739

Experimental models

A449T mouse embryonic fibroblast mtDNA recovery CELL LINE Recovery after experimentally induced mtDNA depletion was impaired.

Downstream

Mitochondrial DNA Depletion Impaired genome maintenance can lead to net loss of mitochondrial DNA copies.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Polymerase (pol) gamma is the major DNA polymerase in humans required for replication and repair of mtDNA."

Established mitochondrial polymerase function.

Mitochondrial DNA Depletion

Reduced mitochondrial genome copy number occurs in affected tissues and in Alpers patient-derived neural stem cells. It is not uniformly detectable in all tissues or at every disease stage. TFAM staining in organoids is a proxy; the neural-stem-cell experiment also used mtDNA/nuclear-DNA qPCR.

mitochondrion GO:0005739

Experimental models

Alpers iPSC-derived neural stem cells IPSC DERIVED MODEL ND1/APP qPCR was reduced in Alpers neural stem cells.

Valproate exposure in primary muscle-cell cultures PRIMARY CELL CULTURE Valproate did not further reduce mtDNA in the tested muscle-cell conditions.

Downstream

Respiratory Chain Deficiency Loss of mitochondrial genomes reduces production of mtDNA-encoded respiratory-chain components through transcription, translation and complex assembly.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"To corroborate the reduction in the mtDNA levels as observed through the ND1/APP measurements in Alpers' NSCs, we performed qPCR (Figure 2P), which confirmed the same."

Primary qPCR in neural stem cells from one A467T/P589L donor; no isogenic control.

Respiratory Chain Deficiency

Respiratory-chain impairment is prominent in vulnerable neurons. Postmortem Alpers tissue showed reduced complex I and, more variably, complex IV subunit immunoreactivity; those assays estimate dysfunction from protein abundance rather than directly measuring electron flux. Neural stem-cell experiments also showed complex I/IV protein loss.

mitochondrion GO:0005739

Downstream

Reduced Cellular ATP Availability Impaired oxidative phosphorylation contributes to reduced cellular energy availability.

Increased Mitochondrial Oxidative Stress Respiratory dysfunction can contribute to ROS imbalance; increased probe signals were observed in Alpers neural stem cells.

Show evidence (1 reference)

PMID:30021052 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We showed that occipital cortex GABAergic interneurons and pyramidal neurons, as well as Purkinje cells in the cerebellum, exhibited extensive respiratory chain defects as evidenced by significant downregulation of complex I subunit proteins and milder downregulation of complex IV subunit proteins."

Postmortem study of 13 clinically defined cases, only five with confirmed POLG genotypes; examined regions were limited.

Reduced Cellular ATP Availability

Cellular ATP availability is reduced in differentiated Alpers neural stem cells, whereas the corresponding pluripotent cells did not show a significant ATP deficit. Energy failure is a proposed contributor to neural and hepatic injury rather than a universal measured state in every cell.

Experimental models

Alpers iPSC-derived neural stem cells IPSC DERIVED MODEL ATP content per cell was reduced after neural differentiation.

Downstream

Cortical Neuronal Loss Bioenergetic dysfunction may contribute to cortical neurodegeneration; postmortem observations cannot establish temporal sequence.

Purkinje Cell Loss Bioenergetic dysfunction may contribute to cerebellar degeneration.

Hepatocellular Injury Mitochondrial dysfunction can impair hepatocyte function and survival through incompletely resolved tissue-specific mechanisms.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"A direct measurement of intracellular ATP production revealed a marked decrease in ATP production in Alpers' NSCs compared to the control NSCs"

Cell-normalized luminescent assay measured ATP abundance, not an isolated oxidative-phosphorylation production rate.

Increased Mitochondrial Oxidative Stress

Increased mitochondrial ROS probe signals and altered antioxidant transcription were observed in Alpers-derived neural stem cells. This is experimental evidence from one donor, not proof that oxidative stress is the initiating event in patient brains.

response to oxidative stress GO:0006979

Downstream

Cortical Neuronal Loss Oxidative stress may contribute to neuronal injury; necessity or sufficiency was not established.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"For Alpers' NSCs, a significant increase was observed in specific intracellular ROS (DCFDA/MTDR) and mitochondrial ROS at both total (MitoSOX Red) and specific level (MitoSOX Red/MTG) when compared to control NSCs"

Differentiated-cell result; pluripotent cells did not show the same ROS pattern.

Cortical Neuronal Loss

Reduced densities of inhibitory interneurons and pyramidal neurons were observed in occipital cortex at autopsy, with gliosis and areas of laminar necrosis. Loss was similar between these two populations; respiratory-chain deficiency was more pronounced in interneurons. Regional specificity and a within-patient sequence from deficiency to cell loss were not demonstrated.

cerebral cortex UBERON:0000956

Experimental models

Alpers cortical organoids with nicotinamide riboside ORGANOID Patient organoids had lower neuronal marker expression.

Alpers cortical organoids with nicotinamide riboside ORGANOID Nicotinamide riboside increased neuronal marker expression relative to untreated patient organoids.

Downstream

Reduced Cortical Inhibition Dysfunction and loss of inhibitory interneurons may reduce inhibitory network control.

Developmental Regression Progressive cortical dysfunction contributes to loss of acquired abilities.

Cortical visual impairment Occipital cortical injury can compromise vision.

Spasticity Progressive cortical/corticospinal dysfunction contributes to spasticity.

Show evidence (1 reference)

PMID:30021052 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Quantification revealed reduced densities of both interneurons (Figure 5A) and pyramidal neurons (Figure 5B) throughout patient cortical layers relative to controls suggestive of interneuron and pyramidal neuron loss."

End-stage histology; cell-density measurements were descriptive because of small sample size.

Reduced Cortical Inhibition

Reduced inhibitory interneuron function is a proposed contributor to cortical hyperexcitability. The human evidence is postmortem and the Alpers organoid evidence includes lower GAD65 staining and synaptic gene-set changes; neither directly measures the excitation-inhibition ratio in living patients.

Downstream

Recurrent Seizure Activity Reduced inhibitory control may lower seizure threshold.

Show evidence (1 reference)

PMID:30021052 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"Although loss of interneurons and pyramidal cells was similar, the magnitude of respiratory chain deficiency was more pronounced in interneurons raising the possibility that the loss of inhibitory neural networks plays a role in the seizure development in these patients."

Explicit hypothesis based on the neuropathological association.

Recurrent Seizure Activity

Epilepsy often begins focally and may progress to drug-resistant seizures, status epilepticus or epilepsia partialis continua. Initial control is possible in some children; refractory disease is not necessarily present from the first seizure.

Downstream

Focal Seizures Recurrent focal seizures may become medication resistant.

Status Epilepticus Seizure activity can become sustained.

Epilepsia Partialis Continua Continuous focal motor seizure activity is a characteristic possible manifestation.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"In some children, seizures are initially controllable with standard dosages of anti-seizure medications (ASM); in others, seizures, such as EPC, are refractory from the onset. Over time, seizures become increasingly resistant to ASMs."

GeneReviews clinical synthesis.

Purkinje Cell Loss

Reduced cerebellar Purkinje-cell density accompanies respiratory-chain protein deficiency in surviving cells. The study could not separate intrinsic mitochondrial injury from effects of seizures or treatment; loss did not correlate with residual-cell complex I/IV deficiency.

Purkinje cell CL:0000121

cerebellum UBERON:0002037

Downstream

Ataxia Cerebellar degeneration is a plausible contributor to ataxia; peripheral neuropathy can also impair coordination.

Show evidence (1 reference)

PMID:30021052 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Quantification of Purkinje cell density revealed lower densities in patient cerebellum (Figure 6B) relative to controls."

Descriptive postmortem cell counts.

Hepatocellular Injury

Intrinsic hepatic disease can develop independently of valproate exposure. Hepatocyte loss, steatosis and architectural disruption can lead to impaired metabolic and synthetic function. The specific sequence connecting POLG dysfunction to hepatic injury remains incompletely resolved.

hepatocyte CL:0000182

liver UBERON:0002107

Animal models

Homozygous Polg A449T knock-in mouse Mus musculus partially recapitulates Recovery from carbon-tetrachloride injury was delayed, with greater residual necrosis at day four.

Downstream

Hepatic Failure Loss of viable hepatic tissue and function may progress to liver failure.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Liver histology may demonstrate macro- and microvesicular steatosis, centrilobular necrosis, disorganization of the normal lobular architecture, hepatocyte loss with or without bridging fibrosis or cirrhosis, regenerative nodules, bile duct proliferation, or mitochondrial proliferation with a..."

Review of hepatic pathology.

Valproate-Associated Hepatocellular Injury

Valproate can precipitate or accelerate severe liver injury in POLG-related disease, including without pre-existing biochemical liver disease. The molecular mediator is unresolved. The 2010 muscle-cell and yeast experiments neither established hepatocyte regeneration failure nor excluded liver-specific mtDNA or fatty-acid mechanisms.

hepatocyte CL:0000182

liver UBERON:0002107

Animal models

Homozygous Polg A449T knock-in mouse Mus musculus fails to recapitulate The tested valproate protocols did not induce hepatic failure or histological injury.

Downstream

Hepatocellular Injury Valproate exposure can add a drug-associated injury pathway to the intrinsic hepatic vulnerability.

Show evidence (2 references)

PMID:20138553 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure"

Clinical drug-associated risk.

PMID:21038416 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Human hepatocyte cell lines from patients with POLG variants are not available."

The mechanistic cell experiments used muscle cells, so their negative results cannot exclude liver-specific mechanisms.

Impaired Polymerase Gamma Holoenzyme Assembly

Mouse A449T and corresponding human A467T impair productive interaction between catalytic POLG and accessory POLG2 subunits. Assembly is reduced, not absent. This allele-specific route is separate from the measured DNA-binding and long-template synthesis defects.

mitochondrion GO:0005739

Downstream

Increased Degradation of Unprotected POLG Reduced accessory-subunit protection permits LONP1-dependent degradation of the catalytic subunit.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Thus, the A449T mutation significantly reduces the interaction between POLγA and POLγB subunits."

Reconstituted-protein assembly assay.

Increased Degradation of Unprotected POLG

LONP1 degrades unprotected catalytic polymerase gamma in an ATP-dependent assay. The mutant difference is incomplete protection by POLG2 in the assembled mixture, not intrinsically faster degradation of free mutant protein. Additional proteases may contribute in vivo.

mitochondrion GO:0005739

Experimental models

Reconstituted human and mouse polymerase gamma assays OTHER POLG2 protected wild-type catalytic subunit more effectively than mutant.

Downstream

Reduced POLG Protein Abundance Enhanced susceptibility to proteolysis provides an experimentally supported explanation for lower catalytic-subunit abundance.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"In contrast, mPOLγB was unable to efficiently block degradation of mPOLγAA449T and the levels of the mutant protein decreased significantly over the time of the experiment"

Purified mouse-protein result, reproduced with human A467T.

Reduced POLG Protein Abundance

Lower catalytic-subunit abundance was observed in the A449T mouse model. HeLa LONP1 knockdown increased endogenous wild-type POLG protein, but no mutant-patient or clinical rescue was demonstrated.

mitochondrion GO:0005739

Experimental models

HeLa LONP1 and POLG2 knockdown CELL LINE Reducing LONP1 increased endogenous catalytic-subunit abundance.

Animal models

Homozygous Polg A449T knock-in mouse Mus musculus partially recapitulates Catalytic-subunit abundance was reduced in knock-in tissues.

Downstream

Reduced DNA Polymerase Gamma Function A reduced available catalytic-subunit pool can compound the intrinsic activity defect.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"The amount of mPOLγAA449T was reduced in the PolgA449T/A449T mice, which could also contribute to impaired mtDNA replication."

Knock-in mouse tissue abundance result.

✶

Histopathology

2

Alpers liver injury pattern

Steatosis, centrilobular necrosis, hepatocyte loss, architectural disorganization, fibrosis/cirrhosis, regenerative nodules and bile-duct proliferation form a variable constellation. Historical criteria used at least two characteristic features, but biopsy is not required when molecular and clinical findings establish the diagnosis; it may be unsafe in severe coagulopathy.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Liver histology may demonstrate macro- and microvesicular steatosis, centrilobular necrosis, disorganization of the normal lobular architecture, hepatocyte loss with or without bridging fibrosis or cirrhosis, regenerative nodules, bile duct proliferation, or mitochondrial proliferation with a..."

Review synthesis of the characteristic but variable pattern.

PMID:28471437 SUPPORT DIRECT BACKGROUND Human Clinical

"liver biopsy is rarely performed in the neonatal and pediatric setting, because of the attendant risks of morbidity and mortality."

Clinical discussion explains limited use of biopsy.

Cortical neuronal loss and gliosis

Laminar neuronal loss, spongiform change, astrocytosis and focal necrosis affect cortex, often with prominent occipital injury. Purkinje-cell loss can accompany cerebellar involvement. These are pathological observations rather than proof of a uniquely occipital initiating defect.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Early in the course of the disease, spongiosis, astrocytosis, and neuronal loss are prevalent in the superficial cortex. Later, the deeper laminae are affected."

Review synthesis.

PMID:30021052 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Quantification revealed reduced densities of both interneurons (Figure 5A) and pyramidal neurons (Figure 5B) throughout patient cortical layers relative to controls suggestive of interneuron and pyramidal neuron loss."

Descriptive postmortem neuronal-density findings.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

17

Digestive 4

Hepatic Failure HP:0001399

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"End-stage liver disease is often heralded by hypoalbuminemia and prolonged coagulation time, followed shortly thereafter by fasting hypoglycemia and hyperammonemia."

Alpers-specific description of hepatic decompensation.

Feeding Difficulties HP:0011968

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis."

Broader early-onset POLG summary supports relevance without an Alpers-specific frequency.

Dysphagia HP:0002015

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"A feeding eval &/or radiographic swallowing study should be considered when showing clinical signs or symptoms of dysphagia."

Management chapter recognizes dysphagia; no frequency is inferred.

Vomiting HP:0002013

Show evidence (1 reference)

PMID:30021052 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Symptoms preceding seizure onset often included headaches, vomiting and visual abnormalities (including visual hallucinations and visual blindness)."

Historical clinical cohort with only five confirmed POLG genotypes.

Eye 2

Cortical visual impairment Cerebral visual impairment HP:0100704

Show evidence (1 reference)

PMID:30021052 SUPPORT DIRECT BACKGROUND Human Clinical

"Concomitant symptoms may also include cortical blindness, vomiting, headaches, and hemianopia."

Background clinical description identifies cortical visual involvement.

Nystagmus HP:0000639

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"All neurologic signs and symptoms, including ataxia and nystagmus, may worsen during infections or with other physiologic stressors."

Alpers-specific symptom description.

Musculoskeletal 2

Hypotonia VERY_FREQUENT HP:0001252

Show evidence (1 reference)

PMID:28471437 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Hypotonia 6/6 (100%) 15/17 (88%) Developmental delay 6/6 (100%) 16/19 (84%)"

Alpers-specific table column; not the pooled early-onset estimate.

Spasticity HP:0001257

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The major motor manifestation is a progressive spastic paraparesis resulting from progressive loss of cortical neuronal function."

Alpers-specific motor progression.

Nervous System 8

Focal Seizures FREQUENT Focal-onset seizure HP:0007359

Show evidence (1 reference)

PMID:28471437 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Focal 14/19 (74%) Infantile spasm 1/19 (5%) Therapy-resistant epilepsy 17/19 (89%)"

Seizure-type denominator corresponds to the Alpers subgroup; phenotype binding describes focal onset, not medication resistance.

Status Epilepticus FREQUENT HP:0002133

Show evidence (1 reference)

PMID:28471437 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Myoclonic 13/19 (68%) Status epilepticus 13/19 (68%) Epilepsia partialis continua 11/19 (58%)"

Alpers seizure subgroup; retrospective ascertainment.

Epilepsia Partialis Continua FREQUENT HP:0012847

Show evidence (2 references)

PMID:28471437 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Myoclonic 13/19 (68%) Status epilepticus 13/19 (68%) Epilepsia partialis continua 11/19 (58%)"

EPC in 11/19 of the Alpers subgroup.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"EPC is not always apparent as an abnormality on EEG and can be mistaken for a conversion reaction. EEG may be normal or show only focal slowing of the background rhythm."

Review warns against excluding EPC on EEG alone.

Developmental Regression HP:0002376

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Significant sudden or rapid regression is often seen during infectious illnesses. The clinical manifestations may include somnolence, loss of concentration, loss of language skills (both receptive and expressive), irritability with loss of normal emotional responses, and memory deficits."

Alpers-specific natural-history synthesis.

Neurodevelopmental Delay VERY_FREQUENT HP:0012758

Show evidence (1 reference)

PMID:28471437 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Hypotonia 6/6 (100%) 15/17 (88%) Developmental delay 6/6 (100%) 16/19 (84%) Seizures 0/6 (0%) 19/19 (100%)"

Table 3 columns are MCHS then Alpers; use the Alpers-specific denominator rather than pooled 24/24.

Ataxia HP:0001251

Show evidence (2 references)

PMID:30021052 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We believe interneuron and Purkinje cell pathology underpins the clinical development of seizures and ataxia seen in Alpers' syndrome."

Clinical feature and proposed pathological correlate; causal direction remains inferential.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"develop in all persons with AHS unless the disease process is so rapid that it results in early death. All neurologic signs and symptoms, including ataxia and nystagmus, may worsen during infections or with other physiologic stressors."

Chapter discusses neuropathy and ataxia with a survival-dependent qualification.

Peripheral Neuropathy HP:0009830

Show evidence (1 reference)

PMID:20138553 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"EMG examination demonstrated a moderate to severe symmetric sensory and motor axonal peripheral neuropathy of lower extremities."

Documented peripheral neuropathy in a later-presenting biallelic POLG case; no childhood frequency is inferred.

Headache HP:0002315

Show evidence (1 reference)

PMID:30021052 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Symptoms preceding seizure onset often included headaches, vomiting and visual abnormalities (including visual hallucinations and visual blindness)."

Observed clinical feature in the neuropathology cohort; no population frequency.

Growth 1

Failure to Thrive HP:0001508

Show evidence (1 reference)

PMID:30021052 SUPPORT DIRECT BACKGROUND Human Clinical

"Other symptoms include developmental delay, failure to thrive, hypotonia, spasticity and ataxia."

Background description of Alpers clinical features.

🧬

Genetic Associations

1

POLG

Gene: POLG hgnc:9179 gene page relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:20138553 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Molecular studies revealed homozygous p.R597W or p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S."

Primary molecular diagnoses in the selected case series.

PMID:16024923 SUPPORT DIRECT PRIMARY RESULT In Vitro

"The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in kcat with minimal effect on exonuclease function."

Allele-specific recombinant-enzyme result; the available abstract does not provide complete assay methods.

💊

Medical Actions

21

Avoidance of Valproate and Divalproex

Category: Therapeutic Action: Avoidance of Valproate and Divalproex Ontology label: Supportive Care NCIT:C15747

Platform: Other

Avoid valproate and divalproex in established POLG-related Alpers, including before hepatic dysfunction is apparent. This precaution is supported by clinical reports, GeneReviews and the 2024 mitochondrial-epilepsy consensus. The 2024 published-case review confirms severe outcomes but cannot estimate an unbiased individual risk.

Mechanism Target:

INHIBITS Valproate-Associated Hepatocellular Injury — Avoidance removes the drug exposure that can trigger hepatic injury.

Show evidence (1 reference)

PMID:38576261 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Valproic acid is contraindicated in patients with pathogenic variants in POLG"

Consensus contraindication for POLG disease, not a claim about all common polymorphisms.

Show evidence (2 references)

PMID:38576261 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Valproic acid is contraindicated in patients with pathogenic variants in POLG"

Consensus contraindication for POLG disease, not a claim about all common polymorphisms.

PMID:38860231 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"There was no pre-existing liver disease in 92/102 patients (90%)."

Selected published POLG cases exposed to valproate; absence of baseline liver disease does not eliminate risk.

Rapid Molecular Evaluation When POLG Disease Is Suspected

Category: Diagnostic Action: Rapid Molecular Evaluation When POLG Disease Is Suspected Ontology label: Genetic Testing NCIT:C15709

Platform: Other

In a child with early-onset epilepsy and features suggesting POLG disease, arrange prompt comprehensive genetic evaluation before considering valproate. Testing strategy and seizure treatment proceed with specialist input; a negative small founder panel or common-variant result does not safely exclude Alpers.

Show evidence (1 reference)

PMID:38860231 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"clinicians should consider requesting rapid genomic testing in children with early-onset epilepsies where POLG-mitochondrial disease is a differential diagnosis, prior to commencing VPA."

Systematic-review recommendation focused on suspected POLG disease.

Individualized Non-Valproate Antiseizure Therapy

Category: Therapeutic Action: Individualized Non-Valproate Antiseizure Therapy Ontology label: Pharmacotherapy NCIT:C15986

Platform: Small molecule

Use specialist-led treatment matched to seizure type and clinical condition. The 2024 consensus generally follows standard epilepsy guidance for children older than 28 days and adults, with the POLG valproate contraindication and other patient-specific restrictions. Levetiracetam and several other ASMs are not generally contraindicated by mitochondrial disease alone, but this does not establish comparative Alpers efficacy. Lamotrigine may worsen myoclonus; topiramate warrants caution with renal tubular acidosis.

Mechanism Target:

MODULATES Recurrent Seizure Activity — Antiseizure treatment aims to reduce seizure activity without repairing the POLG defect.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Many ASMs may be effective; none has been demonstrated effective specifically for this disorder."

GeneReviews distinguishes individualized treatment from proven Alpers-specific efficacy.

Show evidence (4 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Many ASMs may be effective; none has been demonstrated effective specifically for this disorder."

GeneReviews distinguishes individualized treatment from proven Alpers-specific efficacy.

PMID:38576261 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"It is not contraindicated to use levetiracetam in adults and children with PMDs"

Safety consensus is not a disease-specific efficacy trial.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Treatment of epilepsy is similar to non-mitochondrial disease w/seizures. Lamotrigine may worsen myoclonic seizures."

Seizure-type precaution.

+ 1 more reference

Emergency Status Epilepticus Management

Category: Therapeutic Action: Emergency Status Epilepticus Management Ontology label: Supportive Care NCIT:C15747

Platform: Other

Treat convulsive status urgently using local specialist protocols, including benzodiazepines, subsequent non-valproate ASMs and intensive-care escalation when necessary. Anesthetic selection, respiratory support and metabolic monitoring are individualized. Prolonged propofol requires close monitoring for infusion syndrome. Retrospective multidrug use does not establish the efficacy of any one agent.

Mechanism Target:

MODULATES Status Epilepticus — Acute treatment aims to terminate sustained seizures.

Show evidence (1 reference)

PMID:38576261 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"If the patient develops generalized, convulsive status epilepticus, management and when needed escalation to intensive care setting should follow the local status epilepticus guidelines (e.g., NICE Clinical Guidelines, SIGN guidelines, EFNS guidelines), except sodium valproate which is..."

Expert consensus supports prompt standard escalation with the genotype-specific exception.

Show evidence (2 references)

PMID:38576261 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"If the patient develops generalized, convulsive status epilepticus, management and when needed escalation to intensive care setting should follow the local status epilepticus guidelines (e.g., NICE Clinical Guidelines, SIGN guidelines, EFNS guidelines), except sodium valproate which is..."

Expert consensus supports prompt standard escalation with the genotype-specific exception.

PMID:38576261 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Propofol should be closely monitored for prolonged use in the context of refractory status epilepticus due to the risk of propofol infusion syndrome"

Precaution applies to prolonged use, not a blanket prohibition.

Careful Management of Refractory EPC

Category: Therapeutic Action: Careful Management of Refractory EPC Ontology label: Supportive Care NCIT:C15747

Platform: Other

Balance seizure reduction against sedation, aspiration and ventilatory failure. Persistent EPC can be impossible to abolish, so escalating medication indefinitely may impose greater burden than benefit.

Mechanism Target:

MODULATES Epilepsia Partialis Continua — Individualized symptomatic management accounts for both seizure burden and treatment toxicity.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Many ASMs may be effective; none has been demonstrated effective specifically for this disorder."

GeneReviews distinguishes individualized treatment from proven Alpers-specific efficacy.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Refractory epilepsy, esp EPC, may be impossible to control w/any treatment. In persons w/EPC, use of high-dose ASM may control the clinical seizures, but assoc obtundation & subsequent risk of aspiration & ventilatory failure may outweigh the benefit."

Alpers-specific risk-benefit guidance.

Selected Adjuncts for Refractory Epilepsy

Category: Therapeutic Action: Selected Adjuncts for Refractory Epilepsy Ontology label: Supportive Care NCIT:C15747

Platform: Other

Ketogenic diet or neuromodulation may be considered by specialist teams where appropriate, but Alpers-specific efficacy is unproven. In the 2024 mixed POLG status cohort, only 2/13 diet-treated patients reported benefit and both had juvenile/adult-onset disease; VNS was not used. Late rescue use and confounding prevent a definitive negative efficacy conclusion. Immunomodulatory therapies likewise lack demonstrated benefit for Alpers status.

Mechanism Target:

MODULATES Recurrent Seizure Activity — Selected adjuncts aim to improve seizure control, with uncertain Alpers-specific benefit.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The use of other treatments for refractory epilepsy, such as corticotropin or prednisone, ketogenic diet, and intravenous immunoglobulin G, are unproven in the treatment of AHS."

Link denotes the intended clinical target and explicitly uncertain benefit.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The use of other treatments for refractory epilepsy, such as corticotropin or prednisone, ketogenic diet, and intravenous immunoglobulin G, are unproven in the treatment of AHS."

Review clearly separates investigational adjuncts from proven therapy.

PMID:38822839 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"KD was administered during an SE episode in 13 patients, with only two with juvenile to adult-onset disease reporting some effect on seizure control."

Retrospective mixed-POLG observation, not an Alpers controlled trial.

Hepatic and Metabolic Monitoring

Category: Monitoring Action: Hepatic and Metabolic Monitoring Ontology label: Supportive Care NCIT:C15747

Platform: Other

Assess liver enzymes and synthetic/metabolic function approximately every three months or as clinical circumstances require, with more frequent assessment during deterioration or after medication changes. GeneReviews suggests liver enzymes every 2–4 weeks after introducing a new ASM. Monitoring detects complications; it does not itself reverse hepatocyte injury.

Show evidence (2 references)

PMID:20301791 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"monitoring of liver enzymes every three months or as clinically indicated; monitoring of epilepsy with repeat liver function tests after introduction of any new anti-seizure medication."

Review surveillance recommendation.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Because other ASMs may also accelerate liver deterioration, it is reasonable to monitor liver enzymes every 2-4 weeks after introducing any new ASM."

Suggested intensified follow-up after treatment change.

Support for Hepatic Decompensation

Category: Therapeutic Action: Support for Hepatic Decompensation Ontology label: Supportive Care NCIT:C15747

Platform: Other

Hepatology and metabolic teams manage hypoglycemia, hyperammonemia, nutritional needs and other liver-failure complications. Feeding schedules and ammonia-lowering strategies depend on clinical status. These measures support function without correcting the underlying mitochondrial defect.

Mechanism Target:

BYPASSES Hepatic Failure — Supports metabolic consequences of liver failure.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Treatment may incl small, frequent meals or continuous feeding to compensate for defective gluconeogenesis; reduction in dietary protein; use of non-absorbable sugars to create an osmotic diarrhea; & use of conjugating agents to treat hyperammonemia."

Specialist supportive hepatic/metabolic management; components are individualized.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Treatment may incl small, frequent meals or continuous feeding to compensate for defective gluconeogenesis; reduction in dietary protein; use of non-absorbable sugars to create an osmotic diarrhea; & use of conjugating agents to treat hyperammonemia."

Specialist supportive hepatic/metabolic management; components are individualized.

Liver Transplantation Assessment

Category: Counseling / Informational Action: Liver Transplantation Assessment Ontology label: Supportive Care NCIT:C15747

Platform: Other

Liver transplantation is generally not advised for children with established Alpers because it does not halt progressive brain disease. Selected older patients with other POLG phenotypes have survived transplantation; those reports do not establish benefit for classic childhood Alpers. Decisions require multidisciplinary assessment of neurological trajectory and goals of care.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Liver transplantation is not advised in children with Alpers-Huttenlocher syndrome (AHS) because transplanting the liver does not alter the rapid progression of the brain disease"

Alpers-specific limitation; broader POLG transplant experience is phenotype dependent.

Feeding, Swallowing and Nutritional Support

Category: Therapeutic Action: Feeding, Swallowing and Nutritional Support Ontology label: Nutritional Therapy NCIT:C65017

Platform: Other

Assess growth, oral intake and aspiration risk; obtain swallow evaluation when indicated. Adapt feeds and feeding therapy, and use nasogastric or gastrostomy support for severe dysfunction when consistent with clinical goals. Tube feeding does not remove every source of aspiration.

Mechanism Target:

BYPASSES Feeding Difficulties — Provides nutrition when oral intake is inadequate or unsafe.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Placement of a gastric feeding tube when appropriate can maintain nutritional status &/or prevent aspiration."

Supportive nutritional intervention.

BYPASSES Dysphagia — Provides nutrition when oral intake is inadequate or unsafe.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Placement of a gastric feeding tube when appropriate can maintain nutritional status &/or prevent aspiration."

Supportive nutritional intervention.

BYPASSES Failure to Thrive — Provides nutrition when oral intake is inadequate or unsafe.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Placement of a gastric feeding tube when appropriate can maintain nutritional status &/or prevent aspiration."

Supportive nutritional intervention.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Placement of a gastric feeding tube when appropriate can maintain nutritional status &/or prevent aspiration."

Supportive nutritional intervention.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"When feeding dysfunction is severe, an NG-tube or G-tube may be necessary."

Escalation for severe feeding impairment.

Rehabilitation and Communication Support

Category: Therapeutic Action: Rehabilitation and Communication Support Ontology label: Rehabilitation NCIT:C15315

Platform: Other

Offer physical, occupational and speech therapy, positioning and mobility equipment, educational accommodations and augmentative communication according to need. Goals include maintaining function, participation and comfort rather than reversing neurodegeneration.

Mechanism Target:

MODULATES Developmental Regression — Supports retained function and adaptation to changing abilities.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"OT, PT, & ST are indicated in AHS to maintain or improve neurologic function for as long as possible & for comfort care."

Alpers-specific rehabilitation recommendation.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"OT, PT, & ST are indicated in AHS to maintain or improve neurologic function for as long as possible & for comfort care."

Alpers-specific rehabilitation recommendation.

Spasticity and Movement-Disorder Management

Category: Therapeutic Action: Spasticity and Movement-Disorder Management Ontology label: Supportive Care NCIT:C15747

Platform: Other

Use rehabilitation and individualized symptom-directed medications for painful or function-limiting spasticity and movement disorders. Balance benefit against sedation and respiratory or swallowing impairment.

Mechanism Target:

MODULATES Spasticity — Reduces symptomatic tone and movement burden.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The use of benzodiazepines often ↓ severity of abnormal movements & also assists in seizure control & reduction of spasticity."

Symptomatic movement and tone management; sedation and respiratory effects remain relevant.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The use of benzodiazepines often ↓ severity of abnormal movements & also assists in seizure control & reduction of spasticity."

Symptomatic movement and tone management; sedation and respiratory effects remain relevant.

Respiratory and Sleep Support

Category: Therapeutic Action: Respiratory and Sleep Support Ontology label: Supportive Care NCIT:C15747

Platform: Device

Monitor for aspiration and respiratory insufficiency; assess sleep-related apnea or hypoventilation when indicated. Noninvasive or invasive ventilatory support is individualized according to physiology, disease trajectory and goals of care.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Treatment w/CPAP, BiPAP, or more invasive ventilatory therapy as indicated."

Supportive respiratory care in the POLG management chapter.

Vision and Hearing Care

Category: Therapeutic Action: Vision and Hearing Care Ontology label: Supportive Care NCIT:C15747

Platform: Other

Arrange ophthalmologic assessment, low-vision support and audiological evaluation according to symptoms. Correct treatable ocular or hearing problems and adapt communication and education to sensory impairment.

Mechanism Target:

MODULATES Cortical visual impairment — Supports function with visual impairment; it does not restore injured cortex.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Clinical management is largely supportive and involves standard approaches for associated complications including occupational, physical, and speech therapy; nutritional support; respiratory support; and standard treatment of liver failure, epilepsy, movement abnormalities, sleep disorders,..."

Review includes supportive sensory care.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Clinical management is largely supportive and involves standard approaches for associated complications including occupational, physical, and speech therapy; nutritional support; respiratory support; and standard treatment of liver failure, epilepsy, movement abnormalities, sleep disorders,..."

Chapter includes sensory care in multidisciplinary management.

Intercurrent-Illness Planning

Category: Counseling / Informational Action: Intercurrent-Illness Planning Ontology label: Supportive Care NCIT:C15747

Platform: Other

Provide an individualized plan for infection, fever, dehydration, poor intake or sudden neurological deterioration, with prompt assessment and supportive treatment. Caregiver seizure education and coordination between neurology, hepatology and metabolic teams reduce delays.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"As with some other mitochondrial diseases, physical stressors such as infection, fever, dehydration, and anorexia can result in a sudden deterioration and should be avoided if possible."

Review identifies stress-related deterioration.

Selective Cofactor Supplementation

Category: Therapeutic Action: Selective Cofactor Supplementation Ontology label: Supportive Care NCIT:C15747

Platform: Other

Routine mitochondrial supplement combinations have not demonstrated Alpers-specific benefit. Levocarnitine is generally reserved for documented low free carnitine, with monitoring. Folinic acid may be considered by metabolic specialists in the appropriate biochemical context; these measures are not established disease-modifying treatment.

Show evidence (3 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Vitamin and cofactor therapy with the intent to fortify mitochondrial function may be offered, yet there is insufficient evidence demonstrating objective benefit in cohorts of persons."

Review limits the evidence.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The use of levocarnitine should be reserved for individuals with reduced free carnitine levels in the blood, and the levels should be monitored"

Specific biochemical selection.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The use of folinic acid should be considered"

Historical GeneReviews consideration; no controlled Alpers-specific efficacy is established.

Palliative, Family and Care Coordination Support

Category: Therapeutic Action: Palliative, Family and Care Coordination Support Ontology label: Palliative Therapy NCIT:C15292

Platform: Other

Integrate symptom relief, respite, home nursing and palliative care according to need throughout the disease course. Discuss treatment burden, comfort and family goals alongside active neurological and hepatic management.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Ongoing assessment of need for palliative care involvement &/or home nursing (esp for persons w/AHS)"

Alpers-specific supportive-care emphasis.

Genetic Counseling and Family Testing

Category: Counseling / Informational Action: Genetic Counseling and Family Testing Ontology label: Genetic Counseling NCIT:C15240

Platform: Other

Offer parental testing, recurrence-risk counseling and targeted testing of relatives once familial pathogenic variants are known. Discuss prenatal and preimplantation testing options according to family preferences; asymptomatic siblings may still need evaluation because onset varies.

Show evidence (1 reference)

PMID:20301791 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Once the POLG pathogenic variants have been identified in an affected family member, testing for at-risk family members is possible."

Family testing requires the established familial variants.

Nicotinamide Riboside: Preclinical Investigation

Category: Therapeutic Action: Nicotinamide Riboside: Preclinical Investigation Ontology label: Pharmacotherapy NCIT:C15986

Agent: Nicotinamide riboside CHEBI:15927

Platform: Small molecule

Nicotinamide riboside improved several neuronal and mitochondrial markers in one Alpers donor's cortical organoids. This result motivates further research but does not establish dosing, safety or benefit in affected children. It should not be presented as an established Alpers therapy.

Mechanism Target:

MODULATES Cortical Neuronal Loss — Intended neuroprotective target supported only by organoid marker changes.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"We observed that the NR-treated organoids exhibited organized structures (Figure 7B) and increased expression of MAP2 and Tuj1 compared to those untreated"

Primary treated-versus-untreated marker result.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"We observed that the NR-treated organoids exhibited organized structures (Figure 7B) and increased expression of MAP2 and Tuj1 compared to those untreated"

Primary treated-versus-untreated marker result.

Vatiquinone: Investigational Evidence

Category: Therapeutic Action: Vatiquinone: Investigational Evidence Ontology label: Pharmacotherapy NCIT:C15986

Agent: Vatiquinone NCIT:C152840

Platform: Small molecule

Vatiquinone has been investigated for mitochondrial disease with refractory epilepsy. The randomized MIT-E primary endpoint was not statistically significant in its mixed-disease population, and no Alpers-specific clinical benefit is established here. The later open-label safety study does not provide a controlled efficacy comparison. It is not presented as standard Alpers treatment.

Mechanism Target:

MODULATES Recurrent Seizure Activity — Intended antiseizure target; the randomized primary endpoint did not establish efficacy.

Show evidence (1 reference)

url:https://clinicaltrials.gov/api/v2/studies/NCT04378075 SUPPORT DIRECT PRIMARY RESULT Human Clinical

""pValue":"= 0.173","statisticalMethod":"ANCOVA","paramType":"Median Difference (Final Values)","paramValue":"-8.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-31.3","ciUpperLimit":"16.4""

Posted primary motor-seizure analysis in 68 mixed mitochondrial-disease participants; not an Alpers-specific analysis.

Show evidence (1 reference)

url:https://clinicaltrials.gov/api/v2/studies/NCT04378075 SUPPORT DIRECT PRIMARY RESULT Human Clinical

""pValue":"= 0.173","statisticalMethod":"ANCOVA","paramType":"Median Difference (Final Values)","paramValue":"-8.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-31.3","ciUpperLimit":"16.4""

Posted primary motor-seizure analysis in 68 mixed mitochondrial-disease participants; not an Alpers-specific analysis.

Deoxycytidine and Deoxythymidine: Clinical Investigation

Category: Therapeutic Action: Deoxycytidine and Deoxythymidine: Clinical Investigation Ontology label: Pharmacotherapy NCIT:C15986

Agent: 2'-deoxycytidine CHEBI:15698 Deoxythymidine CHEBI:17748

Platform: Small molecule

Enteral deoxycytidine/deoxythymidine is being studied in recessive POLG disease. An initial 10-person report, including six Alpers participants, was followed by a 25-person mixed-POLG report from the same open-label program. Disease-scale and seizure improvements warrant further study, but unblinded assessment, cointerventions, missing observations and survival selection preclude a proven Alpers-specific benefit. Diarrhea sometimes required dose reduction; five deaths in the expanded cohort mean that absence of attributed serious drug toxicity is not proof of safety. This remains investigational for POLG disease, distinct from treatment of TK2 deficiency.

Mechanism Target:

MODULATES Mitochondrial DNA Depletion — Proposed nucleotide-substrate strategy; no direct restoration of patient-tissue mtDNA was demonstrated in these clinical reports.

Show evidence (1 reference)

PMID:42296640 SUPPORT INDIRECT BACKGROUND In Vitro

"supplementation with three or fewer deoxynucleosides is sufficient to increase mtDNA levels in POLG-deficient fibroblasts"

The trial cites prior cell evidence for the proposed substrate-rescue target; it did not measure patient-tissue mtDNA rescue.

MODULATES Recurrent Seizure Activity — Intended clinical target with uncontrolled seizure observations, not established comparative efficacy.

Show evidence (1 reference)

PMID:42296640 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Of the patients with uncontrolled seizures at the time of enrollment, 10/14 (71%) had >50% improvement in seizures, including three who were seizure-free at last review."

Uncontrolled observational seizure change in the mixed POLG cohort; concurrent treatment changes and selection limit attribution.

Show evidence (5 references)

PMID:39091670 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We present 6-month interim data from the first ten people with POLG-related disorders enrolled in the trial, six with Alpers-Huttenlocher syndrome, two with ataxia-neuropathy spectrum, and two who do not fit into a classical POLG-related phenotype."

Initial ten-person report included six Alpers patients; pooled results are not an Alpers-only estimate.

PMID:42296640 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Twenty-five patients (14 males, 11 females) with POLG-related disorders meeting inclusion/exclusion criteria were enrolled and started dC/dT"

Expanded follow-up of the same NCT04802707 program, not an independent replication trial.

PMID:42296640 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Of the patients with uncontrolled seizures at the time of enrollment, 10/14 (71%) had >50% improvement in seizures, including three who were seizure-free at last review."

Uncontrolled observational seizure change in the mixed POLG cohort; concurrent treatment changes and selection limit attribution.

+ 2 more references

🌍

Environmental Factors

1

Valproate exposure

Valproate or divalproex exposure can precipitate or accelerate severe liver injury in POLG-related disease, including Alpers. This is a clinically established gene–drug interaction; the molecular mediator remains unresolved and exposure is contraindicated.

Show evidence (1 reference)

PMID:20138553 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure"

Clinical drug-associated risk.

Mechanism Target:

TRIGGERS Valproate-Associated Hepatocellular Injury — Exposure can trigger the drug-associated injury pathway on a background of POLG-related vulnerability.

Show evidence (1 reference)

PMID:20138553 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure"

Clinical drug-associated risk.

🔬

Biochemical Markers

3

Blood and cerebrospinal fluid lactate (INCREASED)

Context: Lactate may be elevated but a normal value does not exclude POLG-related Alpers. The 2017 mixed early-onset cohort found increased blood lactate in 12/20 and CSF lactate in 2/5 at presentation; these are not Alpers-specific sensitivities.

Show evidence (1 reference)

PMID:28471437 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Laboratory investigations at presentation revealed increased lactate in blood in 60% ( n = 12/20) and in cerebrospinal fluid in 40% ( n = 2/5)."

Primary mixed-cohort observation with incomplete testing.

Hepatic synthetic and metabolic dysfunction (VARIABLE)

Context: Aminotransferase elevation, low albumin, prolonged coagulation times, hypoglycemia or hyperammonemia can accompany hepatic involvement. Synthetic dysfunction can be clinically important even when isolated enzyme measurements are not striking.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Evidence of liver dysfunction or failure can be present, which may occur following exposure to certain anti-seizure medications."

Review of hepatic manifestations.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"End-stage liver disease is often heralded by hypoalbuminemia and prolonged coagulation time, followed shortly thereafter by fasting hypoglycemia and hyperammonemia."

Alpers-specific hepatic progression.

Elevated cerebrospinal fluid protein (INCREASED)

Context: CSF protein may be elevated and can support suspicion in the appropriate presentation; it is nonspecific and not required for molecular diagnosis.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"CSF protein levels are generally elevated in individuals with Alpers-Huttenlocher syndrome (AHS) and other"

Alpers explicitly included in the chapter description; the observation is not specific to this syndrome.

🔬

Diagnosis

4

Molecular diagnosis and parental phasing

Confirm a compatible phenotype with biallelic pathogenic or likely pathogenic POLG variants. Variants of uncertain significance do not confirm or exclude disease. Sequence analysis should cover the whole gene; deletion/duplication testing, a mitochondrial/epilepsy panel or broader genomic testing may be needed. A small founder-variant screen can miss causal variants. Parental testing clarifies phase and recurrence risk.

Genetic Testing NCIT:C15709

Show evidence (2 references)

PMID:20301791 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Establishing the diagnosis of a POLG-related disorder relies on clinical findings and the identification of biallelic POLG pathogenic variants on molecular genetic testing"

GeneReviews molecular diagnosis.

PMID:28471437 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"we demonstrate the need to perform full sequence analysis of the entire POLG gene rather than targeting common POLG mutations in patients with unexplained encephalopathy and multisystem disorders with or without epilepsy"

Clinical study conclusion; targeted variants are not a sufficient exclusion test.

Electroencephalography and clinical seizure assessment

EEG and video EEG characterize seizures and assess possible nonconvulsive status. Occipital discharges are an important clue but are not specific or invariably present; clinically apparent EPC can lack a clear EEG correlate.

Electroencephalography NCIT:C38054

Show evidence (2 references)

PMID:20138553 SUPPORT DIRECT BACKGROUND Human Clinical

"early predominance of epileptiform discharges over the occipital region is common in POLG-induced epilepsy"

Clinical recognition feature.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"EPC is not always apparent as an abnormality on EEG and can be mistaken for a conversion reaction. EEG may be normal or show only focal slowing of the background rhythm."

Important diagnostic limitation.

Neuroimaging

Brain MRI may initially be normal. Evolving cortical or subcortical signal change, occipital-pulvinar involvement and cortical or cerebellar atrophy support the clinical assessment but do not replace molecular testing.

Magnetic Resonance Imaging NCIT:C16809

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"CT or MRI of the brain may be normal early in the course of AHS. As the illness evolves, neuroimaging shows gliosis (initially more pronounced in the occipital lobe regions) and generalized cortical atrophy."

Alpers imaging evolution.

Hepatic, metabolic and tissue assessment

Assess liver enzymes, synthetic function, glucose, ammonia and lactate alongside neurological findings. Tissue mtDNA measurement and respiratory-chain testing can be informative when needed, but normal muscle histology, enzyme activity or mtDNA content does not exclude disease. Do not delay appropriate genetic evaluation because a screening test is normal.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"In muscle biopsy samples, ragged-red fibers, COX-negative fibers, excessive lipid deposits, and abnormal respiratory chain activities can be present. However, biochemical findings on muscle biopsy can be normal."

Review explicitly limits muscle-biopsy sensitivity.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Depletion of mtDNA can be measured by comparing mtDNA to nuclear DNA content in an affected tissue (e.g., liver)."

Tissue measurement approach.

📈

Progression

3

Variable childhood or later presentation

Age: Usually ages two to four years; reported range one month to 36 years

Children may initially develop normally, but developmental delay can precede recognized neurodegeneration. Seizures, visual symptoms, poor growth or hepatic disease may bring the child to attention; a fixed brain-then-liver sequence is not required.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Children with AHS appear healthy at birth and may develop normally over the first few weeks to years of life. Some have variable degrees of developmental delay prior to the initial recognition of neurodegeneration. Onset is usually between ages two and four years but ranges overall from one..."

Alpers-specific onset synthesis.

Progressive neurological and hepatic involvement

Seizures often become resistant to medication, and regression, spasticity, visual loss or ataxia can accumulate. Hepatic involvement has variable timing and can be precipitated or accelerated by valproate. Intercurrent illness may trigger abrupt decline.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"In some children, seizures are initially controllable with standard dosages of anti-seizure medications (ASM); in others, seizures, such as EPC, are refractory from the onset. Over time, seizures become increasingly resistant to ASMs."

Variable seizure progression.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Significant sudden or rapid regression is often seen during infectious illnesses."

Stress-associated deterioration.

Variable survival with risk of fatal decompensation

The course is usually life limiting, but survival is variable and may include periods of stability. GeneReviews describes three months to 12 years from symptom onset. The 2017 Alpers subgroup had a median reported survival of four months (range 0.5–181 months); the pooled cohort's median age at death must not be treated as a universal Alpers prognosis.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The rate of neurodegeneration varies and is marked by periods of stability. The typical life expectancy from onset of first symptoms ranges from three months to 12 years."

Review summary; not an individual prognostic prediction.

PMID:28471437 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Twenty-seven patients (15 male, 12 female) from 22 pedigrees (including two patients from consanguineous families) with genetically confirmed POLG mutations were identified. ... Of 27 patients, four were alive at the time of data analysis, and one had been lost to follow-up. Median age at death..."

Reports survival in a mixed early-onset POLG cohort, including Alpers and myocerebrohepatopathy. Pooled age-at-death and cause-of-death statistics must not be presented as Alpers-only estimates; the phenotype-specific median is retained.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Alpers-Huttenlocher Syndrome:

Other early-onset POLG phenotypes

Overlapping Features Myocerebrohepatopathy and severe digestive-predominant presentations overlap with Alpers but can lack epilepsy, especially with rapidly fatal hepatic disease. Age categories and clinical syndromes are not equivalent.

Distinguishing Features

Phenotypic classification depends on the full neurological and hepatic course, rather than the POLG genotype or age alone.

Show evidence (1 reference)

PMID:38975049 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Although a fraction of patients met inclusion criteria for AHS (triad of refractory seizures, psychomotor regression, and hepatopathy), this seminal description is an imperfect fit for all the pediatric population reported here"

Primary cohort explicitly limits the Alpers label.

MELAS Syndrome MONDO:0010789

Overlapping Features MELAS can share seizures, cortical visual symptoms and stroke-like episodes. Mitochondrial DNA pathogenic variants and maternal inheritance distinguish typical MELAS from recessive nuclear POLG-related Alpers.

Distinguishing Features

Stroke-like episodes can occur in both; they are not an exclusive discriminator.
Typical MELAS is associated with maternally inherited mtDNA variants.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"MELAS is caused by pathogenic variants in mtDNA and is transmitted by maternal inheritance."

Direct differential-diagnosis statement.

Other hepatocerebral mitochondrial disorders

Overlapping Features DGUOK, MPV17 and other mitochondrial disorders can combine liver disease and neurological dysfunction. Historical Alpers-like encephalopathy also includes non-POLG genetic causes, so an unresolved molecular diagnosis warrants broader testing.

Distinguishing Features

A different causal gene establishes a separate molecular disorder; liver and seizure findings can overlap.

Show evidence (1 reference)

PMID:30021052 SUPPORT DIRECT BACKGROUND Human Clinical

"Recent whole exome sequencing has identified other molecular genetic causes of Alpers’ syndrome, including pathogenic mutations in FARS2"

Background acknowledges genetically heterogeneous historical clinical usage.

Leigh syndrome

Overlapping Features Leigh syndrome can share developmental regression, motor signs and epilepsy. Brainstem and deep-gray involvement often precede cortical lesions, whereas Alpers commonly begins with cortical injury. Molecular testing resolves overlapping cases.

Distinguishing Features

Typical lesion sequence and distribution differ, but neither pattern is fully specific.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"whereas in AHS the initial lesions form in the cerebral cortex (usually the occipital lobes), followed by the cerebellum, basal ganglia, thalamus, and brain stem."

Chapter comparison of neuroimaging evolution.

📊

Related Datasets

1

RNA sequencing in POLG-iPSC derived brain cells geo:GSE207007

Transcriptomic collection covering POLG patient-specific fibroblasts, iPSCs and differentiated neural cells. The Alpers organoid study deposited its bulk RNA-seq in this collection; the broader accession also includes other POLG genotypes and should not be treated as one homogeneous Alpers cohort.

BULK RNA SEQ

PMID:38385069

Verified through a generated per-record GEO cache. The organoid study used one successfully differentiated Alpers donor with two clones and unrelated controls; cell replicates do not increase the patient count.

Show evidence (1 reference)

GEO:GSE207007 SUPPORT DIRECT BACKGROUND In Vitro

"including patient-specific fibroblasts, iPSCs and iPSCs-derived neural stem cells (NSCs), and astrocytes."

Repository scope includes several cell types and broader POLG genotypes.

🔬

Clinical Trials

4

NCT04802707 PHASE_II RECRUITING

Single-centre open-label phase 2 pyrimidine deoxynucleoside study across mitochondrial depletion disorders. The 2024 POLG interim report included 10 participants, six with Alpers; the 2026 report extends the same program to 25 participants with varied POLG phenotypes, including adults. Disease-scale scores improved among available follow-up observations, and 10/14 with uncontrolled epilepsy had reported seizure reductions over 50%. Five participants died and five withdrew. These uncontrolled mixed-phenotype findings do not establish Alpers-specific efficacy or a survival benefit.

Target Phenotypes: Seizure HP:0001250 Developmental regression HP:0002376

Show evidence (7 references)

clinicaltrials:NCT04802707 SUPPORT DIRECT BACKGROUND Human Clinical

"In this phase II Trial a mix of Deoxynucleosides Pyrimidine (Deoxycytidine dC and Deoxythymidine dT) will be used as early treatment of MDS."

Protocol intervention, not proof of efficacy.

PMID:39091670 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We present 6-month interim data from the first ten people with POLG-related disorders enrolled in the trial, six with Alpers-Huttenlocher syndrome, two with ataxia-neuropathy spectrum, and two who do not fit into a classical POLG-related phenotype."

Initial ten-person report included six Alpers patients; pooled results are not an Alpers-only estimate.

PMID:42296640 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Twenty-five patients (14 males, 11 females) with POLG-related disorders meeting inclusion/exclusion criteria were enrolled and started dC/dT"

Expanded follow-up of the same NCT04802707 program, not an independent replication trial.

+ 4 more references

NCT03034512 NOT_APPLICABLE TERMINATED

Alpers natural-history study intended to follow clinical manifestations over time. The registry lists two enrolled participants and termination because the research focus changed. This is an observational design, not a treatment trial or published estimate of disease progression.

Show evidence (1 reference)

clinicaltrials:NCT03034512 SUPPORT DIRECT BACKGROUND Human Clinical

"This is a natural history study of Alpers Huttenlocher Syndrome. Patients will be followed over time to assess clinical symptoms for the purpose of expanding knowledge of this disorder in the medical community."

Protocol purpose only.

NCT04378075 PHASE_III TERMINATED

MIT-E was a randomized placebo-controlled phase 2/3 study of vatiquinone in mitochondrial disease with refractory epilepsy, including Alpers among eligible conditions. Sixty-eight participants were randomized (34 per arm). The posted 24-week primary motor-seizure analysis did not demonstrate a statistically significant benefit (P = 0.173; reported between-arm median difference -8.31 percentage points, 95% CI -31.3 to 16.4). These are mixed-disease results, not an Alpers-specific efficacy estimate. The trial was terminated by sponsor decision.

Target Phenotypes: Seizure HP:0001250

Show evidence (3 references)

clinicaltrials:NCT04378075 SUPPORT DIRECT BACKGROUND Human Clinical

"This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase."

Design evidence.

url:https://clinicaltrials.gov/api/v2/studies/NCT04378075 SUPPORT DIRECT PRIMARY RESULT Human Clinical

""pValue":"= 0.173","statisticalMethod":"ANCOVA","paramType":"Median Difference (Final Values)","paramValue":"-8.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-31.3","ciUpperLimit":"16.4""

Posted primary motor-seizure analysis in 68 mixed mitochondrial-disease participants; not an Alpers-specific analysis.

url:https://clinicaltrials.gov/api/v2/studies/NCT04378075 SUPPORT DIRECT BACKGROUND Human Clinical

"The study was terminated early due to Sponsor decision."

Current registry status and stated reason, rather than a causal attribution to toxicity.

NCT05218655 PHASE_III COMPLETED

Open-label phase 3 safety study in 101 previously vatiquinone-treated participants with inherited mitochondrial disease. The registry is marked completed, but the posted limitations state that it ended early because the sponsor discontinued development for this indication based on prior trial results. The primary outcome was treatment-emergent adverse events, not Alpers seizure efficacy; 91/101 experienced at least one TEAE. This selected uncontrolled cohort does not establish an Alpers-specific benefit or comparative safety.

Show evidence (4 references)

clinicaltrials:NCT05218655 SUPPORT DIRECT BACKGROUND Human Clinical

"The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan."

Safety-design population; no efficacy claim.

url:https://clinicaltrials.gov/api/v2/studies/NCT05218655 SUPPORT DIRECT PRIMARY RESULT Human Clinical

""title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)""

Primary registered endpoint.

url:https://clinicaltrials.gov/api/v2/studies/NCT05218655 SUPPORT DIRECT PRIMARY RESULT Human Clinical

""groupId":"OG000","value":"91"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline (Day 1) up to 30 days after last dose of study drug (956 days)""

Primary endpoint numerator in the 101-person safety population.

+ 1 more reference

🧫

Experimental Models

6

Alpers iPSC-derived neural stem cells IPSC_DERIVED_MODEL

Differentiated neural stem cells showed reduced mtDNA/nuclear-DNA ratio, complex I/IV protein expression, mitochondrial membrane potential and cellular ATP, with increased mitochondrial ROS probe signals. The pluripotent cells showed a milder phenotype and no significant ATP deficit. Cell-state differences are essential to interpretation.

Cell source

Neural stem cells differentiated from an A467T/P589L Alpers donor and unrelated controls

Publication

PMID:38385069

Pathograph links

Mitochondrial DNA Depletion partially recapitulates fidelity: moderate observes: cellular ND1/APP qPCR was reduced in Alpers neural stem cells.

Limitations: One Alpers donor with compound A467T/P589L variants, two clones, compared with five clones from three unrelated controls. A second patient line failed differentiation; no isogenic control was obtained. Cellular replicates are not independent patients. Findings do not establish a universal allele effect or clinical treatment benefit.

Readouts

Relative ND1/APP DNA ratio

Direction: DECREASED

Interpretation: ND1/APP qPCR was reduced in Alpers neural stem cells.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"To corroborate the reduction in the mtDNA levels as observed through the ND1/APP measurements in Alpers' NSCs, we performed qPCR (Figure 2P), which confirmed the same."

Measured mtDNA-to-nuclear-DNA ratio in neural stem cells.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"To corroborate the reduction in the mtDNA levels as observed through the ND1/APP measurements in Alpers' NSCs, we performed qPCR (Figure 2P), which confirmed the same."

Measured mtDNA-to-nuclear-DNA ratio in neural stem cells.

Reduced Cellular ATP Availability partially recapitulates fidelity: moderate observes: cellular ATP content per cell was reduced after neural differentiation.

Limitations: One Alpers donor with compound A467T/P589L variants, two clones, compared with five clones from three unrelated controls. A second patient line failed differentiation; no isogenic control was obtained. Cellular replicates are not independent patients. Findings do not establish a universal allele effect or clinical treatment benefit. This is not an isolated ATP synthesis-flux assay.

Readouts

Cell-normalized ATP luminescence

Direction: DECREASED

Interpretation: ATP content per cell was reduced after neural differentiation.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"A direct measurement of intracellular ATP production revealed a marked decrease in ATP production in Alpers' NSCs compared to the control NSCs"

Cell-normalized ATP content measured by luminescence.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"A direct measurement of intracellular ATP production revealed a marked decrease in ATP production in Alpers' NSCs compared to the control NSCs"

Cell-normalized ATP content measured by luminescence.

Alpers cortical organoids with nicotinamide riboside ORGANOID

Day-90 organoids showed abnormal organization, lower neuronal/GAD65 and complex I marker expression, increased GFAP staining and altered synaptic/mitochondrial gene sets. One-month-old organoids received 1 mM nicotinamide riboside for two months; neuronal and complex I markers increased and GFAP decreased. Organoid TFAM staining is a proxy for mtDNA content, and mtDNA transcripts did not significantly increase after treatment. No patient seizure, survival or liver outcome was tested.

Cell source

Cortical organoids from the same A467T/P589L Alpers donor

Publication

PMID:38385069

Pathograph links

Cortical Neuronal Loss partially recapitulates fidelity: moderate observes: cellular Patient organoids had lower neuronal marker expression.

Limitations: One Alpers donor with compound A467T/P589L variants, two clones, compared with five clones from three unrelated controls. A second patient line failed differentiation; no isogenic control was obtained. Cellular replicates are not independent patients. Findings do not establish a universal allele effect or clinical treatment benefit. Marker abundance may reflect cell number, state or differentiation; no longitudinal cell-fate tracing.

Readouts

MAP2, NeuN and TUJ1 marker expression

Direction: DECREASED

Interpretation: Patient organoids had lower neuronal marker expression.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"the level of all neural marker MAP2, NeuN and Tuj1 expression (Figure 5C, D, E, F, I, L and Supplementary Figure 14) was also lower in Alpers' organoids"

Neuronal marker reduction, not longitudinal lineage tracing.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"the level of all neural marker MAP2, NeuN and Tuj1 expression (Figure 5C, D, E, F, I, L and Supplementary Figure 14) was also lower in Alpers' organoids"

Neuronal marker reduction, not longitudinal lineage tracing.

Cortical Neuronal Loss measures fidelity: moderate observes: cellular Nicotinamide riboside increased neuronal marker expression relative to untreated patient organoids.

Limitations: One Alpers donor with compound A467T/P589L variants, two clones, compared with five clones from three unrelated controls. A second patient line failed differentiation; no isogenic control was obtained. Cellular replicates are not independent patients. Findings do not establish a universal allele effect or clinical treatment benefit. A partial in-vitro rescue does not establish clinical efficacy.

Readouts

Neuronal marker expression after nicotinamide riboside

Direction: INCREASED

Interpretation: Nicotinamide riboside increased neuronal marker expression relative to untreated patient organoids.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"We observed that the NR-treated organoids exhibited organized structures (Figure 7B) and increased expression of MAP2 and Tuj1 compared to those untreated"

Primary treated-versus-untreated marker result.

Show evidence (1 reference)

PMID:38385069 SUPPORT DIRECT PRIMARY RESULT In Vitro

"We observed that the NR-treated organoids exhibited organized structures (Figure 7B) and increased expression of MAP2 and Tuj1 compared to those untreated"

Primary treated-versus-untreated marker result.

Reconstituted human and mouse polymerase gamma assays OTHER

A467T/A449T impairs binding, long-template synthesis and accessory-subunit interaction. Accessory subunit addition restored short-template activity toward wild type in mouse assays but did not normalize long-template synthesis. LONP1 proteolysis showed equal susceptibility of free wild-type and mutant catalytic subunits, with incomplete accessory-subunit protection of the mutant. These are direct biochemical assays, not patient-derived hepatocytes.

Cell source

Purified recombinant wild-type and mutant POLG catalytic/accessory subunits with DNA substrates and LONP1

Publication

PMID:33956154

Pathograph links

Reduced DNA Polymerase Gamma Function partially recapitulates fidelity: moderate observes: molecular Mutant long-template DNA synthesis remained slower despite accessory subunit.

Limitations: Allele-, species-, substrate- and reaction-condition-dependent result.

Readouts

Long-template DNA synthesis

Direction: DECREASED

Interpretation: Mutant long-template DNA synthesis remained slower despite accessory subunit.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"mPOLγAA449T displayed a clearly slower DNA synthesis rate compared to the mPOLγAWT, even in the presence of the mPOLγB subunit"

Long-template synthesis assay.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"mPOLγAA449T displayed a clearly slower DNA synthesis rate compared to the mPOLγAWT, even in the presence of the mPOLγB subunit"

Long-template synthesis assay.

Increased Degradation of Unprotected POLG partially recapitulates fidelity: moderate observes: molecular POLG2 protected wild-type catalytic subunit more effectively than mutant.

Limitations: Free wild-type and mutant were degraded at similar rates; do not infer an in-vivo half-life.

Readouts

Catalytic-subunit loss in assembled proteolysis assay

Direction: INCREASED

Interpretation: POLG2 protected wild-type catalytic subunit more effectively than mutant.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"In contrast, mPOLγB was unable to efficiently block degradation of mPOLγAA449T and the levels of the mutant protein decreased significantly over the time of the experiment"

Purified LONP1 degradation assay.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"In contrast, mPOLγB was unable to efficiently block degradation of mPOLγAA449T and the levels of the mutant protein decreased significantly over the time of the experiment"

Purified LONP1 degradation assay.

A449T mouse embryonic fibroblast mtDNA recovery CELL_LINE

Baseline mtDNA content was not reduced, but mutant cells accumulated more replicating foci and failed to recover mtDNA during the observed interval after ethidium-bromide depletion. More replication foci were interpreted as stalled or slow replication, not greater productive synthesis.

Cell source

Embryonic fibroblasts from homozygous Polg A449T mice and wild-type littermates

Publication

PMID:33956154

Pathograph links

Impaired Mitochondrial DNA Replication partially recapitulates fidelity: moderate observes: cellular Recovery after experimentally induced mtDNA depletion was impaired.

Limitations: Cultured mouse cells and a chemical depletion challenge, not untreated human Alpers liver.

Readouts

mtDNA copy-number recovery after ethidium bromide

Direction: DECREASED

Interpretation: Recovery after experimentally induced mtDNA depletion was impaired.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"whereas no recovery at all was observed in the mutant cells"

Primary post-depletion recovery observation.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"whereas no recovery at all was observed in the mutant cells"

Primary post-depletion recovery observation.

HeLa LONP1 and POLG2 knockdown CELL_LINE

LONP1 knockdown increased endogenous POLG catalytic-subunit abundance; POLG2 knockdown reduced it. These cells do not carry an Alpers genotype, and the experiment did not establish rescue of mutant mtDNA replication, neuronal survival or clinical disease.

Cell source

HeLa cells with siRNA-mediated LONP1 or POLG2 depletion

Publication

PMID:33956154

Pathograph links

Reduced POLG Protein Abundance measures fidelity: moderate observes: molecular Reducing LONP1 increased endogenous catalytic-subunit abundance.

Limitations: Wild-type regulatory experiment; not mutant rescue or a validated therapeutic strategy.

Readouts

POLG protein after LONP1 knockdown

Direction: INCREASED

Interpretation: Reducing LONP1 increased endogenous catalytic-subunit abundance.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"LONP1 knockdown caused a robust increase in POLγA levels"

Primary cellular protein readout.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT In Vitro

"LONP1 knockdown caused a robust increase in POLγA levels"

Primary cellular protein readout.

Valproate exposure in primary muscle-cell cultures PRIMARY_CELL_CULTURE

The 2010 study examined p.Gln1236His and A467T/K1191N donor muscle cells, not hepatocytes. Baseline patient myotubes had reduced mtDNA, but 10 mM valproate did not further reduce it. Growth/death effects at high experimental concentrations cannot establish a physiological-dose liver mechanism. Failure to observe additional mtDNA depletion in this context does not exclude liver-specific toxicity.

Cell source

Primary human myoblasts/myotubes from control, common-variant and AHS donors

Publication

PMID:21038416

Pathograph links

Mitochondrial DNA Depletion measures fidelity: moderate observes: cellular Valproate did not further reduce mtDNA in the tested muscle-cell conditions.

Limitations: Small donor set, nonhepatic lineage and concentration-dependent exposure; no conclusion about patient liver mechanisms.

Readouts

Additional mtDNA loss after valproate

Direction: UNCHANGED

Interpretation: Valproate did not further reduce mtDNA in the tested muscle-cell conditions.

Show evidence (1 reference)

PMID:21038416 SUPPORT DIRECT PRIMARY RESULT In Vitro

"but there was no further decrease in mtDNA content with the addition of 10mM VPA"

Direct negative muscle-cell result.

Show evidence (1 reference)

PMID:21038416 SUPPORT DIRECT PRIMARY RESULT In Vitro

"but there was no further decrease in mtDNA content with the addition of 10mM VPA"

Direct negative muscle-cell result.

🐁

Animal Models

1

Homozygous Polg A449T knock-in mouse Knock-in model

The mouse ortholog of human A467T impairs mitochondrial genome maintenance and reduces catalytic-subunit abundance. Young mice showed reduced exercise/rearing performance and mild skeletal-muscle mtDNA depletion; spontaneous severe neurological or liver failure was not demonstrated. After carbon tetrachloride, residual liver necrosis was greater at day four despite similar early injury. This challenge does not establish ATP failure as the mediator of delayed recovery.

Species

Mus musculus

Genotype

Polg A449T/A449T

Publication

PMID:33956154

Pathograph links

Reduced POLG Protein Abundance partially recapitulates fidelity: moderate observes: molecular Catalytic-subunit abundance was reduced in knock-in tissues.

Limitations: The homozygous Polg A449T mouse models one allele corresponding to human A467T. It had mild, tissue-dependent mtDNA changes, unchanged liver/muscle OXPHOS activities and no shortened lifespan through two years. It does not reproduce the severe human Alpers triad. Tested valproate exposures did not cause hepatic failure, so the model cannot establish human drug safety.

Readouts

Tissue POLG catalytic-subunit abundance

Direction: DECREASED

Interpretation: Catalytic-subunit abundance was reduced in knock-in tissues.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"The amount of mPOLγAA449T was reduced in the PolgA449T/A449T mice, which could also contribute to impaired mtDNA replication."

Primary tissue protein finding.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"The amount of mPOLγAA449T was reduced in the PolgA449T/A449T mice, which could also contribute to impaired mtDNA replication."

Primary tissue protein finding.

Hepatocellular Injury partially recapitulates fidelity: low observes: tissue Recovery from carbon-tetrachloride injury was delayed, with greater residual necrosis at day four.

Limitations: The homozygous Polg A449T mouse models one allele corresponding to human A467T. It had mild, tissue-dependent mtDNA changes, unchanged liver/muscle OXPHOS activities and no shortened lifespan through two years. It does not reproduce the severe human Alpers triad. Tested valproate exposures did not cause hepatic failure, so the model cannot establish human drug safety. Chemical injury is distinct from spontaneous human disease or valproate toxicity.

Readouts

Residual hepatic necrosis after chemical injury

Direction: INCREASED

Interpretation: Recovery from carbon-tetrachloride injury was delayed, with greater residual necrosis at day four.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Two days after the injection, both WT and PolgA449T/A449T showed extensive areas of necrosis (∼35% of the liver), which was reduced to 6 ± 0.46% in WT mice after 4 days, whereas it was still above 10% in PolgA449T/A449T mice (10 ± 1.15%, P < 0.05)"

Similar initial chemical injury followed by more residual necrosis at day four in the mutant.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Two days after the injection, both WT and PolgA449T/A449T showed extensive areas of necrosis (∼35% of the liver), which was reduced to 6 ± 0.46% in WT mice after 4 days, whereas it was still above 10% in PolgA449T/A449T mice (10 ± 1.15%, P < 0.05)"

Similar initial chemical injury followed by more residual necrosis at day four in the mutant.

Valproate-Associated Hepatocellular Injury fails to recapitulate fidelity: low observes: tissue The tested valproate protocols did not induce hepatic failure or histological injury.

Limitations: The homozygous Polg A449T mouse models one allele corresponding to human A467T. It had mild, tissue-dependent mtDNA changes, unchanged liver/muscle OXPHOS activities and no shortened lifespan through two years. It does not reproduce the severe human Alpers triad. Tested valproate exposures did not cause hepatic failure, so the model cannot establish human drug safety.

Readouts

Valproate-associated hepatic histological damage

Direction: UNCHANGED

Interpretation: The tested valproate protocols did not induce hepatic failure or histological injury.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Both WT and PolgA449T/A449T did not show any sign of hepatic failure or histological damage."

Tested negative model phenotype; does not refute clinical toxicity.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Both WT and PolgA449T/A449T did not show any sign of hepatic failure or histological damage."

Tested negative model phenotype; does not refute clinical toxicity.

The homozygous Polg A449T mouse models one allele corresponding to human A467T. It had mild, tissue-dependent mtDNA changes, unchanged liver/muscle OXPHOS activities and no shortened lifespan through two years. It does not reproduce the severe human Alpers triad. Tested valproate exposures did not cause hepatic failure, so the model cannot establish human drug safety.

Show evidence (1 reference)

PMID:33956154 SUPPORT DIRECT PRIMARY RESULT Model Organism

"We monitored the PolgA449T/A449T and WT littermates up to 2 years of age, but neither reduction of the lifespan nor the presence of obvious age-related phenotypes was observed."

Longitudinal model limitation.

{ }

Source YAML

click to show

name: Alpers-Huttenlocher Syndrome
creation_date: '2026-08-05T00:00:00Z'
category: Genetic
description: Alpers-Huttenlocher syndrome is a severe POLG-related mitochondrial encephalopathy characterized by progressive loss of developmental or cognitive abilities, epilepsy that commonly becomes drug resistant, and variable hepatic disease. Biallelic pathogenic POLG variants impair mitochondrial DNA maintenance, leading to tissue-dependent mitochondrial dysfunction and neurodegeneration. Onset is usually in early childhood, but later presentation occurs; preceding development and the timing of liver involvement vary. Valproate can precipitate or accelerate life-threatening liver failure and is contraindicated in POLG-related disease.
parents:
- Epilepsy
- Mitochondrial Disease
- Neurological Disease
synonyms:
- AHS
- Alpers syndrome
- Alpers disease
- progressive sclerosing poliodystrophy
- mitochondrial DNA depletion syndrome 4A
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    notes: A POLG-related mitochondrial disorder presenting as a cerebrohepatopathy, managed by neurology together with hepatology and metabolic medicine.
disease_term:
  preferred_term: Alpers-Huttenlocher syndrome
  term:
    id: MONDO:0008758
    label: mitochondrial DNA depletion syndrome 4a
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0008758
      label: mitochondrial DNA depletion syndrome 4a
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO:0008758 is the entity for Alpers-Huttenlocher syndrome, carried under the molecular label mitochondrial DNA depletion syndrome 4a and defined as the cerebrohepatopathy characterized by the triad of progressive developmental regression, intractable seizures, and hepatic failure. The clinical eponym is used as the entry name and preferred_term because that is what the literature and the clinic use.
references:
- reference: GEO:GSE207007
  title: RNA sequencing in POLG-iPSC derived brain cells
- reference: PMID:16024923
  title: The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit.
- reference: PMID:20138553
  title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
- reference: PMID:20301791
  title: POLG-Related Disorders.
  tags:
  - GeneReviews
- reference: PMID:21038416
  title: Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
- reference: PMID:28471437
  title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
- reference: PMID:30021052
  title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
- reference: PMID:30255931
  title: 'Variants p.Q1236H and p.E1143G in mitochondrial DNA polymerase gamma POLG1 are not associated with increased risk for valproate-induced hepatotoxicity or pancreatic toxicity: A retrospective cohort study of patients with epilepsy.'
- reference: PMID:33956154
  title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
- reference: PMID:38385069
  title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
- reference: PMID:38576261
  title: 'Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.'
- reference: PMID:38822839
  title: 'Status epilepticus in POLG disease: a large multinational study.'
- reference: PMID:38860231
  title: 'Evidence for sodium valproate toxicity in mitochondrial diseases: a systematic analysis.'
- reference: PMID:38975049
  title: Distinct Clinical Courses and Shortened Lifespans in Childhood-Onset DNA Polymerase Gamma Deficiency.
- reference: PMID:39091670
  title: 'Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in POLG-related disorders: 6-month interim results of an open-label, single arm, phase 2 trial.'
- reference: PMID:42296640
  title: Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.
- reference: clinicaltrials:NCT03034512
  title: Natural History Study of Alpers Huttenlocher Syndrome
- reference: clinicaltrials:NCT04378075
  title: Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
- reference: clinicaltrials:NCT04802707
  title: A Phase II, Monocenter, Single Arm Study To Assess The Safety and Efficacy Of Combination Deoxycytidine and Deoxythymidine For Mitochondrial Depletion Disorders
- reference: clinicaltrials:NCT05218655
  title: An Open-Label, Safety Study for Previously Treated Vatiquinone (PTC743) Subjects With Inherited Mitochondrial Disease
- reference: url:https://clinicaltrials.gov/api/v2/studies/NCT04378075
  title: https://clinicaltrials.gov/api/v2/studies/NCT04378075
- reference: url:https://clinicaltrials.gov/api/v2/studies/NCT05218655
  title: https://clinicaltrials.gov/api/v2/studies/NCT05218655
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
  title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
notes: This entry covers POLG-related Alpers-Huttenlocher syndrome (mitochondrial DNA depletion syndrome 4A), rather than all early-onset POLG disease. Historical clinically defined Alpers cohorts may include individuals without molecular confirmation or with other genetic causes. Myocerebrohepatopathy and juvenile/adult POLG phenotypes overlap but are not interchangeable with this syndrome. Frequencies from mixed POLG cohorts are not assigned to Alpers phenotypes; the 2017 study explicitly identifies an Alpers subgroup of 19. Mechanistic experiments retain their allele, tissue and model limitations. The falcon deep-research report was checked against primary sources and the complete GeneReviews chapter.
inheritance:
- name: Autosomal recessive
  description: Alpers-Huttenlocher syndrome due to POLG is associated with biallelic pathogenic or likely pathogenic variants, usually inherited from asymptomatic heterozygous parents. Parental testing establishes phase and recurrence risk. If both parents carry one familial pathogenic variant, each pregnancy has a 25% chance of an affected child; severity can differ between siblings. Common POLG polymorphisms and dominant POLG-associated ophthalmoplegia require separate interpretation.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - &id001
    reference: PMID:20138553
    reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Molecular studies revealed homozygous p.R597W or p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S.
    explanation: Biallelic genotypes in four selected patients with subsequent valproate-associated liver failure.
  - reference: PMID:20301791
    reference_title: POLG-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: If both parents are known to be heterozygous for a POLG pathogenic variant, each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants and being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial POLG pathogenic variants.
    explanation: GeneReviews recurrence-risk counseling.
genetic:
- name: POLG
  gene_term:
    preferred_term: POLG
    term:
      id: hgnc:9179
      label: POLG
  relationship_type: CAUSATIVE
  notes: POLG encodes the catalytic subunit of mitochondrial DNA polymerase gamma. Pathogenic alleles can impair catalysis, processivity, DNA binding, proofreading or protein stability; effects differ between alleles and do not imply complete loss of all enzyme functions. Recurrent p.Ala467Thr is associated with several POLG phenotypes, so its presence alone does not determine Alpers severity. Common p.Gln1236His and p.Glu1143Gly substitutions are not equivalent to biallelic Alpers-causing variants.
  evidence:
  - reference: PMID:20138553
    reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Molecular studies revealed homozygous p.R597W or p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations, p.A467T/p.Q68X and p.L83P/p.G888S.
    explanation: Primary molecular diagnoses in the selected case series.
  - reference: PMID:16024923
    reference_title: The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in kcat with minimal effect on exonuclease function.
    explanation: Allele-specific recombinant-enzyme result; the available abstract does not provide complete assay methods.
pathophysiology:
- name: Biallelic Pathogenic POLG Variation
  description: Biallelic pathogenic POLG variants cause the molecularly defined Alpers phenotype. The combination of alleles and other modifiers influences presentation; a common polymorphism alone is not the initiating lesion modeled here.
  biological_scale: MOLECULAR
  evidence:
  - *id001
  downstream:
  - target: Reduced DNA Polymerase Gamma Function
    description: Pathogenic alleles can compromise catalytic performance or protein abundance through allele-specific defects.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16024923
      reference_title: The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in kcat with minimal effect on exonuclease function.
      explanation: Direct functional evidence for A467T, not a uniform effect of every clinical allele.
  - target: Impaired Polymerase Gamma Holoenzyme Assembly
    description: A subset of interface variants impairs association with the accessory subunit.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Thus, the A449T mutation significantly reduces the interaction between POLγA and POLγB subunits.
      explanation: Direct biochemical evidence for mouse A449T corresponding to human A467T; not every pathogenic allele.
  - target: Neurodevelopmental Delay
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28471437
      reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Hypotonia 6/6 (100%) 15/17 (88%) Developmental delay 6/6 (100%) 16/19 (84%) Seizures 0/6 (0%) 19/19 (100%)
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  - target: Hypotonia
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28471437
      reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Hypotonia 6/6 (100%) 15/17 (88%) Developmental delay 6/6 (100%) 16/19 (84%)
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  - target: Failure to Thrive
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30021052
      reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      directness: INDIRECT
      snippet: Other symptoms include developmental delay, failure to thrive, hypotonia, spasticity and ataxia.
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  - target: Peripheral Neuropathy
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20138553
      reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: EMG examination demonstrated a moderate to severe symmetric sensory and motor axonal peripheral neuropathy of lower extremities.
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  - target: Nystagmus
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: All neurologic signs and symptoms, including ataxia and nystagmus, may worsen during infections or with other physiologic stressors.
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  - target: Feeding Difficulties
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis.
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  - target: Dysphagia
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: A feeding eval &#x00026;/or radiographic swallowing study should be considered when showing clinical signs or symptoms of dysphagia.
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  - target: Vomiting
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30021052
      reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Symptoms preceding seizure onset often included headaches, vomiting and visual abnormalities (including visual hallucinations and visual blindness).
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  - target: Headache
    description: A reported manifestation of POLG-related Alpers disease through incompletely resolved downstream mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30021052
      reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Symptoms preceding seizure onset often included headaches, vomiting and visual abnormalities (including visual hallucinations and visual blindness).
      explanation: Clinical evidence supports this reported manifestation of the POLG-related syndrome. The intervening tissue and cellular mechanism for this feature is not resolved by this source.
  genes:
  - preferred_term: POLG
    term:
      id: hgnc:9179
      label: POLG
- name: Reduced DNA Polymerase Gamma Function
  description: Reduced catalytic activity and/or processivity impairs mitochondrial genome maintenance. Recombinant A467T retains residual polymerase activity and relatively preserved exonuclease function; other alleles need not have the same biochemical profile.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:16024923
    reference_title: The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in kcat with minimal effect on exonuclease function.
    explanation: Allele-specific biochemical result.
  downstream:
  - target: Impaired Mitochondrial DNA Replication
    description: Reduced polymerase performance compromises synthesis of mitochondrial DNA.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Polymerase (pol) gamma is the major DNA polymerase in humans required for replication and repair of mtDNA.
      explanation: Review establishes the enzyme function; quantitative impairment is allele-specific.
  molecular_functions:
  - preferred_term: DNA-directed DNA polymerase activity
    term:
      id: GO:0003887
      label: DNA-directed DNA polymerase activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
- name: Impaired Mitochondrial DNA Replication
  description: Impaired synthesis and maintenance of mitochondrial genomes can reduce copy number as tissues develop and genomes turn over. Depletion is tissue- and stage-dependent, so an initially normal muscle assay does not exclude the disorder.
  biological_scale: MOLECULAR
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Polymerase (pol) gamma is the major DNA polymerase in humans required for replication and repair of mtDNA.
    explanation: Established mitochondrial polymerase function.
  downstream:
  - target: Mitochondrial DNA Depletion
    description: Impaired genome maintenance can lead to net loss of mitochondrial DNA copies.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:16024923
      reference_title: The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: We propose that reduced polymerase activity and loss of accessory subunit interaction are responsible for the depletion and deletion of mitochondrial DNA observed in patients with this POLG mutation.
      explanation: Authors connect biochemical defects to patient depletion; this mechanistic bridge was not a longitudinal patient experiment.
  biological_processes:
  - preferred_term: mitochondrial DNA replication
    term:
      id: GO:0006264
      label: mitochondrial DNA replication
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
- name: Mitochondrial DNA Depletion
  description: Reduced mitochondrial genome copy number occurs in affected tissues and in Alpers patient-derived neural stem cells. It is not uniformly detectable in all tissues or at every disease stage. TFAM staining in organoids is a proxy; the neural-stem-cell experiment also used mtDNA/nuclear-DNA qPCR.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:38385069
    reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: To corroborate the reduction in the mtDNA levels as observed through the ND1/APP measurements in Alpers' NSCs, we performed qPCR (Figure 2P), which confirmed the same.
    explanation: Primary qPCR in neural stem cells from one A467T/P589L donor; no isogenic control.
  downstream:
  - target: Respiratory Chain Deficiency
    description: Loss of mitochondrial genomes reduces production of mtDNA-encoded respiratory-chain components through transcription, translation and complex assembly.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The loss of mtDNA results in loss of normal mitochondrial translation as well as loss of function involving mtDNA-encoded subunits found in complexes I, III, IV, and V.
      explanation: Review-supported bridge includes mitochondrial gene expression and complex assembly.
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
- name: Respiratory Chain Deficiency
  description: Respiratory-chain impairment is prominent in vulnerable neurons. Postmortem Alpers tissue showed reduced complex I and, more variably, complex IV subunit immunoreactivity; those assays estimate dysfunction from protein abundance rather than directly measuring electron flux. Neural stem-cell experiments also showed complex I/IV protein loss.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We showed that occipital cortex GABAergic interneurons and pyramidal neurons, as well as Purkinje cells in the cerebellum, exhibited extensive respiratory chain defects as evidenced by significant downregulation of complex I subunit proteins and milder downregulation of complex IV subunit proteins.
    explanation: Postmortem study of 13 clinically defined cases, only five with confirmed POLG genotypes; examined regions were limited.
  downstream:
  - target: Reduced Cellular ATP Availability
    description: Impaired oxidative phosphorylation contributes to reduced cellular energy availability.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The result is loss of normal ATP production and elevated free radical production and other mitochondrial functions, with resultant injury to neurons and other cells.
      explanation: Review-supported consequence; cellular ATP abundance does not directly measure synthesis flux.
  - target: Increased Mitochondrial Oxidative Stress
    description: Respiratory dysfunction can contribute to ROS imbalance; increased probe signals were observed in Alpers neural stem cells.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38385069
      reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: For Alpers' NSCs, a significant increase was observed in specific intracellular ROS (DCFDA/MTDR) and mitochondrial ROS at both total (MitoSOX Red) and specific level (MitoSOX Red/MTG) when compared to control NSCs
      explanation: Primary association in the differentiated model, not proof of a unique electron-leak site.
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
- name: Reduced Cellular ATP Availability
  description: Cellular ATP availability is reduced in differentiated Alpers neural stem cells, whereas the corresponding pluripotent cells did not show a significant ATP deficit. Energy failure is a proposed contributor to neural and hepatic injury rather than a universal measured state in every cell.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:38385069
    reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: A direct measurement of intracellular ATP production revealed a marked decrease in ATP production in Alpers' NSCs compared to the control NSCs
    explanation: Cell-normalized luminescent assay measured ATP abundance, not an isolated oxidative-phosphorylation production rate.
  downstream:
  - target: Cortical Neuronal Loss
    description: Bioenergetic dysfunction may contribute to cortical neurodegeneration; postmortem observations cannot establish temporal sequence.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The result is loss of normal ATP production and elevated free radical production and other mitochondrial functions, with resultant injury to neurons and other cells.
      explanation: Mechanistic synthesis; seizures and other stresses may also contribute.
  - target: Purkinje Cell Loss
    description: Bioenergetic dysfunction may contribute to cerebellar degeneration.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The result is loss of normal ATP production and elevated free radical production and other mitochondrial functions, with resultant injury to neurons and other cells.
      explanation: General injury mechanism; the postmortem association does not prove a direct causal step.
  - target: Hepatocellular Injury
    description: Mitochondrial dysfunction can impair hepatocyte function and survival through incompletely resolved tissue-specific mechanisms.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The result is loss of normal ATP production and elevated free radical production and other mitochondrial functions, with resultant injury to neurons and other cells.
      explanation: General mitochondrial injury mechanism applied to the established hepatic phenotype.
- name: Increased Mitochondrial Oxidative Stress
  description: Increased mitochondrial ROS probe signals and altered antioxidant transcription were observed in Alpers-derived neural stem cells. This is experimental evidence from one donor, not proof that oxidative stress is the initiating event in patient brains.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:38385069
    reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: For Alpers' NSCs, a significant increase was observed in specific intracellular ROS (DCFDA/MTDR) and mitochondrial ROS at both total (MitoSOX Red) and specific level (MitoSOX Red/MTG) when compared to control NSCs
    explanation: Differentiated-cell result; pluripotent cells did not show the same ROS pattern.
  downstream:
  - target: Cortical Neuronal Loss
    description: Oxidative stress may contribute to neuronal injury; necessity or sufficiency was not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The result is loss of normal ATP production and elevated free radical production and other mitochondrial functions, with resultant injury to neurons and other cells.
      explanation: Review synthesis supports a possible contribution, not an isolated rescue experiment.
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
- name: Cortical Neuronal Loss
  description: Reduced densities of inhibitory interneurons and pyramidal neurons were observed in occipital cortex at autopsy, with gliosis and areas of laminar necrosis. Loss was similar between these two populations; respiratory-chain deficiency was more pronounced in interneurons. Regional specificity and a within-patient sequence from deficiency to cell loss were not demonstrated.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Quantification revealed reduced densities of both interneurons (Figure 5A) and pyramidal neurons (Figure 5B) throughout patient cortical layers relative to controls suggestive of interneuron and pyramidal neuron loss.
    explanation: End-stage histology; cell-density measurements were descriptive because of small sample size.
  downstream:
  - target: Reduced Cortical Inhibition
    description: Dysfunction and loss of inhibitory interneurons may reduce inhibitory network control.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30021052
      reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Since interneurons often function as modulators of cortical neuron activity, the loss of any inhibitory activity could potentially lead to a lower seizure threshold and increase the probability of neuronal network becoming hyperexcitable.
      explanation: Authors' mechanistic interpretation; no electrophysiologic perturbation experiment in these patients.
  - target: Developmental Regression
    description: Progressive cortical dysfunction contributes to loss of acquired abilities.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Loss of neurologic function culminates in dementia, spastic quadriparesis from corticospinal tract involvement, visual loss, and death.
      explanation: Clinical-neuropathological synthesis; treatment sedation and seizures also affect function.
  - target: Cortical visual impairment
    description: Occipital cortical injury can compromise vision.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: As AHS evolves, neuroimaging shows gliosis (initially more pronounced in occipital lobe regions) and generalized brain atrophy.
      explanation: Anatomical inference combined with the separately documented visual phenotype.
  - target: Spasticity
    description: Progressive cortical/corticospinal dysfunction contributes to spasticity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The major motor manifestation is a progressive spastic paraparesis resulting from progressive loss of cortical neuronal function.
      explanation: Review explicitly connects cortical dysfunction with pyramidal motor signs.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
- name: Reduced Cortical Inhibition
  description: Reduced inhibitory interneuron function is a proposed contributor to cortical hyperexcitability. The human evidence is postmortem and the Alpers organoid evidence includes lower GAD65 staining and synaptic gene-set changes; neither directly measures the excitation-inhibition ratio in living patients.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: INDIRECT
    snippet: Although loss of interneurons and pyramidal cells was similar, the magnitude of respiratory chain deficiency was more pronounced in interneurons raising the possibility that the loss of inhibitory neural networks plays a role in the seizure development in these patients.
    explanation: Explicit hypothesis based on the neuropathological association.
  downstream:
  - target: Recurrent Seizure Activity
    description: Reduced inhibitory control may lower seizure threshold.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30021052
      reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Since interneurons often function as modulators of cortical neuron activity, the loss of any inhibitory activity could potentially lead to a lower seizure threshold and increase the probability of neuronal network becoming hyperexcitable.
      explanation: Hypothesized mechanistic contribution, not a proven sole driver.
- name: Recurrent Seizure Activity
  description: Epilepsy often begins focally and may progress to drug-resistant seizures, status epilepticus or epilepsia partialis continua. Initial control is possible in some children; refractory disease is not necessarily present from the first seizure.
  biological_scale: ORGANISM
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: In some children, seizures are initially controllable with standard dosages of anti-seizure medications (ASM); in others, seizures, such as EPC, are refractory from the onset. Over time, seizures become increasingly resistant to ASMs.
    explanation: GeneReviews clinical synthesis.
  downstream:
  - target: Focal Seizures
    description: Recurrent focal seizures may become medication resistant.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Over time, seizures become increasingly resistant to ASMs.
      explanation: Clinical progression.
  - target: Status Epilepticus
    description: Seizure activity can become sustained.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Over time, seizures can evolve into a complex epileptic disorder such as focal status epilepticus, EPC, or multifocal myoclonic epilepsy
      explanation: Clinical progression.
  - target: Epilepsia Partialis Continua
    description: Continuous focal motor seizure activity is a characteristic possible manifestation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: In some instances, the initial seizure type is epilepsia partialis continua (EPC), a classic motor seizure type that involves only one portion of the body (e.g., a limb) with constant and repetitive myoclonic jerking, continuing for hours or days with or without dramatic effects on consciousness.
      explanation: Clinical syndrome description.
  conforms_to: epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures
- name: Purkinje Cell Loss
  description: Reduced cerebellar Purkinje-cell density accompanies respiratory-chain protein deficiency in surviving cells. The study could not separate intrinsic mitochondrial injury from effects of seizures or treatment; loss did not correlate with residual-cell complex I/IV deficiency.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Quantification of Purkinje cell density revealed lower densities in patient cerebellum (Figure 6B) relative to controls.
    explanation: Descriptive postmortem cell counts.
  downstream:
  - target: Ataxia
    description: Cerebellar degeneration is a plausible contributor to ataxia; peripheral neuropathy can also impair coordination.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30021052
      reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: We believe interneuron and Purkinje cell pathology underpins the clinical development of seizures and ataxia seen in Alpers' syndrome.
      explanation: Authors' interpretation; not a causal intervention.
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  cell_types:
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
- name: Hepatocellular Injury
  description: Intrinsic hepatic disease can develop independently of valproate exposure. Hepatocyte loss, steatosis and architectural disruption can lead to impaired metabolic and synthetic function. The specific sequence connecting POLG dysfunction to hepatic injury remains incompletely resolved.
  biological_scale: TISSUE
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Liver histology may demonstrate macro- and microvesicular steatosis, centrilobular necrosis, disorganization of the normal lobular architecture, hepatocyte loss with or without bridging fibrosis or cirrhosis, regenerative nodules, bile duct proliferation, or mitochondrial proliferation with a vivid eosinophilic cytoplasm.
    explanation: Review of hepatic pathology.
  downstream:
  - target: Hepatic Failure
    description: Loss of viable hepatic tissue and function may progress to liver failure.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: End-stage liver disease is often heralded by hypoalbuminemia and prolonged coagulation time, followed shortly thereafter by fasting hypoglycemia and hyperammonemia.
      explanation: Clinical course of synthetic and metabolic failure.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
- name: Valproate-Associated Hepatocellular Injury
  description: Valproate can precipitate or accelerate severe liver injury in POLG-related disease, including without pre-existing biochemical liver disease. The molecular mediator is unresolved. The 2010 muscle-cell and yeast experiments neither established hepatocyte regeneration failure nor excluded liver-specific mtDNA or fatty-acid mechanisms.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:20138553
    reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure
    explanation: Clinical drug-associated risk.
  - reference: PMID:21038416
    reference_title: Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Human hepatocyte cell lines from patients with POLG variants are not available.
    explanation: The mechanistic cell experiments used muscle cells, so their negative results cannot exclude liver-specific mechanisms.
  downstream:
  - target: Hepatocellular Injury
    description: Valproate exposure can add a drug-associated injury pathway to the intrinsic hepatic vulnerability.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20138553
      reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure
      explanation: Clinical causal attribution; intracellular mediator remains unresolved.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
- name: Impaired Polymerase Gamma Holoenzyme Assembly
  description: Mouse A449T and corresponding human A467T impair productive interaction between catalytic POLG and accessory POLG2 subunits. Assembly is reduced, not absent. This allele-specific route is separate from the measured DNA-binding and long-template synthesis defects.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:33956154
    reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Thus, the A449T mutation significantly reduces the interaction between POLγA and POLγB subunits.
    explanation: Reconstituted-protein assembly assay.
  downstream:
  - target: Increased Degradation of Unprotected POLG
    description: Reduced accessory-subunit protection permits LONP1-dependent degradation of the catalytic subunit.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: In contrast, mPOLγB was unable to efficiently block degradation of mPOLγAA449T and the levels of the mutant protein decreased significantly over the time of the experiment
      explanation: Direct proteolysis assay; free mutant and free wild-type proteins were degraded at similar rates.
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
- name: Increased Degradation of Unprotected POLG
  description: LONP1 degrades unprotected catalytic polymerase gamma in an ATP-dependent assay. The mutant difference is incomplete protection by POLG2 in the assembled mixture, not intrinsically faster degradation of free mutant protein. Additional proteases may contribute in vivo.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:33956154
    reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: In contrast, mPOLγB was unable to efficiently block degradation of mPOLγAA449T and the levels of the mutant protein decreased significantly over the time of the experiment
    explanation: Purified mouse-protein result, reproduced with human A467T.
  downstream:
  - target: Reduced POLG Protein Abundance
    description: Enhanced susceptibility to proteolysis provides an experimentally supported explanation for lower catalytic-subunit abundance.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: We conclude that the impaired interaction between POLγB and mPOLγAA449T leads to increased LONP1-dependent degradation of mPOLγAA449T.
      explanation: Assay directly supports degradation; its quantitative contribution in patient tissues is inferred.
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
- name: Reduced POLG Protein Abundance
  description: Lower catalytic-subunit abundance was observed in the A449T mouse model. HeLa LONP1 knockdown increased endogenous wild-type POLG protein, but no mutant-patient or clinical rescue was demonstrated.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:33956154
    reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The amount of mPOLγAA449T was reduced in the PolgA449T/A449T mice, which could also contribute to impaired mtDNA replication.
    explanation: Knock-in mouse tissue abundance result.
  downstream:
  - target: Reduced DNA Polymerase Gamma Function
    description: A reduced available catalytic-subunit pool can compound the intrinsic activity defect.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: The amount of mPOLγAA449T was reduced in the PolgA449T/A449T mice, which could also contribute to impaired mtDNA replication.
      explanation: Mechanistic inference from lower protein abundance and impaired replication.
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
phenotypes:
- name: Focal Seizures
  category: Neurological
  description: Focal seizures are characteristic and commonly become medication resistant. In the 2017 study, all 19 Alpers-classified patients had epilepsy; focal seizures were recorded in 14/19 and therapy resistance in 17/19. These selected retrospective data do not establish universal focal onset.
  phenotype_term:
    preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Focal 14/19 (74%) Infantile spasm 1/19 (5%) Therapy-resistant epilepsy 17/19 (89%)
    explanation: Seizure-type denominator corresponds to the Alpers subgroup; phenotype binding describes focal onset, not medication resistance.
  frequency: FREQUENT
- name: Status Epilepticus
  category: Neurological
  description: Sustained seizure activity can be presenting or emerge during progression. The 2017 Alpers subgroup recorded status epilepticus in 13/19; broader POLG status cohorts are not used as Alpers frequency estimates.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Myoclonic 13/19 (68%) Status epilepticus 13/19 (68%) Epilepsia partialis continua 11/19 (58%)
    explanation: Alpers seizure subgroup; retrospective ascertainment.
  frequency: FREQUENT
- name: Epilepsia Partialis Continua
  category: Neurological
  description: Continuous focal motor seizures may last hours or days. EEG can show only focal slowing or appear normal during clinically apparent EPC.
  phenotype_term:
    preferred_term: Epilepsia partialis continua
    term:
      id: HP:0012847
      label: Epilepsia partialis continua
  evidence:
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Myoclonic 13/19 (68%) Status epilepticus 13/19 (68%) Epilepsia partialis continua 11/19 (58%)
    explanation: EPC in 11/19 of the Alpers subgroup.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: EPC is not always apparent as an abnormality on EEG and can be mistaken for a conversion reaction. EEG may be normal or show only focal slowing of the background rhythm.
    explanation: Review warns against excluding EPC on EEG alone.
  frequency: FREQUENT
- name: Developmental Regression
  category: Neurological
  description: Loss of acquired motor, language or cognitive skills has variable timing and can accelerate during illness or severe seizures. Prior development is not always normal.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Significant sudden or rapid regression is often seen during infectious illnesses. The clinical manifestations may include somnolence, loss of concentration, loss of language skills (both receptive and expressive), irritability with loss of normal emotional responses, and memory deficits.
    explanation: Alpers-specific natural-history synthesis.
- name: Neurodevelopmental Delay
  category: Neurological
  description: Developmental delay may precede recognized regression. Table 3 of the 2017 study reports delay in 16/19 Alpers patients; this does not require every child to have global developmental delay.
  phenotype_term:
    preferred_term: Neurodevelopmental delay
    term:
      id: HP:0012758
      label: Neurodevelopmental delay
  evidence:
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Hypotonia 6/6 (100%) 15/17 (88%) Developmental delay 6/6 (100%) 16/19 (84%) Seizures 0/6 (0%) 19/19 (100%)
    explanation: Table 3 columns are MCHS then Alpers; use the Alpers-specific denominator rather than pooled 24/24.
  frequency: VERY_FREQUENT
- name: Hypotonia
  category: Neurological
  description: Reduced tone is common early and can coexist with neuropathy or evolve toward pyramidal signs. Hypotonia occurred in 15/17 assessable Alpers patients in the 2017 cohort.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Hypotonia 6/6 (100%) 15/17 (88%) Developmental delay 6/6 (100%) 16/19 (84%)
    explanation: Alpers-specific table column; not the pooled early-onset estimate.
  frequency: VERY_FREQUENT
- name: Hepatic Failure
  category: Hepatic
  description: Hepatic disease ranges from biochemical or synthetic dysfunction to liver failure and may occur spontaneously or after valproate exposure. Liver involvement is not synonymous with failure; no failure frequency is inferred from the cohort's liver-dysfunction count.
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: End-stage liver disease is often heralded by hypoalbuminemia and prolonged coagulation time, followed shortly thereafter by fasting hypoglycemia and hyperammonemia.
    explanation: Alpers-specific description of hepatic decompensation.
- name: Failure to Thrive
  category: Growth
  description: Poor growth can accompany feeding difficulties and progressive systemic disease. The 24/27 growth estimate in the original entry came from a mixed early-onset POLG cohort and is not an Alpers-specific frequency.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: Other symptoms include developmental delay, failure to thrive, hypotonia, spasticity and ataxia.
    explanation: Background description of Alpers clinical features.
- name: Ataxia
  category: Neurological
  description: Cerebellar dysfunction and peripheral neuropathy can both contribute to impaired coordination. Patients dying rapidly may not develop recognizable ataxia.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We believe interneuron and Purkinje cell pathology underpins the clinical development of seizures and ataxia seen in Alpers' syndrome.
    explanation: Clinical feature and proposed pathological correlate; causal direction remains inferential.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: develop in all persons with AHS unless the disease process is so rapid that it results in early death. All neurologic signs and symptoms, including ataxia and nystagmus, may worsen during infections or with other physiologic stressors.
    explanation: Chapter discusses neuropathy and ataxia with a survival-dependent qualification.
- name: Spasticity
  category: Neurological
  description: Progressive pyramidal motor signs can emerge after early hypotonia and advance to spastic paresis.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The major motor manifestation is a progressive spastic paraparesis resulting from progressive loss of cortical neuronal function.
    explanation: Alpers-specific motor progression.
- name: Cortical visual impairment
  category: Ophthalmological
  description: Progressive cortical visual dysfunction can lead to blindness; retinal disease can also contribute and should be assessed separately.
  phenotype_term:
    preferred_term: Cerebral visual impairment
    term:
      id: HP:0100704
      label: Cerebral visual impairment
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: Concomitant symptoms may also include cortical blindness, vomiting, headaches, and hemianopia.
    explanation: Background clinical description identifies cortical visual involvement.
- name: Peripheral Neuropathy
  category: Neurological
  description: Peripheral nerve involvement can cause reduced reflexes, weakness and sensory contributions to ataxia. Its prominence depends on survival and disease stage.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:20138553
    reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: EMG examination demonstrated a moderate to severe symmetric sensory and motor axonal peripheral neuropathy of lower extremities.
    explanation: Documented peripheral neuropathy in a later-presenting biallelic POLG case; no childhood frequency is inferred.
- name: Nystagmus
  category: Ophthalmological
  description: Nystagmus can accompany cerebellar or other neurological involvement and may worsen with physiological stress.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: All neurologic signs and symptoms, including ataxia and nystagmus, may worsen during infections or with other physiologic stressors.
    explanation: Alpers-specific symptom description.
- name: Feeding Difficulties
  category: Gastrointestinal
  description: Feeding impairment can compromise growth and increase aspiration risk; clinical assessment guides nutritional support.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features. This group has the worst prognosis.
    explanation: Broader early-onset POLG summary supports relevance without an Alpers-specific frequency.
- name: Dysphagia
  category: Gastrointestinal
  description: Swallowing dysfunction can arise with neurological deterioration; assessment distinguishes safe oral feeding from a need for assisted nutrition.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: A feeding eval &#x00026;/or radiographic swallowing study should be considered when showing clinical signs or symptoms of dysphagia.
    explanation: Management chapter recognizes dysphagia; no frequency is inferred.
- name: Vomiting
  category: Gastrointestinal
  description: Vomiting may occur before or during neurological episodes and also contributes to poor intake. It is not specific to Alpers.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Symptoms preceding seizure onset often included headaches, vomiting and visual abnormalities (including visual hallucinations and visual blindness).
    explanation: Historical clinical cohort with only five confirmed POLG genotypes.
- name: Headache
  category: Neurological
  description: Headaches may be associated with visual phenomena and precede recognized seizures in some patients.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Symptoms preceding seizure onset often included headaches, vomiting and visual abnormalities (including visual hallucinations and visual blindness).
    explanation: Observed clinical feature in the neuropathology cohort; no population frequency.
biochemical:
- name: Blood and cerebrospinal fluid lactate
  presence: INCREASED
  biomarker_term:
    preferred_term: lactate
    term:
      id: CHEBI:24996
      label: lactate
  context: Lactate may be elevated but a normal value does not exclude POLG-related Alpers. The 2017 mixed early-onset cohort found increased blood lactate in 12/20 and CSF lactate in 2/5 at presentation; these are not Alpers-specific sensitivities.
  evidence:
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Laboratory investigations at presentation revealed increased lactate in blood in 60% ( n = 12/20) and in cerebrospinal fluid in 40% ( n = 2/5).
    explanation: Primary mixed-cohort observation with incomplete testing.
- name: Hepatic synthetic and metabolic dysfunction
  presence: VARIABLE
  context: Aminotransferase elevation, low albumin, prolonged coagulation times, hypoglycemia or hyperammonemia can accompany hepatic involvement. Synthetic dysfunction can be clinically important even when isolated enzyme measurements are not striking.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Evidence of liver dysfunction or failure can be present, which may occur following exposure to certain anti-seizure medications.
    explanation: Review of hepatic manifestations.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: End-stage liver disease is often heralded by hypoalbuminemia and prolonged coagulation time, followed shortly thereafter by fasting hypoglycemia and hyperammonemia.
    explanation: Alpers-specific hepatic progression.
- name: Elevated cerebrospinal fluid protein
  presence: INCREASED
  context: CSF protein may be elevated and can support suspicion in the appropriate presentation; it is nonspecific and not required for molecular diagnosis.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: CSF protein levels are generally elevated in individuals with Alpers-Huttenlocher syndrome (AHS) and other
    explanation: Alpers explicitly included in the chapter description; the observation is not specific to this syndrome.
histopathology:
- name: Alpers liver injury pattern
  description: Steatosis, centrilobular necrosis, hepatocyte loss, architectural disorganization, fibrosis/cirrhosis, regenerative nodules and bile-duct proliferation form a variable constellation. Historical criteria used at least two characteristic features, but biopsy is not required when molecular and clinical findings establish the diagnosis; it may be unsafe in severe coagulopathy.
  diagnostic: false
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Liver histology may demonstrate macro- and microvesicular steatosis, centrilobular necrosis, disorganization of the normal lobular architecture, hepatocyte loss with or without bridging fibrosis or cirrhosis, regenerative nodules, bile duct proliferation, or mitochondrial proliferation with a vivid eosinophilic cytoplasm.
    explanation: Review synthesis of the characteristic but variable pattern.
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: liver biopsy is rarely performed in the neonatal and pediatric setting, because of the attendant risks of morbidity and mortality.
    explanation: Clinical discussion explains limited use of biopsy.
- name: Cortical neuronal loss and gliosis
  description: Laminar neuronal loss, spongiform change, astrocytosis and focal necrosis affect cortex, often with prominent occipital injury. Purkinje-cell loss can accompany cerebellar involvement. These are pathological observations rather than proof of a uniquely occipital initiating defect.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Early in the course of the disease, spongiosis, astrocytosis, and neuronal loss are prevalent in the superficial cortex. Later, the deeper laminae are affected.
    explanation: Review synthesis.
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Quantification revealed reduced densities of both interneurons (Figure 5A) and pyramidal neurons (Figure 5B) throughout patient cortical layers relative to controls suggestive of interneuron and pyramidal neuron loss.
    explanation: Descriptive postmortem neuronal-density findings.
progression:
- phase: Variable childhood or later presentation
  age_range: Usually ages two to four years; reported range one month to 36 years
  notes: Children may initially develop normally, but developmental delay can precede recognized neurodegeneration. Seizures, visual symptoms, poor growth or hepatic disease may bring the child to attention; a fixed brain-then-liver sequence is not required.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Children with AHS appear healthy at birth and may develop normally over the first few weeks to years of life. Some have variable degrees of developmental delay prior to the initial recognition of neurodegeneration. Onset is usually between ages two and four years but ranges overall from one month to 36 years.
    explanation: Alpers-specific onset synthesis.
- phase: Progressive neurological and hepatic involvement
  notes: Seizures often become resistant to medication, and regression, spasticity, visual loss or ataxia can accumulate. Hepatic involvement has variable timing and can be precipitated or accelerated by valproate. Intercurrent illness may trigger abrupt decline.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: In some children, seizures are initially controllable with standard dosages of anti-seizure medications (ASM); in others, seizures, such as EPC, are refractory from the onset. Over time, seizures become increasingly resistant to ASMs.
    explanation: Variable seizure progression.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Significant sudden or rapid regression is often seen during infectious illnesses.
    explanation: Stress-associated deterioration.
- phase: Variable survival with risk of fatal decompensation
  notes: The course is usually life limiting, but survival is variable and may include periods of stability. GeneReviews describes three months to 12 years from symptom onset. The 2017 Alpers subgroup had a median reported survival of four months (range 0.5–181 months); the pooled cohort's median age at death must not be treated as a universal Alpers prognosis.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The rate of neurodegeneration varies and is marked by periods of stability. The typical life expectancy from onset of first symptoms ranges from three months to 12 years.
    explanation: Review summary; not an individual prognostic prediction.
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Twenty-seven patients (15 male, 12 female) from 22 pedigrees (including two patients from
      consanguineous families) with genetically confirmed POLG mutations were identified. ... Of 27
      patients, four were alive at the time of data analysis, and one had been lost to follow-up.
      Median age at death was 15.8 months (range 1.0 to 184.6 months), whereas median time from
      disease onset to death was 4.9 months (range 0.5 to 181.2 months). The main causes of death
      were liver failure (13/22), sepsis (5/22), and status epilepticus (4/22). ... Survival
      analysis by phenotype showed that the median survival time for patients with MCHS was 5 months
      (range 0.6 –22) and 4 months (range 0.5 –181) for Alpers.
    explanation: >-
      Reports survival in a mixed early-onset POLG cohort, including Alpers and
      myocerebrohepatopathy. Pooled age-at-death and cause-of-death statistics must not be presented
      as Alpers-only estimates; the phenotype-specific median is retained.
treatments:
- name: Avoidance of Valproate and Divalproex
  description: Avoid valproate and divalproex in established POLG-related Alpers, including before hepatic dysfunction is apparent. This precaution is supported by clinical reports, GeneReviews and the 2024 mitochondrial-epilepsy consensus. The 2024 published-case review confirms severe outcomes but cannot estimate an unbiased individual risk.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Avoidance of Valproate and Divalproex
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - &id002
    reference: PMID:38576261
    reference_title: 'Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Valproic acid is contraindicated in patients with pathogenic variants in POLG
    explanation: Consensus contraindication for POLG disease, not a claim about all common polymorphisms.
  - reference: PMID:38860231
    reference_title: 'Evidence for sodium valproate toxicity in mitochondrial diseases: a systematic analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: There was no pre-existing liver disease in 92/102 patients (90%).
    explanation: Selected published POLG cases exposed to valproate; absence of baseline liver disease does not eliminate risk.
  target_mechanisms:
  - target: Valproate-Associated Hepatocellular Injury
    treatment_effect: INHIBITS
    description: Avoidance removes the drug exposure that can trigger hepatic injury.
    evidence:
    - *id002
- name: Rapid Molecular Evaluation When POLG Disease Is Suspected
  description: In a child with early-onset epilepsy and features suggesting POLG disease, arrange prompt comprehensive genetic evaluation before considering valproate. Testing strategy and seizure treatment proceed with specialist input; a negative small founder panel or common-variant result does not safely exclude Alpers.
  action_category: DIAGNOSTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Rapid Molecular Evaluation When POLG Disease Is Suspected
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:38860231
    reference_title: 'Evidence for sodium valproate toxicity in mitochondrial diseases: a systematic analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: clinicians should consider requesting rapid genomic testing in children with early-onset epilepsies where POLG-mitochondrial disease is a differential diagnosis, prior to commencing VPA.
    explanation: Systematic-review recommendation focused on suspected POLG disease.
- name: Individualized Non-Valproate Antiseizure Therapy
  description: Use specialist-led treatment matched to seizure type and clinical condition. The 2024 consensus generally follows standard epilepsy guidance for children older than 28 days and adults, with the POLG valproate contraindication and other patient-specific restrictions. Levetiracetam and several other ASMs are not generally contraindicated by mitochondrial disease alone, but this does not establish comparative Alpers efficacy. Lamotrigine may worsen myoclonus; topiramate warrants caution with renal tubular acidosis.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Individualized Non-Valproate Antiseizure Therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - &id003
    reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Many ASMs may be effective; none has been demonstrated effective specifically for this disorder.
    explanation: GeneReviews distinguishes individualized treatment from proven Alpers-specific efficacy.
  - reference: PMID:38576261
    reference_title: 'Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: It is not contraindicated to use levetiracetam in adults and children with PMDs
    explanation: Safety consensus is not a disease-specific efficacy trial.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Treatment of epilepsy is similar to non-mitochondrial disease w/seizures. Lamotrigine may worsen myoclonic seizures.
    explanation: Seizure-type precaution.
  - reference: PMID:38576261
    reference_title: 'Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Topiramate should be used with caution in patients with PMD who are at particular risk for renal tubular acidosis.
    explanation: Patient-specific metabolic precaution.
  target_mechanisms:
  - target: Recurrent Seizure Activity
    treatment_effect: MODULATES
    description: Antiseizure treatment aims to reduce seizure activity without repairing the POLG defect.
    evidence:
    - *id003
- name: Emergency Status Epilepticus Management
  description: Treat convulsive status urgently using local specialist protocols, including benzodiazepines, subsequent non-valproate ASMs and intensive-care escalation when necessary. Anesthetic selection, respiratory support and metabolic monitoring are individualized. Prolonged propofol requires close monitoring for infusion syndrome. Retrospective multidrug use does not establish the efficacy of any one agent.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Emergency Status Epilepticus Management
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - &id004
    reference: PMID:38576261
    reference_title: 'Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: If the patient develops generalized, convulsive status epilepticus, management and when needed escalation to intensive care setting should follow the local status epilepticus guidelines (e.g., NICE Clinical Guidelines, SIGN guidelines, EFNS guidelines), except sodium valproate which is contraindicated in POLG patients
    explanation: Expert consensus supports prompt standard escalation with the genotype-specific exception.
  - reference: PMID:38576261
    reference_title: 'Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Propofol should be closely monitored for prolonged use in the context of refractory status epilepticus due to the risk of propofol infusion syndrome
    explanation: Precaution applies to prolonged use, not a blanket prohibition.
  target_mechanisms:
  - target: Status Epilepticus
    treatment_effect: MODULATES
    description: Acute treatment aims to terminate sustained seizures.
    evidence:
    - *id004
- name: Careful Management of Refractory EPC
  description: Balance seizure reduction against sedation, aspiration and ventilatory failure. Persistent EPC can be impossible to abolish, so escalating medication indefinitely may impose greater burden than benefit.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Careful Management of Refractory EPC
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Refractory epilepsy, esp EPC, may be impossible to control w/any treatment. In persons w/EPC, use of high-dose ASM may control the clinical seizures, but assoc obtundation &#x00026; subsequent risk of aspiration &#x00026; ventilatory failure may outweigh the benefit.
    explanation: Alpers-specific risk-benefit guidance.
  target_mechanisms:
  - target: Epilepsia Partialis Continua
    treatment_effect: MODULATES
    description: Individualized symptomatic management accounts for both seizure burden and treatment toxicity.
    evidence:
    - *id003
- name: Selected Adjuncts for Refractory Epilepsy
  description: Ketogenic diet or neuromodulation may be considered by specialist teams where appropriate, but Alpers-specific efficacy is unproven. In the 2024 mixed POLG status cohort, only 2/13 diet-treated patients reported benefit and both had juvenile/adult-onset disease; VNS was not used. Late rescue use and confounding prevent a definitive negative efficacy conclusion. Immunomodulatory therapies likewise lack demonstrated benefit for Alpers status.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Selected Adjuncts for Refractory Epilepsy
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The use of other treatments for refractory epilepsy, such as corticotropin or prednisone, ketogenic diet, and intravenous immunoglobulin G, are unproven in the treatment of AHS.
    explanation: Review clearly separates investigational adjuncts from proven therapy.
  - reference: PMID:38822839
    reference_title: 'Status epilepticus in POLG disease: a large multinational study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: KD was administered during an SE episode in 13 patients, with only two with juvenile to adult-onset disease reporting some effect on seizure control.
    explanation: Retrospective mixed-POLG observation, not an Alpers controlled trial.
  target_mechanisms:
  - target: Recurrent Seizure Activity
    treatment_effect: MODULATES
    description: Selected adjuncts aim to improve seizure control, with uncertain Alpers-specific benefit.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: The use of other treatments for refractory epilepsy, such as corticotropin or prednisone, ketogenic diet, and intravenous immunoglobulin G, are unproven in the treatment of AHS.
      explanation: Link denotes the intended clinical target and explicitly uncertain benefit.
- name: Hepatic and Metabolic Monitoring
  description: Assess liver enzymes and synthetic/metabolic function approximately every three months or as clinical circumstances require, with more frequent assessment during deterioration or after medication changes. GeneReviews suggests liver enzymes every 2–4 weeks after introducing a new ASM. Monitoring detects complications; it does not itself reverse hepatocyte injury.
  action_category: MONITORING
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Hepatic and Metabolic Monitoring
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301791
    reference_title: POLG-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: monitoring of liver enzymes every three months or as clinically indicated; monitoring of epilepsy with repeat liver function tests after introduction of any new anti-seizure medication.
    explanation: Review surveillance recommendation.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Because other ASMs may also accelerate liver deterioration, it is reasonable to monitor liver enzymes every 2-4 weeks after introducing any new ASM.
    explanation: Suggested intensified follow-up after treatment change.
- name: Support for Hepatic Decompensation
  description: Hepatology and metabolic teams manage hypoglycemia, hyperammonemia, nutritional needs and other liver-failure complications. Feeding schedules and ammonia-lowering strategies depend on clinical status. These measures support function without correcting the underlying mitochondrial defect.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Support for Hepatic Decompensation
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - &id005
    reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Treatment may incl small, frequent meals or continuous feeding to compensate for defective gluconeogenesis; reduction in dietary protein; use of non-absorbable sugars to create an osmotic diarrhea; &#x00026; use of conjugating agents to treat hyperammonemia.
    explanation: Specialist supportive hepatic/metabolic management; components are individualized.
  target_mechanisms:
  - target: Hepatic Failure
    treatment_effect: BYPASSES
    description: Supports metabolic consequences of liver failure.
    evidence:
    - *id005
- name: Liver Transplantation Assessment
  description: Liver transplantation is generally not advised for children with established Alpers because it does not halt progressive brain disease. Selected older patients with other POLG phenotypes have survived transplantation; those reports do not establish benefit for classic childhood Alpers. Decisions require multidisciplinary assessment of neurological trajectory and goals of care.
  action_category: COUNSELING_INFORMATIONAL
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Liver Transplantation Assessment
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Liver transplantation is not advised in children with Alpers-Huttenlocher syndrome (AHS) because transplanting the liver does not alter the rapid progression of the brain disease
    explanation: Alpers-specific limitation; broader POLG transplant experience is phenotype dependent.
- name: Feeding, Swallowing and Nutritional Support
  description: Assess growth, oral intake and aspiration risk; obtain swallow evaluation when indicated. Adapt feeds and feeding therapy, and use nasogastric or gastrostomy support for severe dysfunction when consistent with clinical goals. Tube feeding does not remove every source of aspiration.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Feeding, Swallowing and Nutritional Support
    term:
      id: NCIT:C65017
      label: Nutritional Therapy
  evidence:
  - &id006
    reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Placement of a gastric feeding tube when appropriate can maintain nutritional status &#x00026;/or prevent aspiration.
    explanation: Supportive nutritional intervention.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: When feeding dysfunction is severe, an NG-tube or G-tube may be necessary.
    explanation: Escalation for severe feeding impairment.
  target_mechanisms:
  - target: Feeding Difficulties
    treatment_effect: BYPASSES
    description: Provides nutrition when oral intake is inadequate or unsafe.
    evidence:
    - *id006
  - target: Dysphagia
    treatment_effect: BYPASSES
    description: Provides nutrition when oral intake is inadequate or unsafe.
    evidence:
    - *id006
  - target: Failure to Thrive
    treatment_effect: BYPASSES
    description: Provides nutrition when oral intake is inadequate or unsafe.
    evidence:
    - *id006
- name: Rehabilitation and Communication Support
  description: Offer physical, occupational and speech therapy, positioning and mobility equipment, educational accommodations and augmentative communication according to need. Goals include maintaining function, participation and comfort rather than reversing neurodegeneration.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Rehabilitation and Communication Support
    term:
      id: NCIT:C15315
      label: Rehabilitation
  evidence:
  - &id007
    reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: OT, PT, &#x00026; ST are indicated in AHS to maintain or improve neurologic function for as long as possible &#x00026; for comfort care.  # codespell:ignore-line
    explanation: Alpers-specific rehabilitation recommendation.
  target_mechanisms:
  - target: Developmental Regression
    treatment_effect: MODULATES
    description: Supports retained function and adaptation to changing abilities.
    evidence:
    - *id007
- name: Spasticity and Movement-Disorder Management
  description: Use rehabilitation and individualized symptom-directed medications for painful or function-limiting spasticity and movement disorders. Balance benefit against sedation and respiratory or swallowing impairment.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Spasticity and Movement-Disorder Management
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - &id008
    reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The use of benzodiazepines often &#x02193; severity of abnormal movements &#x00026; also assists in seizure control &#x00026; reduction of spasticity.
    explanation: Symptomatic movement and tone management; sedation and respiratory effects remain relevant.
  target_mechanisms:
  - target: Spasticity
    treatment_effect: MODULATES
    description: Reduces symptomatic tone and movement burden.
    evidence:
    - *id008
- name: Respiratory and Sleep Support
  description: Monitor for aspiration and respiratory insufficiency; assess sleep-related apnea or hypoventilation when indicated. Noninvasive or invasive ventilatory support is individualized according to physiology, disease trajectory and goals of care.
  action_category: THERAPEUTIC
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: Respiratory and Sleep Support
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Treatment w/CPAP, BiPAP, or more invasive ventilatory therapy as indicated.
    explanation: Supportive respiratory care in the POLG management chapter.
- name: Vision and Hearing Care
  description: Arrange ophthalmologic assessment, low-vision support and audiological evaluation according to symptoms. Correct treatable ocular or hearing problems and adapt communication and education to sensory impairment.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Vision and Hearing Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Clinical management is largely supportive and involves standard approaches for associated complications including occupational, physical, and speech therapy; nutritional support; respiratory support; and standard treatment of liver failure, epilepsy, movement abnormalities, sleep disorders, vision, and hearing issues.
    explanation: Chapter includes sensory care in multidisciplinary management.
  target_mechanisms:
  - target: Cortical visual impairment
    treatment_effect: MODULATES
    description: Supports function with visual impairment; it does not restore injured cortex.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
      reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Clinical management is largely supportive and involves standard approaches for associated complications including occupational, physical, and speech therapy; nutritional support; respiratory support; and standard treatment of liver failure, epilepsy, movement abnormalities, sleep disorders, vision, and hearing issues.
      explanation: Review includes supportive sensory care.
- name: Intercurrent-Illness Planning
  description: Provide an individualized plan for infection, fever, dehydration, poor intake or sudden neurological deterioration, with prompt assessment and supportive treatment. Caregiver seizure education and coordination between neurology, hepatology and metabolic teams reduce delays.
  action_category: COUNSELING_INFORMATIONAL
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Intercurrent-Illness Planning
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: As with some other mitochondrial diseases, physical stressors such as infection, fever, dehydration, and anorexia can result in a sudden deterioration and should be avoided if possible.
    explanation: Review identifies stress-related deterioration.
- name: Selective Cofactor Supplementation
  description: Routine mitochondrial supplement combinations have not demonstrated Alpers-specific benefit. Levocarnitine is generally reserved for documented low free carnitine, with monitoring. Folinic acid may be considered by metabolic specialists in the appropriate biochemical context; these measures are not established disease-modifying treatment.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Selective Cofactor Supplementation
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Vitamin and cofactor therapy with the intent to fortify mitochondrial function may be offered, yet there is insufficient evidence demonstrating objective benefit in cohorts of persons.
    explanation: Review limits the evidence.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The use of levocarnitine should be reserved for individuals with reduced free carnitine levels in the blood, and the levels should be monitored
    explanation: Specific biochemical selection.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The use of folinic acid should be considered
    explanation: Historical GeneReviews consideration; no controlled Alpers-specific efficacy is established.
- name: Palliative, Family and Care Coordination Support
  description: Integrate symptom relief, respite, home nursing and palliative care according to need throughout the disease course. Discuss treatment burden, comfort and family goals alongside active neurological and hepatic management.
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Palliative, Family and Care Coordination Support
    term:
      id: NCIT:C15292
      label: Palliative Therapy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Ongoing assessment of need for palliative care involvement &#x00026;/or home nursing (esp for persons w/AHS)
    explanation: Alpers-specific supportive-care emphasis.
- name: Genetic Counseling and Family Testing
  description: Offer parental testing, recurrence-risk counseling and targeted testing of relatives once familial pathogenic variants are known. Discuss prenatal and preimplantation testing options according to family preferences; asymptomatic siblings may still need evaluation because onset varies.
  action_category: COUNSELING_INFORMATIONAL
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling and Family Testing
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301791
    reference_title: POLG-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Once the POLG pathogenic variants have been identified in an affected family member, testing for at-risk family members is possible.
    explanation: Family testing requires the established familial variants.
- name: 'Nicotinamide Riboside: Preclinical Investigation'
  description: Nicotinamide riboside improved several neuronal and mitochondrial markers in one Alpers donor's cortical organoids. This result motivates further research but does not establish dosing, safety or benefit in affected children. It should not be presented as an established Alpers therapy.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: 'Nicotinamide Riboside: Preclinical Investigation'
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Nicotinamide riboside
      term:
        id: CHEBI:15927
        label: N-ribosylnicotinamide
  evidence:
  - &id009
    reference: PMID:38385069
    reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We observed that the NR-treated organoids exhibited organized structures (Figure 7B) and increased expression of MAP2 and Tuj1 compared to those untreated
    explanation: Primary treated-versus-untreated marker result.
  target_mechanisms:
  - target: Cortical Neuronal Loss
    treatment_effect: MODULATES
    description: Intended neuroprotective target supported only by organoid marker changes.
    evidence:
    - *id009
- name: 'Vatiquinone: Investigational Evidence'
  description: Vatiquinone has been investigated for mitochondrial disease with refractory epilepsy. The randomized MIT-E primary endpoint was not statistically significant in its mixed-disease population, and no Alpers-specific clinical benefit is established here. The later open-label safety study does not provide a controlled efficacy comparison. It is not presented as standard Alpers treatment.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: 'Vatiquinone: Investigational Evidence'
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Vatiquinone
      term:
        id: NCIT:C152840
        label: Vatiquinone
  evidence:
  - &id010
    reference: url:https://clinicaltrials.gov/api/v2/studies/NCT04378075
    reference_title: https://clinicaltrials.gov/api/v2/studies/NCT04378075
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: '"pValue":"= 0.173","statisticalMethod":"ANCOVA","paramType":"Median Difference (Final Values)","paramValue":"-8.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-31.3","ciUpperLimit":"16.4"'
    explanation: Posted primary motor-seizure analysis in 68 mixed mitochondrial-disease participants; not an Alpers-specific analysis.
  target_mechanisms:
  - target: Recurrent Seizure Activity
    treatment_effect: MODULATES
    description: Intended antiseizure target; the randomized primary endpoint did not establish efficacy.
    evidence:
    - *id010
- name: 'Deoxycytidine and Deoxythymidine: Clinical Investigation'
  description: Enteral deoxycytidine/deoxythymidine is being studied in recessive POLG disease. An initial 10-person report, including six Alpers participants, was followed by a 25-person mixed-POLG report from the same open-label program. Disease-scale and seizure improvements warrant further study, but unblinded assessment, cointerventions, missing observations and survival selection preclude a proven Alpers-specific benefit. Diarrhea sometimes required dose reduction; five deaths in the expanded cohort mean that absence of attributed serious drug toxicity is not proof of safety. This remains investigational for POLG disease, distinct from treatment of TK2 deficiency.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: 'Deoxycytidine and Deoxythymidine: Clinical Investigation'
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: 2'-deoxycytidine
      term:
        id: CHEBI:15698
        label: 2'-deoxycytidine
    - preferred_term: Deoxythymidine
      term:
        id: CHEBI:17748
        label: thymidine
  evidence:
  - &id012
    reference: PMID:39091670
    reference_title: 'Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in POLG-related disorders: 6-month interim results of an open-label, single arm, phase 2 trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We present 6-month interim data from the first ten people with POLG-related disorders enrolled in the trial, six with Alpers-Huttenlocher syndrome, two with ataxia-neuropathy spectrum, and two who do not fit into a classical POLG-related phenotype.
    explanation: Initial ten-person report included six Alpers patients; pooled results are not an Alpers-only estimate.
  - &id013
    reference: PMID:42296640
    reference_title: Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Twenty-five patients (14 males, 11 females) with POLG-related disorders meeting inclusion/exclusion criteria were enrolled and started dC/dT
    explanation: Expanded follow-up of the same NCT04802707 program, not an independent replication trial.
  - &id011
    reference: PMID:42296640
    reference_title: Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Of the patients with uncontrolled seizures at the time of enrollment, 10/14 (71%) had >50% improvement in seizures, including three who were seizure-free at last review.
    explanation: Uncontrolled observational seizure change in the mixed POLG cohort; concurrent treatment changes and selection limit attribution.
  - &id014
    reference: PMID:42296640
    reference_title: Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Patients were allowed to start, stop, or adjust other treatments during the trial, and this could influence our results.
    explanation: Explicit confounding in the open-label study.
  - reference: PMID:42296640
    reference_title: Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: No serious adverse effects were attributed to dC/dT. Diarrhea, the primary adverse event attributed to dC/dT, was either transient or manageable through dose reduction.
    explanation: Investigator attribution in a small uncontrolled study, not exclusion of risk.
  target_mechanisms:
  - target: Mitochondrial DNA Depletion
    treatment_effect: MODULATES
    description: Proposed nucleotide-substrate strategy; no direct restoration of patient-tissue mtDNA was demonstrated in these clinical reports.
    evidence:
    - reference: PMID:42296640
      reference_title: Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: BACKGROUND
      directness: INDIRECT
      snippet: supplementation with three or fewer deoxynucleosides is sufficient to increase mtDNA levels in POLG-deficient fibroblasts
      explanation: The trial cites prior cell evidence for the proposed substrate-rescue target; it did not measure patient-tissue mtDNA rescue.
  - target: Recurrent Seizure Activity
    treatment_effect: MODULATES
    description: Intended clinical target with uncontrolled seizure observations, not established comparative efficacy.
    evidence:
    - *id011
diagnosis:
- name: Molecular diagnosis and parental phasing
  description: Confirm a compatible phenotype with biallelic pathogenic or likely pathogenic POLG variants. Variants of uncertain significance do not confirm or exclude disease. Sequence analysis should cover the whole gene; deletion/duplication testing, a mitochondrial/epilepsy panel or broader genomic testing may be needed. A small founder-variant screen can miss causal variants. Parental testing clarifies phase and recurrence risk.
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:20301791
    reference_title: POLG-Related Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Establishing the diagnosis of a POLG-related disorder relies on clinical findings and the identification of biallelic POLG pathogenic variants on molecular genetic testing
    explanation: GeneReviews molecular diagnosis.
  - reference: PMID:28471437
    reference_title: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: we demonstrate the need to perform full sequence analysis of the entire POLG gene rather than targeting common POLG mutations in patients with unexplained encephalopathy and multisystem disorders with or without epilepsy
    explanation: Clinical study conclusion; targeted variants are not a sufficient exclusion test.
- name: Electroencephalography and clinical seizure assessment
  description: EEG and video EEG characterize seizures and assess possible nonconvulsive status. Occipital discharges are an important clue but are not specific or invariably present; clinically apparent EPC can lack a clear EEG correlate.
  diagnosis_term:
    preferred_term: Electroencephalography
    term:
      id: NCIT:C38054
      label: Electroencephalography
  evidence:
  - reference: PMID:20138553
    reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: early predominance of epileptiform discharges over the occipital region is common in POLG-induced epilepsy
    explanation: Clinical recognition feature.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: EPC is not always apparent as an abnormality on EEG and can be mistaken for a conversion reaction. EEG may be normal or show only focal slowing of the background rhythm.
    explanation: Important diagnostic limitation.
- name: Neuroimaging
  description: Brain MRI may initially be normal. Evolving cortical or subcortical signal change, occipital-pulvinar involvement and cortical or cerebellar atrophy support the clinical assessment but do not replace molecular testing.
  diagnosis_term:
    preferred_term: Magnetic Resonance Imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: CT or MRI of the brain may be normal early in the course of AHS. As the illness evolves, neuroimaging shows gliosis (initially more pronounced in the occipital lobe regions) and generalized cortical atrophy.
    explanation: Alpers imaging evolution.
- name: Hepatic, metabolic and tissue assessment
  description: Assess liver enzymes, synthetic function, glucose, ammonia and lactate alongside neurological findings. Tissue mtDNA measurement and respiratory-chain testing can be informative when needed, but normal muscle histology, enzyme activity or mtDNA content does not exclude disease. Do not delay appropriate genetic evaluation because a screening test is normal.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: In muscle biopsy samples, ragged-red fibers, COX-negative fibers, excessive lipid deposits, and abnormal respiratory chain activities can be present. However, biochemical findings on muscle biopsy can be normal.
    explanation: Review explicitly limits muscle-biopsy sensitivity.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Depletion of mtDNA can be measured by comparing mtDNA to nuclear DNA content in an affected tissue (e.g., liver).
    explanation: Tissue measurement approach.
differential_diagnoses:
- name: Other early-onset POLG phenotypes
  description: Myocerebrohepatopathy and severe digestive-predominant presentations overlap with Alpers but can lack epilepsy, especially with rapidly fatal hepatic disease. Age categories and clinical syndromes are not equivalent.
  distinguishing_features:
  - Phenotypic classification depends on the full neurological and hepatic course, rather than the POLG genotype or age alone.
  evidence:
  - reference: PMID:38975049
    reference_title: Distinct Clinical Courses and Shortened Lifespans in Childhood-Onset DNA Polymerase Gamma Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Although a fraction of patients met inclusion criteria for AHS (triad of refractory seizures, psychomotor regression, and hepatopathy), this seminal description is an imperfect fit for all the pediatric population reported here
    explanation: Primary cohort explicitly limits the Alpers label.
- name: MELAS Syndrome
  disease_term:
    preferred_term: MELAS syndrome
    term:
      id: MONDO:0010789
      label: MELAS syndrome
  description: MELAS can share seizures, cortical visual symptoms and stroke-like episodes. Mitochondrial DNA pathogenic variants and maternal inheritance distinguish typical MELAS from recessive nuclear POLG-related Alpers.
  distinguishing_features:
  - Stroke-like episodes can occur in both; they are not an exclusive discriminator.
  - Typical MELAS is associated with maternally inherited mtDNA variants.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: MELAS is caused by pathogenic variants in mtDNA and is transmitted by maternal inheritance.
    explanation: Direct differential-diagnosis statement.
- name: Other hepatocerebral mitochondrial disorders
  description: DGUOK, MPV17 and other mitochondrial disorders can combine liver disease and neurological dysfunction. Historical Alpers-like encephalopathy also includes non-POLG genetic causes, so an unresolved molecular diagnosis warrants broader testing.
  distinguishing_features:
  - A different causal gene establishes a separate molecular disorder; liver and seizure findings can overlap.
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: Recent whole exome sequencing has identified other molecular genetic causes of Alpers’ syndrome, including pathogenic mutations in FARS2
    explanation: Background acknowledges genetically heterogeneous historical clinical usage.
- name: Leigh syndrome
  description: Leigh syndrome can share developmental regression, motor signs and epilepsy. Brainstem and deep-gray involvement often precede cortical lesions, whereas Alpers commonly begins with cortical injury. Molecular testing resolves overlapping cases.
  distinguishing_features:
  - Typical lesion sequence and distribution differ, but neither pattern is fully specific.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/
    reference_title: POLG-Related Disorders - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: whereas in AHS the initial lesions form in the cerebral cortex (usually the occipital lobes), followed by the cerebellum, basal ganglia, thalamus, and brain stem.
    explanation: Chapter comparison of neuroimaging evolution.
discussions:
- discussion_id: alpers-valproate-mediator
  prompt: Which liver-specific mechanisms explain the severe valproate vulnerability of recessive POLG disease?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Valproate-Associated Hepatocellular Injury
  rationale: Clinical risk is well established, but the 2010 assays used yeast chimeras and primary muscle cells. Failure to observe extra mtDNA depletion there does not exclude mitochondrial-genome or fatty-acid pathways in liver. Impaired regeneration and an HDAC-mediated explanation were proposed, not directly demonstrated in human hepatocytes. Mechanistic research should use appropriate models without exposing affected children to a contraindicated drug.
  evidence:
  - reference: PMID:21038416
    reference_title: Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Human hepatocyte cell lines from patients with POLG variants are not available.
    explanation: Explicit lineage limitation.
  - reference: PMID:21038416
    reference_title: Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: but there was no further decrease in mtDNA content with the addition of 10mM VPA
    explanation: Negative result in the tested muscle-cell context.
- discussion_id: alpers-common-polymorphism-risk
  prompt: How should common POLG polymorphisms be interpreted separately from biallelic Alpers-causing variants?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - genetic#POLG
  rationale: The 2010 association in selected suspected valproate liver-injury cases used population controls and differs from a recessive molecular diagnosis. A later small monotherapy comparison did not reproduce increased toxicity for Q1236H/E1143G in the absence of other pathogenic variants. Neither study establishes universal heterozygote risk or relaxes the contraindication for established Alpers.
  evidence:
  - reference: PMID:21038416
    reference_title: Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Heterozygous genetic variation in POLG was strongly associated with VPA-induced liver toxicity
    explanation: Selected association-study conclusion; variant classes and comparator population require separate interpretation.
  - reference: PMID:30255931
    reference_title: 'Variants p.Q1236H and p.E1143G in mitochondrial DNA polymerase gamma POLG1 are not associated with increased risk for valproate-induced hepatotoxicity or pancreatic toxicity: A retrospective cohort study of patients with epilepsy.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Transient liver dysfunction was identified in three (n = 33, 9.1%) variant group patients and in one (n = 28, 3.6%) nonvariant group patient (P = 0.62).
    explanation: Small available-abstract null comparison, not proof of zero risk.
- discussion_id: alpers-neural-selectivity
  prompt: Does early inhibitory-network dysfunction drive seizures, or does prolonged epilepsy amplify the observed neuronal injury?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Reduced Cortical Inhibition
  - pathophysiology#Cortical Neuronal Loss
  rationale: End-stage human tissue shows respiratory-chain protein deficiency and cell loss, but cannot order these events. Both interneuron and pyramidal-cell densities were reduced; respiratory-chain abnormalities were more pronounced in interneurons. Limited sampled regions do not establish occipital exclusivity. Longitudinal, appropriately controlled neural models are needed to separate intrinsic dysfunction from seizure-related injury.
  evidence:
  - reference: PMID:30021052
    reference_title: 'Dissecting the neuronal vulnerability underpinning Alpers'' syndrome: a clinical and neuropathological study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: INDIRECT
    snippet: Although loss of interneurons and pyramidal cells was similar, the magnitude of respiratory chain deficiency was more pronounced in interneurons raising the possibility that the loss of inhibitory neural networks plays a role in the seizure development in these patients.
    explanation: Authors explicitly frame the causal network mechanism as a possibility.
- discussion_id: alpers-a449t-model-mismatch
  prompt: Why does the A449T knock-in mouse remain much milder than human Alpers and resist the tested valproate challenges?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - animal_models#Homozygous Polg A449T knock-in mouse
  - pathophysiology#Valproate-Associated Hepatocellular Injury
  rationale: The model recapitulates proximal biochemical defects and stress-dependent mtDNA recovery but not the severe human triad, shortened lifespan or tested valproate-associated hepatic damage. Compensatory processes, species biology and allele combinations remain unresolved. The negative mouse drug phenotype cannot establish safety in affected people.
  evidence:
  - reference: PMID:33956154
    reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We monitored the PolgA449T/A449T and WT littermates up to 2 years of age, but neither reduction of the lifespan nor the presence of obvious age-related phenotypes was observed.
    explanation: Explicit long-term mild phenotype.
  - reference: PMID:33956154
    reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Both WT and PolgA449T/A449T did not show any sign of hepatic failure or histological damage.
    explanation: Explicit negative result after the tested valproate protocols.
animal_models:
- name: Homozygous Polg A449T knock-in mouse
  species: Mus musculus
  category: Knock-in model
  genotype: Polg A449T/A449T
  description: The mouse ortholog of human A467T impairs mitochondrial genome maintenance and reduces catalytic-subunit abundance. Young mice showed reduced exercise/rearing performance and mild skeletal-muscle mtDNA depletion; spontaneous severe neurological or liver failure was not demonstrated. After carbon tetrachloride, residual liver necrosis was greater at day four despite similar early injury. This challenge does not establish ATP failure as the mediator of delayed recovery.
  publication: PMID:33956154
  notes: The homozygous Polg A449T mouse models one allele corresponding to human A467T. It had mild, tissue-dependent mtDNA changes, unchanged liver/muscle OXPHOS activities and no shortened lifespan through two years. It does not reproduce the severe human Alpers triad. Tested valproate exposures did not cause hepatic failure, so the model cannot establish human drug safety.
  modeled_mechanisms:
  - target: Reduced POLG Protein Abundance
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: MOLECULAR
    description: Catalytic-subunit abundance was reduced in knock-in tissues.
    limitations: The homozygous Polg A449T mouse models one allele corresponding to human A467T. It had mild, tissue-dependent mtDNA changes, unchanged liver/muscle OXPHOS activities and no shortened lifespan through two years. It does not reproduce the severe human Alpers triad. Tested valproate exposures did not cause hepatic failure, so the model cannot establish human drug safety.
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: The amount of mPOLγAA449T was reduced in the PolgA449T/A449T mice, which could also contribute to impaired mtDNA replication.
      explanation: Primary tissue protein finding.
    readouts:
    - name: Tissue POLG catalytic-subunit abundance
      target: Reduced POLG Protein Abundance
      direction: DECREASED
      interpretation: Catalytic-subunit abundance was reduced in knock-in tissues.
      evidence:
      - reference: PMID:33956154
        reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: The amount of mPOLγAA449T was reduced in the PolgA449T/A449T mice, which could also contribute to impaired mtDNA replication.
        explanation: Primary tissue protein finding.
  - target: Hepatocellular Injury
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: TISSUE
    description: Recovery from carbon-tetrachloride injury was delayed, with greater residual necrosis at day four.
    limitations: The homozygous Polg A449T mouse models one allele corresponding to human A467T. It had mild, tissue-dependent mtDNA changes, unchanged liver/muscle OXPHOS activities and no shortened lifespan through two years. It does not reproduce the severe human Alpers triad. Tested valproate exposures did not cause hepatic failure, so the model cannot establish human drug safety. Chemical injury is distinct from spontaneous human disease or valproate toxicity.
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Two days after the injection, both WT and PolgA449T/A449T showed extensive areas of necrosis (∼35% of the liver), which was reduced to 6 ± 0.46% in WT mice after 4 days, whereas it was still above 10% in PolgA449T/A449T mice (10 ± 1.15%, P < 0.05)
      explanation: Similar initial chemical injury followed by more residual necrosis at day four in the mutant.
    readouts:
    - name: Residual hepatic necrosis after chemical injury
      target: Hepatocellular Injury
      direction: INCREASED
      interpretation: Recovery from carbon-tetrachloride injury was delayed, with greater residual necrosis at day four.
      evidence:
      - reference: PMID:33956154
        reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: Two days after the injection, both WT and PolgA449T/A449T showed extensive areas of necrosis (∼35% of the liver), which was reduced to 6 ± 0.46% in WT mice after 4 days, whereas it was still above 10% in PolgA449T/A449T mice (10 ± 1.15%, P < 0.05)
        explanation: Similar initial chemical injury followed by more residual necrosis at day four in the mutant.
  - target: Valproate-Associated Hepatocellular Injury
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    model_scale: TISSUE
    description: The tested valproate protocols did not induce hepatic failure or histological injury.
    limitations: The homozygous Polg A449T mouse models one allele corresponding to human A467T. It had mild, tissue-dependent mtDNA changes, unchanged liver/muscle OXPHOS activities and no shortened lifespan through two years. It does not reproduce the severe human Alpers triad. Tested valproate exposures did not cause hepatic failure, so the model cannot establish human drug safety.
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Both WT and PolgA449T/A449T did not show any sign of hepatic failure or histological damage.
      explanation: Tested negative model phenotype; does not refute clinical toxicity.
    readouts:
    - name: Valproate-associated hepatic histological damage
      target: Valproate-Associated Hepatocellular Injury
      direction: UNCHANGED
      interpretation: The tested valproate protocols did not induce hepatic failure or histological injury.
      evidence:
      - reference: PMID:33956154
        reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: Both WT and PolgA449T/A449T did not show any sign of hepatic failure or histological damage.
        explanation: Tested negative model phenotype; does not refute clinical toxicity.
  evidence:
  - reference: PMID:33956154
    reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We monitored the PolgA449T/A449T and WT littermates up to 2 years of age, but neither reduction of the lifespan nor the presence of obvious age-related phenotypes was observed.
    explanation: Longitudinal model limitation.
experimental_models:
- name: Alpers iPSC-derived neural stem cells
  experimental_model_type: IPSC_DERIVED_MODEL
  cell_source: Neural stem cells differentiated from an A467T/P589L Alpers donor and unrelated controls
  description: Differentiated neural stem cells showed reduced mtDNA/nuclear-DNA ratio, complex I/IV protein expression, mitochondrial membrane potential and cellular ATP, with increased mitochondrial ROS probe signals. The pluripotent cells showed a milder phenotype and no significant ATP deficit. Cell-state differences are essential to interpretation.
  publication: PMID:38385069
  modeled_mechanisms:
  - target: Mitochondrial DNA Depletion
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: ND1/APP qPCR was reduced in Alpers neural stem cells.
    limitations: One Alpers donor with compound A467T/P589L variants, two clones, compared with five clones from three unrelated controls. A second patient line failed differentiation; no isogenic control was obtained. Cellular replicates are not independent patients. Findings do not establish a universal allele effect or clinical treatment benefit.
    evidence:
    - reference: PMID:38385069
      reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: To corroborate the reduction in the mtDNA levels as observed through the ND1/APP measurements in Alpers' NSCs, we performed qPCR (Figure 2P), which confirmed the same.
      explanation: Measured mtDNA-to-nuclear-DNA ratio in neural stem cells.
    readouts:
    - name: Relative ND1/APP DNA ratio
      target: Mitochondrial DNA Depletion
      direction: DECREASED
      interpretation: ND1/APP qPCR was reduced in Alpers neural stem cells.
      evidence:
      - reference: PMID:38385069
        reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: To corroborate the reduction in the mtDNA levels as observed through the ND1/APP measurements in Alpers' NSCs, we performed qPCR (Figure 2P), which confirmed the same.
        explanation: Measured mtDNA-to-nuclear-DNA ratio in neural stem cells.
  - target: Reduced Cellular ATP Availability
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: ATP content per cell was reduced after neural differentiation.
    limitations: One Alpers donor with compound A467T/P589L variants, two clones, compared with five clones from three unrelated controls. A second patient line failed differentiation; no isogenic control was obtained. Cellular replicates are not independent patients. Findings do not establish a universal allele effect or clinical treatment benefit. This is not an isolated ATP synthesis-flux assay.
    evidence:
    - reference: PMID:38385069
      reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: A direct measurement of intracellular ATP production revealed a marked decrease in ATP production in Alpers' NSCs compared to the control NSCs
      explanation: Cell-normalized ATP content measured by luminescence.
    readouts:
    - name: Cell-normalized ATP luminescence
      target: Reduced Cellular ATP Availability
      direction: DECREASED
      interpretation: ATP content per cell was reduced after neural differentiation.
      evidence:
      - reference: PMID:38385069
        reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: A direct measurement of intracellular ATP production revealed a marked decrease in ATP production in Alpers' NSCs compared to the control NSCs
        explanation: Cell-normalized ATP content measured by luminescence.
- name: Alpers cortical organoids with nicotinamide riboside
  experimental_model_type: ORGANOID
  cell_source: Cortical organoids from the same A467T/P589L Alpers donor
  description: Day-90 organoids showed abnormal organization, lower neuronal/GAD65 and complex I marker expression, increased GFAP staining and altered synaptic/mitochondrial gene sets. One-month-old organoids received 1 mM nicotinamide riboside for two months; neuronal and complex I markers increased and GFAP decreased. Organoid TFAM staining is a proxy for mtDNA content, and mtDNA transcripts did not significantly increase after treatment. No patient seizure, survival or liver outcome was tested.
  publication: PMID:38385069
  modeled_mechanisms:
  - target: Cortical Neuronal Loss
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: Patient organoids had lower neuronal marker expression.
    limitations: One Alpers donor with compound A467T/P589L variants, two clones, compared with five clones from three unrelated controls. A second patient line failed differentiation; no isogenic control was obtained. Cellular replicates are not independent patients. Findings do not establish a universal allele effect or clinical treatment benefit. Marker abundance may reflect cell number, state or differentiation; no longitudinal cell-fate tracing.
    evidence:
    - reference: PMID:38385069
      reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: the level of all neural marker MAP2, NeuN and Tuj1 expression (Figure 5C, D, E, F, I, L and Supplementary Figure 14) was also lower in Alpers' organoids
      explanation: Neuronal marker reduction, not longitudinal lineage tracing.
    readouts:
    - name: MAP2, NeuN and TUJ1 marker expression
      target: Cortical Neuronal Loss
      direction: DECREASED
      interpretation: Patient organoids had lower neuronal marker expression.
      evidence:
      - reference: PMID:38385069
        reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: the level of all neural marker MAP2, NeuN and Tuj1 expression (Figure 5C, D, E, F, I, L and Supplementary Figure 14) was also lower in Alpers' organoids
        explanation: Neuronal marker reduction, not longitudinal lineage tracing.
  - target: Cortical Neuronal Loss
    relationship: MEASURES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: Nicotinamide riboside increased neuronal marker expression relative to untreated patient organoids.
    limitations: One Alpers donor with compound A467T/P589L variants, two clones, compared with five clones from three unrelated controls. A second patient line failed differentiation; no isogenic control was obtained. Cellular replicates are not independent patients. Findings do not establish a universal allele effect or clinical treatment benefit. A partial in-vitro rescue does not establish clinical efficacy.
    evidence:
    - *id009
    readouts:
    - name: Neuronal marker expression after nicotinamide riboside
      target: Cortical Neuronal Loss
      direction: INCREASED
      interpretation: Nicotinamide riboside increased neuronal marker expression relative to untreated patient organoids.
      evidence:
      - reference: PMID:38385069
        reference_title: The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: We observed that the NR-treated organoids exhibited organized structures (Figure 7B) and increased expression of MAP2 and Tuj1 compared to those untreated
        explanation: Primary treated-versus-untreated marker result.
- name: Reconstituted human and mouse polymerase gamma assays
  experimental_model_type: OTHER
  cell_source: Purified recombinant wild-type and mutant POLG catalytic/accessory subunits with DNA substrates and LONP1
  description: A467T/A449T impairs binding, long-template synthesis and accessory-subunit interaction. Accessory subunit addition restored short-template activity toward wild type in mouse assays but did not normalize long-template synthesis. LONP1 proteolysis showed equal susceptibility of free wild-type and mutant catalytic subunits, with incomplete accessory-subunit protection of the mutant. These are direct biochemical assays, not patient-derived hepatocytes.
  publication: PMID:33956154
  modeled_mechanisms:
  - target: Reduced DNA Polymerase Gamma Function
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: MOLECULAR
    description: Mutant long-template DNA synthesis remained slower despite accessory subunit.
    limitations: Allele-, species-, substrate- and reaction-condition-dependent result.
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: mPOLγAA449T displayed a clearly slower DNA synthesis rate compared to the mPOLγAWT, even in the presence of the mPOLγB subunit
      explanation: Long-template synthesis assay.
    readouts:
    - name: Long-template DNA synthesis
      target: Reduced DNA Polymerase Gamma Function
      direction: DECREASED
      interpretation: Mutant long-template DNA synthesis remained slower despite accessory subunit.
      evidence:
      - reference: PMID:33956154
        reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: mPOLγAA449T displayed a clearly slower DNA synthesis rate compared to the mPOLγAWT, even in the presence of the mPOLγB subunit
        explanation: Long-template synthesis assay.
  - target: Increased Degradation of Unprotected POLG
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: MOLECULAR
    description: POLG2 protected wild-type catalytic subunit more effectively than mutant.
    limitations: Free wild-type and mutant were degraded at similar rates; do not infer an in-vivo half-life.
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: In contrast, mPOLγB was unable to efficiently block degradation of mPOLγAA449T and the levels of the mutant protein decreased significantly over the time of the experiment
      explanation: Purified LONP1 degradation assay.
    readouts:
    - name: Catalytic-subunit loss in assembled proteolysis assay
      target: Increased Degradation of Unprotected POLG
      direction: INCREASED
      interpretation: POLG2 protected wild-type catalytic subunit more effectively than mutant.
      evidence:
      - reference: PMID:33956154
        reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: In contrast, mPOLγB was unable to efficiently block degradation of mPOLγAA449T and the levels of the mutant protein decreased significantly over the time of the experiment
        explanation: Purified LONP1 degradation assay.
- name: A449T mouse embryonic fibroblast mtDNA recovery
  experimental_model_type: CELL_LINE
  cell_source: Embryonic fibroblasts from homozygous Polg A449T mice and wild-type littermates
  description: Baseline mtDNA content was not reduced, but mutant cells accumulated more replicating foci and failed to recover mtDNA during the observed interval after ethidium-bromide depletion. More replication foci were interpreted as stalled or slow replication, not greater productive synthesis.
  publication: PMID:33956154
  modeled_mechanisms:
  - target: Impaired Mitochondrial DNA Replication
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: Recovery after experimentally induced mtDNA depletion was impaired.
    limitations: Cultured mouse cells and a chemical depletion challenge, not untreated human Alpers liver.
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: whereas no recovery at all was observed in the mutant cells
      explanation: Primary post-depletion recovery observation.
    readouts:
    - name: mtDNA copy-number recovery after ethidium bromide
      target: Impaired Mitochondrial DNA Replication
      direction: DECREASED
      interpretation: Recovery after experimentally induced mtDNA depletion was impaired.
      evidence:
      - reference: PMID:33956154
        reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: whereas no recovery at all was observed in the mutant cells
        explanation: Primary post-depletion recovery observation.
- name: HeLa LONP1 and POLG2 knockdown
  experimental_model_type: CELL_LINE
  cell_source: HeLa cells with siRNA-mediated LONP1 or POLG2 depletion
  description: LONP1 knockdown increased endogenous POLG catalytic-subunit abundance; POLG2 knockdown reduced it. These cells do not carry an Alpers genotype, and the experiment did not establish rescue of mutant mtDNA replication, neuronal survival or clinical disease.
  publication: PMID:33956154
  modeled_mechanisms:
  - target: Reduced POLG Protein Abundance
    relationship: MEASURES
    fidelity: MODERATE
    model_scale: MOLECULAR
    description: Reducing LONP1 increased endogenous catalytic-subunit abundance.
    limitations: Wild-type regulatory experiment; not mutant rescue or a validated therapeutic strategy.
    evidence:
    - reference: PMID:33956154
      reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: LONP1 knockdown caused a robust increase in POLγA levels
      explanation: Primary cellular protein readout.
    readouts:
    - name: POLG protein after LONP1 knockdown
      target: Reduced POLG Protein Abundance
      direction: INCREASED
      interpretation: Reducing LONP1 increased endogenous catalytic-subunit abundance.
      evidence:
      - reference: PMID:33956154
        reference_title: DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: LONP1 knockdown caused a robust increase in POLγA levels
        explanation: Primary cellular protein readout.
- name: Valproate exposure in primary muscle-cell cultures
  experimental_model_type: PRIMARY_CELL_CULTURE
  cell_source: Primary human myoblasts/myotubes from control, common-variant and AHS donors
  description: The 2010 study examined p.Gln1236His and A467T/K1191N donor muscle cells, not hepatocytes. Baseline patient myotubes had reduced mtDNA, but 10 mM valproate did not further reduce it. Growth/death effects at high experimental concentrations cannot establish a physiological-dose liver mechanism. Failure to observe additional mtDNA depletion in this context does not exclude liver-specific toxicity.
  publication: PMID:21038416
  modeled_mechanisms:
  - target: Mitochondrial DNA Depletion
    relationship: MEASURES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: Valproate did not further reduce mtDNA in the tested muscle-cell conditions.
    limitations: Small donor set, nonhepatic lineage and concentration-dependent exposure; no conclusion about patient liver mechanisms.
    evidence:
    - reference: PMID:21038416
      reference_title: Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: but there was no further decrease in mtDNA content with the addition of 10mM VPA
      explanation: Direct negative muscle-cell result.
    readouts:
    - name: Additional mtDNA loss after valproate
      target: Mitochondrial DNA Depletion
      direction: UNCHANGED
      interpretation: Valproate did not further reduce mtDNA in the tested muscle-cell conditions.
      evidence:
      - reference: PMID:21038416
        reference_title: Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: but there was no further decrease in mtDNA content with the addition of 10mM VPA
        explanation: Direct negative muscle-cell result.
clinical_trials:
- name: NCT04802707
  description: Single-centre open-label phase 2 pyrimidine deoxynucleoside study across mitochondrial depletion disorders. The 2024 POLG interim report included 10 participants, six with Alpers; the 2026 report extends the same program to 25 participants with varied POLG phenotypes, including adults. Disease-scale scores improved among available follow-up observations, and 10/14 with uncontrolled epilepsy had reported seizure reductions over 50%. Five participants died and five withdrew. These uncontrolled mixed-phenotype findings do not establish Alpers-specific efficacy or a survival benefit.
  phase: PHASE_II
  status: RECRUITING
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  - preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  notes: 'Live registry checked 2026-09-21: recruiting, estimated total enrollment 200 for the broader protocol. The 2026 POLG publication documents an amended upper age limit of 60 years and treatment duration up to 60 months; the cached brief registry summary still says children 0–18 years. The 2024 and 2026 papers are overlapping reports. One-tailed exploratory analyses, changing denominators, unblinded assessments, missing biomarker measurements, cointerventions and survivor selection constrain causal inference. GDF-15 is not a direct mtDNA-rescue measurement. Pediatric quality-of-life scores alone were not significantly improved in the 2026 report; its positive pooled result normalized different pediatric/adult instruments.'
  evidence:
  - reference: clinicaltrials:NCT04802707
    reference_title: A Phase II, Monocenter, Single Arm Study To Assess The Safety and Efficacy Of Combination Deoxycytidine and Deoxythymidine For Mitochondrial Depletion Disorders
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: In this phase II Trial a mix of Deoxynucleosides Pyrimidine (Deoxycytidine dC and Deoxythymidine dT) will be used as early treatment of MDS.
    explanation: Protocol intervention, not proof of efficacy.
  - *id012
  - *id013
  - *id011
  - *id014
  - reference: PMID:42296640
    reference_title: Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Five patients (20%) died during the trial.
    explanation: Deaths occurred despite therapy; the study did not attribute serious adverse effects to dC/dT. No survival benefit is inferred.
  - reference: PMID:42296640
    reference_title: Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: There were no significant differences in mean NMDS section IV scores for pediatric patients
    explanation: Separates pediatric quality-of-life result from the normalized combined analysis.
- name: NCT03034512
  description: Alpers natural-history study intended to follow clinical manifestations over time. The registry lists two enrolled participants and termination because the research focus changed. This is an observational design, not a treatment trial or published estimate of disease progression.
  phase: NOT_APPLICABLE
  status: TERMINATED
  notes: 'Live registry checked 2026-09-21; actual enrollment 2, reason: Research focus has changed. No natural-history outcome is inferred from registration.'
  evidence:
  - reference: clinicaltrials:NCT03034512
    reference_title: Natural History Study of Alpers Huttenlocher Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: This is a natural history study of Alpers Huttenlocher Syndrome. Patients will be followed over time to assess clinical symptoms for the purpose of expanding knowledge of this disorder in the medical community.
    explanation: Protocol purpose only.
- name: NCT04378075
  description: MIT-E was a randomized placebo-controlled phase 2/3 study of vatiquinone in mitochondrial disease with refractory epilepsy, including Alpers among eligible conditions. Sixty-eight participants were randomized (34 per arm). The posted 24-week primary motor-seizure analysis did not demonstrate a statistically significant benefit (P = 0.173; reported between-arm median difference -8.31 percentage points, 95% CI -31.3 to 16.4). These are mixed-disease results, not an Alpers-specific efficacy estimate. The trial was terminated by sponsor decision.
  phase: PHASE_III
  status: TERMINATED
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  notes: Registry phase is 2/3; PHASE_III is used because the schema has no combined-phase value. Full posted registry results, status, participant flow and adverse-event summaries were checked on 2026-09-21. ClinicalTrials.gov reports 3 deaths among 34 vatiquinone recipients and 0/34 placebo recipients during the double-blind period; the counts alone do not establish drug causation. The open-label extension must not be treated as a continued randomized comparison.
  evidence:
  - reference: clinicaltrials:NCT04378075
    reference_title: Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
    explanation: Design evidence.
  - *id010
  - reference: url:https://clinicaltrials.gov/api/v2/studies/NCT04378075
    reference_title: https://clinicaltrials.gov/api/v2/studies/NCT04378075
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: The study was terminated early due to Sponsor decision.
    explanation: Current registry status and stated reason, rather than a causal attribution to toxicity.
- name: NCT05218655
  description: Open-label phase 3 safety study in 101 previously vatiquinone-treated participants with inherited mitochondrial disease. The registry is marked completed, but the posted limitations state that it ended early because the sponsor discontinued development for this indication based on prior trial results. The primary outcome was treatment-emergent adverse events, not Alpers seizure efficacy; 91/101 experienced at least one TEAE. This selected uncontrolled cohort does not establish an Alpers-specific benefit or comparative safety.
  phase: PHASE_III
  status: COMPLETED
  notes: Current registry and posted results checked 2026-09-21. Completion status describes the study record and does not mean that every enrolled participant completed treatment. Prior exposure and mixed diagnoses constrain generalization.
  evidence:
  - reference: clinicaltrials:NCT05218655
    reference_title: An Open-Label, Safety Study for Previously Treated Vatiquinone (PTC743) Subjects With Inherited Mitochondrial Disease
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan.
    explanation: Safety-design population; no efficacy claim.
  - reference: url:https://clinicaltrials.gov/api/v2/studies/NCT05218655
    reference_title: https://clinicaltrials.gov/api/v2/studies/NCT05218655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: '"title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)"'
    explanation: Primary registered endpoint.
  - reference: url:https://clinicaltrials.gov/api/v2/studies/NCT05218655
    reference_title: https://clinicaltrials.gov/api/v2/studies/NCT05218655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: '"groupId":"OG000","value":"91"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline (Day 1) up to 30 days after last dose of study drug (956 days)"'
    explanation: Primary endpoint numerator in the 101-person safety population.
  - reference: url:https://clinicaltrials.gov/api/v2/studies/NCT05218655
    reference_title: https://clinicaltrials.gov/api/v2/studies/NCT05218655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The study was terminated early as PTC discontinued clinical development of vatiquinone for this indication based on prior clinical study results.
    explanation: Explicit sponsor explanation of early termination, despite the overall completed status.
datasets:
- accession: geo:GSE207007
  title: RNA sequencing in POLG-iPSC derived brain cells
  description: Transcriptomic collection covering POLG patient-specific fibroblasts, iPSCs and differentiated neural cells. The Alpers organoid study deposited its bulk RNA-seq in this collection; the broader accession also includes other POLG genotypes and should not be treated as one homogeneous Alpers cohort.
  data_type: BULK_RNA_SEQ
  publication: PMID:38385069
  notes: Verified through a generated per-record GEO cache. The organoid study used one successfully differentiated Alpers donor with two clones and unrelated controls; cell replicates do not increase the patient count.
  evidence:
  - reference: GEO:GSE207007
    reference_title: RNA sequencing in POLG-iPSC derived brain cells
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: including patient-specific fibroblasts, iPSCs and iPSCs-derived neural stem cells (NSCs), and astrocytes.
    explanation: Repository scope includes several cell types and broader POLG genotypes.
review_notes: 'Comprehensive review checked the original entry, matching falcon research narrative, all original references and genuine cached scientific bodies. Read the complete POLG GeneReviews chapter through diagnosis, clinical course, care, surveillance, counseling and molecular pathogenesis. Full scientific bodies consumed: PMID20138553, 28471437, 30021052, 38860231, 38822839, 38975049, 38385069 and 38576261. Independent full-source peers audited PMID21038416 and 33956154, with claim-local passages also checked here. PMID16024923 and 30255931 remain abstract-supported; inaccessible assay details are not invented. PMID30021052 was regenerated from abstract-only to full XML. The 2017 correction PMID30228318 was checked on the publisher site and corrects Table 2 identifiers/citations, not phenotype results; the current PDF is already corrected. Frequencies come from the explicit 19-person Alpers subgroup, with feature-specific denominators. Mixed early-onset and broad POLG cohorts are not treated as Alpers prevalence samples. Historical neuropathology includes cases without molecular confirmation. Experimental ATP abundance, respiratory protein staining and organoid markers are not
  renamed direct flux or lineage measurements. The 2026 metformin paper PMID41355579 was screened but not used because its main donor is a different POLG phenotype, rather than the Alpers donor in the nicotinamide-riboside paper. The complete consensus distinguishes not-contraindicated advice from proven efficacy. Valproate remains contraindicated; common-polymorphism uncertainty does not weaken this. Registry status was checked live on 2026-09-21 and design evidence is distinguished from outcomes. No reference cache was manually edited and the frozen shared accession blob was not accessed. Both 2024 and 2026 deoxynucleoside trial main bodies, methods, tables and discussions were read fully; the later study extends the same program rather than independently replicating it. In the initial report, 8/10 had no seizures in the preceding two months and one six-month disease-scale result was imputed; no uncontrolled EEG or seizure change is treated as an Alpers-specific causal effect. Baseline-to-follow-up changes are not randomized effects. Pediatric quality of life was nonsignificant when analyzed separately, and onset-to-death natural-history intervals cannot establish a survival advantage
  against enrollment-to-death follow-up in selected survivors. Posted vatiquinone registry results include a nonsignificant randomized primary endpoint and selected open-label safety data, without an Alpers-specific efficacy estimate.'

environmental:
- name: Valproate exposure
  description: Valproate or divalproex exposure can precipitate or accelerate severe liver injury in POLG-related disease, including Alpers. This is a clinically established gene–drug interaction; the molecular mediator remains unresolved and exposure is contraindicated.
  chemicals:
  - valproic acid
  influences_mechanisms:
  - target: Valproate-Associated Hepatocellular Injury
    environmental_effect: TRIGGERS
    description: Exposure can trigger the drug-associated injury pathway on a background of POLG-related vulnerability.
    evidence:
    - reference: PMID:20138553
      reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure
      explanation: Clinical drug-associated risk.
  evidence:
  - reference: PMID:20138553
    reference_title: POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: VPA dosing at any stage of Alpers-Huttenlocher syndrome can precipitate liver failure
    explanation: Clinical drug-associated risk.

📚

References & Deep Research

References

23

GEO:GSE207007

RNA sequencing in POLG-iPSC derived brain cells

No top-level findings curated for this source.

PMID:16024923

The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit.

No top-level findings curated for this source.

PMID:20138553

POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.

No top-level findings curated for this source.

PMID:20301791

POLG-Related Disorders.

No top-level findings curated for this source.

PMID:21038416

Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.

No top-level findings curated for this source.

PMID:28471437

The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations.

No top-level findings curated for this source.

PMID:30021052

Dissecting the neuronal vulnerability underpinning Alpers' syndrome: a clinical and neuropathological study.

No top-level findings curated for this source.

PMID:30255931

Variants p.Q1236H and p.E1143G in mitochondrial DNA polymerase gamma POLG1 are not associated with increased risk for valproate-induced hepatotoxicity or pancreatic toxicity: A retrospective cohort study of patients with epilepsy.

No top-level findings curated for this source.

PMID:33956154

DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion.

No top-level findings curated for this source.

PMID:38385069

The NAD(+) Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease.

No top-level findings curated for this source.

PMID:38576261

Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group.

No top-level findings curated for this source.

PMID:38822839

Status epilepticus in POLG disease: a large multinational study.

No top-level findings curated for this source.

PMID:38860231

Evidence for sodium valproate toxicity in mitochondrial diseases: a systematic analysis.

No top-level findings curated for this source.

PMID:38975049

Distinct Clinical Courses and Shortened Lifespans in Childhood-Onset DNA Polymerase Gamma Deficiency.

No top-level findings curated for this source.

PMID:39091670

Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in POLG-related disorders: 6-month interim results of an open-label, single arm, phase 2 trial.

No top-level findings curated for this source.

PMID:42296640

Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders.

No top-level findings curated for this source.

clinicaltrials:NCT03034512

Natural History Study of Alpers Huttenlocher Syndrome

No top-level findings curated for this source.

clinicaltrials:NCT04378075

Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy

No top-level findings curated for this source.

clinicaltrials:NCT04802707

A Phase II, Monocenter, Single Arm Study To Assess The Safety and Efficacy Of Combination Deoxycytidine and Deoxythymidine For Mitochondrial Depletion Disorders

No top-level findings curated for this source.

clinicaltrials:NCT05218655

An Open-Label, Safety Study for Previously Treated Vatiquinone (PTC743) Subjects With Inherited Mitochondrial Disease

No top-level findings curated for this source.

url:https://clinicaltrials.gov/api/v2/studies/NCT04378075

https://clinicaltrials.gov/api/v2/studies/NCT04378075

No top-level findings curated for this source.

url:https://clinicaltrials.gov/api/v2/studies/NCT05218655

https://clinicaltrials.gov/api/v2/studies/NCT05218655

No top-level findings curated for this source.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK26471/

POLG-Related Disorders - GeneReviews® - NCBI Bookshelf

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record notes

This entry covers POLG-related Alpers-Huttenlocher syndrome (mitochondrial DNA depletion syndrome 4A), rather than all early-onset POLG disease. Historical clinically defined Alpers cohorts may include individuals without molecular confirmation or with other genetic causes. Myocerebrohepatopathy and juvenile/adult POLG phenotypes overlap but are not interchangeable with this syndrome. Frequencies from mixed POLG cohorts are not assigned to Alpers phenotypes; the 2017 study explicitly identifies an Alpers subgroup of 19. Mechanistic experiments retain their allele, tissue and model limitations. The falcon deep-research report was checked against primary sources and the complete GeneReviews chapter.

Review Alpers clinical scope, atomic POLG mechanisms, models and current treatment evidence · 2026-09-21T08:26:04Z · View source

Comprehensive review of the full original Alpers entry, matching falcon deep-research narrative, all original references, and actual cached full scientific bodies. Scope now distinguishes molecularly defined recessive POLG Alpers from the broader early-onset POLG spectrum and historical clinically defined cases. Complete GeneReviews chapter was read through clinical course, diagnosis, differential diagnosis, management, surveillance, counseling and molecular mechanisms. Full original clinical and pathology sources were checked against their Methods, Results, Discussion, tables and captions; PMID30021052 was regenerated from abstract-only to genuine full XML. The 2017 paper's correction was checked and concerns case identifiers/citations, not phenotype results. Replaced bundled mechanisms with 16 atomic nodes. Allele-specific catalytic impairment, accessory-subunit assembly, protection from LONP1 degradation, protein abundance, mtDNA maintenance, respiratory deficiency, ATP availability, oxidative stress, neuronal loss, proposed inhibitory-network dysfunction, seizures and hepatic injury are separate claims. Human postmortem protein staining is not a direct electron-flux assay, ATP luminescence measures cellular content, and organoid markers do not establish lineage tracing. The A449T/A467T proteolysis mechanism depends on impaired accessory-subunit protection rather than faster intrinsic degradation of free mutant protein. The mouse retains normal measured OXPHOS/lifespan and resists tested valproate exposure despite mild mtDNA defects and slower chemical-injury recovery. One mouse and six experimental systems include measured readouts and species, lineage, allele and rescue limitations. Expanded the phenotype set to 17, with clinical denominators taken only from the explicit 19-person Alpers subgroup of the 2017 study. Liver dysfunction is not converted to a liver-failure frequency; pooled mixed-POLG growth, lactate, survival and status-epilepticus estimates are not relabeled Alpers-specific. Developmental delay is not automatically global delay, and normal early MRI, muscle histology, biochemical testing or mtDNA results do not exclude disease. Diagnosis, progression, biochemical abnormalities, histopathology, inheritance, family counseling and overlapping differential diagnoses were revised from the complete chapter and primary clinical cohorts. Expanded care to 21 records, preserving the valproate/divalproex contraindication, rapid evaluation when POLG disease is suspected, individualized antiseizure/status treatment, monitoring, nutrition, rehabilitation, sensory/respiratory support and palliative care. The 2024 expert consensus distinguishes not-contraindicated advice from proven efficacy. The 2010 common-polymorphism association and 2018 small null monotherapy comparison do not relax the contraindication in biallelic disease. Muscle-cell and yeast valproate experiments do not establish human hepatocyte regeneration or HDAC causality. Inherited discussion proposals that implied otherwise or proposed drug exposure in affected children were replaced with qualified mechanistic gaps. Nicotinamide riboside remains a one-donor organoid intervention. Full 2024 and 2026 deoxynucleoside trial papers were read completely: six Alpers patients among the initial ten, later expanded to 25 mixed-POLG participants, are overlapping reports from the same program. Unblinded exploratory outcomes, cointerventions, changing denominators, biomarker censoring, deaths/withdrawals and survivor selection preclude proven Alpers-specific efficacy or survival benefit. Pediatric quality of life alone was nonsignificant in the later report. Full posted vatiquinone registry results show a nonsignificant randomized primary motor-seizure endpoint; later open-label safety results do not prove comparative safety or efficacy. Four live trial statuses were checked on 2026-09-21, including a completed registry record whose own limitations describe early termination. No outcome is inferred from registration alone. Added full generated sources PMID33956154,38385069,38576261,38822839,38860231,38975049,42296640 and regenerated PMID39091670; complete scientific bodies were consumed locally or by named independent peer source audits. PMID16024923 and30255931 remain abstract-supported, without invented methods. The 2026 metformin paper was screened and excluded because its donor represents a different POLG phenotype. GEO GSE207007 was verified through its generated per-record cache; its broader POLG collection is not treated as an Alpers-only cohort. All caches were produced by just fetch-reference; none was manually edited, and the frozen shared accession file was never accessed. Independent peers audited the complete 2010 valproate and 2021 assembly/proteolysis studies; a separate final graph/model pass confirmed scope and identified a day-four necrosis snippet that was repaired using the positive result. Authoritative validate-disorders passed schema, ontology terms and 197/197 snippets. Dataset verification, entity/causal links, GeneReviews baseline and scoped integrity checks passed; whole-KB guards and history validation were completed before publication. Node-class resolution was inspected without inventing missing annotations. Research completeness dimensions were checked; remaining experimental-to-human and temporal causal gaps are explicit.

Create: Alpers-Huttenlocher Syndrome · 2026-08-06T01:09:17Z · View source

Created the Alpers-Huttenlocher entry as a nine-node pathograph running from biallelic loss of DNA polymerase gamma function through failure of mitochondrial DNA replication, tissue mtDNA depletion and respiratory chain deficiency, to selective interneuron and pyramidal neuron loss in occipital cortex, intractable focal epilepsy with epilepsia partialis continua, developmental regression, hepatocellular failure, and valproate-precipitated fulminant hepatic failure. The valproate arm is deliberately modelled as pathophysiology rather than as an adverse effect, because it is a causal path the disease routinely takes through ordinary competent care. Two nodes conform to epilepsy_excitation_inhibition_imbalance, at the excitation-inhibition node and the recurrent-seizure node; the first was added on the strength of post-mortem evidence that the respiratory chain deficiency falls preferentially on inhibitory GABAergic interneurons, after the first draft had explicitly declined that conformance. Three discussions: the refuted mechanism of valproate hepatotoxicity, the POLG testing threshold, and the narrowed occipital selectivity gap. Deep research with the falcon provider changed the entry materially by surfacing the neuropathology paper the first draft had missed. All snippets verified against their own fetched caches.

Falcon ▸

Alpers–Huttenlocher Syndrome: Disease-Characteristics Research Report

Edison Scientific Literature 35 citations 2026-08-05T20:58:28.862777

Alpers–Huttenlocher Syndrome: Disease-Characteristics Research Report

Scope. This report treats classic Alpers–Huttenlocher syndrome (AHS) as the severe childhood hepatocerebral end of the POLG-related-disorder spectrum. Evidence is labeled as human clinical, human pathology, in vitro, or preclinical. Exact PMID links are provided where recoverable from the retrieved evidence; DOI URLs are supplied for all major publications.

Executive summary

AHS is a rare, usually autosomal-recessive mitochondrial DNA (mtDNA)-maintenance disorder characterized by developmental regression, refractory epilepsy—often occipital and progressing to status epilepticus—and hepatopathy/liver failure. More than 90% of classic cases are attributed to biallelic pathogenic variants in POLG, encoding the catalytic subunit of mitochondrial DNA polymerase γ; rare Alpers-like phenotypes occur with other mtDNA-maintenance or mitochondrial translation genes. POLG dysfunction causes tissue-specific mtDNA depletion, respiratory-chain failure—especially complex I deficiency—and selective injury to cortical inhibitory interneurons, pyramidal neurons, cerebellar Purkinje cells, and hepatocytes. The disease is rapidly progressive and generally fatal in childhood. Valproate can precipitate catastrophic hepatic failure and is contraindicated. No approved disease-modifying treatment exists; management is multidisciplinary and mainly palliative. Recent 2024 work has clarified status-epilepticus burden and childhood clinical trajectories and established patient-derived cerebral organoids for therapeutic screening. (rahman2019polgrelateddisordersand pages 3-4, rahman2020mitochondrialdiseasein pages 5-6, hayhurst2019dissectingtheneuronal pages 1-4, rotig2024distinctclinicalcourses pages 1-2, hikmat2024statusepilepticusin pages 1-2)

Domain	Key finding/statistic	Evidence type	Source/year
Childhood clinical course	Retrospective monocentric cohort of 40 children with childhood-onset POLG deficiency identified 3 clinical patterns: neurologic, hepatic, and gastrointestinal; 24/40 (60%) required urgent neurointensive care for seizures/status epilepticus; only 6/40 survived; hepatic presentations had earliest onset and shortest survival; valproate was highlighted as an avoidable precipitant of hepatic failure/death (rotig2024distinctclinicalcourses pages 1-2)	Human clinical cohort	Rötig et al., 2024
Status epilepticus burden	Multinational study of 195 genetically confirmed POLG patients: 67% (130/194) had epilepsy; 77% (97/126) with epilepsy developed status epilepticus; median SE onset 7 years; 97% (91/94) convulsive SE; 67% (56/84) epilepsia partialis continua; 66% (57/86) refractory/super-refractory SE; median time from SE onset to death 5 months (hikmat2024statusepilepticusin pages 1-2)	Human multinational cohort	Hikmat et al., 2024
Pediatric natural history	Early-onset POLG pediatric cohort of 27 patients; for Alpers phenotype (n=19), 100% had seizures and liver dysfunction; overall cohort mortality 85% (22/26); median age at death 15.8 months; median survival from onset 4.9 months; liver failure was main cause of death (13/22) (hikmat2017theclinicalspectrum pages 6-7)	Human clinical natural-history cohort	Hikmat et al., 2017
Core syndrome definition	AHS is a severe pediatric POLG disorder characterized by the triad of developmental regression, intractable seizures, and liver failure; about 70% of childhood POLG presentations are reported as AHS (rahman2019polgrelateddisordersand pages 3-4, rahman2020mitochondrialdiseasein pages 5-6)	Human clinical review synthesizing cohorts	Rahman & Copeland, 2019
EEG/MRI phenotype	POLG-related Alpers disease shows occipital-predominant epileptiform abnormalities; in one pediatric cohort, MRI lesions were present in 82% at onset and 88% during disease course; EEG often showed high-voltage polyspike-slow waves in occipitotemporal regions (hikmat2017theclinicalspectrum pages 4-6)	Human clinical cohort	Hikmat et al., 2017
Neuropathology	Post-mortem study of 13 clinically/histologically defined Alpers patients found severe respiratory-chain deficiency, especially complex I, in inhibitory interneurons, pyramidal neurons of occipital cortex, and Purkinje cells, with reduced neuronal densities supporting selective neuronal vulnerability underlying seizures/ataxia (hayhurst2019dissectingtheneuronal pages 1-4, hayhurst2019dissectingtheneuronal pages 13-15, hayhurst2019dissectingtheneuronal pages 10-13)	Human neuropathology	Hayhurst et al., 2019
Common POLG variants	Frequently reported epilepsy-associated POLG variants include p.Ala467Thr (A467T), p.Trp748Ser (W748S), and p.Gly848Ser (G848S); mtDNA depletion is a key downstream defect in severe disease (anagnostou2016epilepsydueto pages 11-12, saneto2013alpershuttenlochersyndrome. pages 1-2)	Human genetic/clinical review	Anagnostou et al., 2016; Saneto et al., 2013
Liver pathology/biomarkers	Characteristic liver pathology includes microvesicular steatosis, bile duct proliferation, hepatocellular necrosis, bridging fibrosis/cirrhosis; reported biomarkers include elevated FGF21, lactate, and plasma alanine in POLG disease (rahman2019polgrelateddisordersand pages 8-10)	Human pathology/review	Rahman & Copeland, 2019
Experimental therapy: NAD+ precursor	Patient-derived iPSC cortical organoids from Alpers disease with POLG A467T/P589L recapitulated neuronal loss, mtDNA depletion, and complex I defects; nicotinamide riboside improved neuronal markers and normalized mitochondrial/synaptic transcriptomic pathways toward control profiles (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)	In vitro patient-derived organoid study	Hong et al., 2024

Table: This compact table summarizes high-yield evidence for Alpers-Huttenlocher syndrome across natural history, neuropathology, genetics, and emerging experimental therapeutics. It emphasizes the most clinically actionable 2017-2024 findings with clear evidence-type labeling.

1. Disease information

Definition and classification

AHS is an early-onset, progressive mitochondrial hepatocerebral encephalopathy/mtDNA depletion syndrome. The classic triad is progressive neurodevelopmental regression, intractable seizures, and liver disease. Typical onset is between approximately 6 months and 3 years, often after apparently normal early development, although congenital/infantile and juvenile or rare adult-onset POLG phenotypes occur. Later presentations are often dominated by epileptic encephalopathy and ataxia rather than the complete early-childhood triad. (rahman2019polgrelateddisordersand pages 3-4, rahman2020mitochondrialdiseasein pages 5-6, hayhurst2019dissectingtheneuronal pages 1-4)

Direct abstract quote (human neuropathology, published October 2019): “Alpers’ syndrome is characterized by intractable epilepsy, developmental regression and liver failure which typically affects children aged 6 months–3 years.” The same abstract describes the disorder as progressive, incurable, and ultimately fatal from drug-resistant status epilepticus, frequently with liver failure. (hayhurst2019dissectingtheneuronal pages 1-4)

Identifiers and synonyms

Orphanet: ORPHA:726, Alpers syndrome, supported by the Open Targets disease record. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)
MONDO: the closely mapped entity MONDO:0008758, mitochondrial DNA depletion syndrome 4A (Alpers type), is linked to POLG in Open Targets. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)
OMIM: commonly represented as 203700, Mitochondrial DNA depletion syndrome 4A (Alpers type); causal gene POLG, OMIM 174763. This identifier should be independently validated during database ingestion because OMIM itself was not directly retrieved.
MeSH: “Alpers Syndrome.”
ICD-10/ICD-11: no uniquely specific, universally used AHS code was confirmed. Cases are generally coded under mitochondrial metabolism disorders/other specified metabolic or neurologic disease; coding depends on jurisdiction.
Synonyms: Alpers syndrome; Alpers disease; Alpers–Huttenlocher disease; progressive neuronal degeneration of childhood with liver disease; POLG-related Alpers syndrome; mitochondrial DNA depletion syndrome 4A/MTDPS4A.

The evidence is predominantly aggregated disease-level evidence from cohorts, reviews, pathology series, and registries. It is not derived from routine individual-patient EHR extraction, although retrospective cohorts abstracted individual clinical records. (NCT03034512 chunk 1, rotig2024distinctclinicalcourses pages 1-2, hikmat2024statusepilepticusin pages 1-2)

2. Etiology and risk/protective factors

Causal factors

Classic AHS is chiefly caused by biallelic germline pathogenic or likely pathogenic POLG variants. Inheritance is autosomal recessive. POLG encodes the catalytic subunit of the mitochondrial replicase responsible for mtDNA replication and base-excision repair. Impaired polymerase/exonuclease function produces mtDNA depletion and sometimes multiple mtDNA deletions, followed by oxidative-phosphorylation failure. (pronicka2011drugresistantepilepsiaand pages 6-7, hayhurst2019dissectingtheneuronal pages 1-4, saneto2013alpershuttenlochersyndrome. pages 1-2)

Rare Alpers-like phenotypes have been associated with TWNK, FARS2, NARS2, and PARS2. These should be distinguished from molecularly confirmed POLG-AHS in a knowledge base. (hikmat2017theclinicalspectrum pages 6-7, rahman2020mitochondrialdiseasein pages 5-6)

Genetic risk and modifiers

Common POLG variants among epilepsy-spectrum cases include p.Ala467Thr (A467T), p.Trp748Ser (W748S), and p.Gly848Ser (G848S). These variants are not AHS-specific: the same genotype can produce markedly different POLG-spectrum phenotypes. Homozygous linker-region variants may have better outcomes than some compound-heterozygous combinations, but recent childhood data did not identify a reliable genotype–clinical-course correlation. Nuclear modifiers, mtDNA background, and physiologic stress are plausible contributors but are not validated prognostic tests. (anagnostou2016epilepsydueto pages 11-12, rotig2024distinctclinicalcourses pages 1-2)

No established susceptibility locus beyond causal POLG alleles, validated protective POLG allele, or reproducible epigenetic modifier has entered clinical use. Pathogenic alleles are expected to be individually rare in population databases; variant-specific gnomAD frequencies and ClinVar ACMG classifications must be captured per transcript and genome build rather than assigning a disease-wide frequency.

Environmental and gene–environment interactions

AHS is not caused by lifestyle, toxin, occupational exposure, or infection. The most important interaction is POLG deficiency × valproate exposure, which can precipitate rapidly progressive or fulminant hepatic failure and avoidable death. Viral-like prodromes, fever, fasting/catabolism, or intercurrent illness are sometimes temporally associated with neurologic deterioration, but they are triggers of decompensation rather than primary causes. (rahman2019polgrelateddisordersand pages 3-4, pronicka2011drugresistantepilepsiaand pages 6-7, rotig2024distinctclinicalcourses pages 1-2)

No diet, exercise regimen, environmental exposure, or infection has been shown to prevent AHS in genetically affected children. Avoidance of valproate and catabolic stress is protective against preventable deterioration, not against the underlying genetic disease.

3. Phenotypes

Phenotype	Type/course and approximate frequency	Suggested HPO term
Developmental regression/progressive encephalopathy	Core feature; often follows initially normal development; severe, progressive	HP:0002376 Developmental regression; HP:0001298 Encephalopathy
Global developmental delay	100% in one early-onset POLG cohort; variable before explosive seizure onset	HP:0001263 Global developmental delay
Epilepsy	Usually focal/occipital initially; mixed seizure types become drug-resistant; 89% in one pediatric cohort and 67% across a broader 2024 POLG cohort	HP:0001250 Seizure; HP:0007359 Focal-onset seizure
Status epilepticus/EPC	Episodic then recurrent/prolonged; frequently refractory or super-refractory	HP:0002133 Status epilepticus; HP:0011172 Epilepsia partialis continua
Hepatic dysfunction/failure	Progressive or abrupt, especially after valproate; may be absent early	HP:0001410 Decreased liver function; HP:0001399 Hepatic failure
Hypotonia	96% in one early-onset cohort; progressive	HP:0001252 Hypotonia
Failure to thrive/faltering growth	89% in one pediatric cohort	HP:0001508 Failure to thrive
Ataxia	Common in later/juvenile disease; 69% among POLG patients with SE in 2024 cohort	HP:0001251 Ataxia
Stroke-like episodes	Associated with seizure-associated cortical lesions; 57% among patients with SE	HP:0002401 Stroke-like episode
Visual impairment/cortical blindness	Related to occipital cortical disease; variable	HP:0100704 Cortical visual impairment; HP:0000510 Rod-cone dystrophy only if documented
Peripheral neuropathy	More prominent in broader POLG spectrum; may mimic inflammatory polyradiculoneuropathy	HP:0009830 Peripheral neuropathy
Vomiting/gastroparesis/pseudo-obstruction	Neurogastrointestinal POLG course, often later and longer-lived than classic hepatic AHS	HP:0002013, HP:0002578, HP:0004389
Lactic acidemia/elevated alanine	Variable supportive laboratory abnormalities; normal values do not exclude disease	HP:0003128 Lactic acidosis; HP:0003348 Hyperalaninemia
Hypertransaminasemia/hypoalbuminemia/coagulopathy	Progressive hepatic laboratory abnormalities	HP:0002910, HP:0003073, HP:0003256

In the 2017 cohort, global developmental delay, hypotonia, and faltering growth occurred in 100%, 96%, and 89%, respectively. Epilepsy occurred in 89%; liver failure was a major determinant of death. (hikmat2017theclinicalspectrum pages 1-2, hikmat2017theclinicalspectrum pages 6-7)

The 2024 multinational POLG study found epilepsy in 130/194 (67%). Among evaluable epileptic patients, 97/126 (77%) developed status epilepticus at a median age of 7 years; 97% had convulsive SE, 67% EPC, and 66% refractory/super-refractory SE. These figures encompass the broader POLG spectrum and should not be interpreted as AHS-only frequencies. (hikmat2024statusepilepticusin pages 1-2)

Quality of life: no validated AHS-specific EQ-5D, SF-36, or PROMIS series was identified. Functional impact is nevertheless profound: loss of developmental abilities, recurrent intensive-care admissions, feeding and respiratory dependence, severe visual/motor disability, and high caregiver burden. Formal patient-reported outcomes are a major evidence gap.

4. Genetic and molecular information

Causal gene

POLG — DNA polymerase gamma, catalytic subunit; Ensembl ENSG00000140521; autosomal nuclear gene. Open Targets shows strong disease association with Alpers syndrome and MTDPS4A based on genetic and literature evidence. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)
POLGARF appears computationally in Open Targets because it overlaps the POLG locus/alternative reading frame, but current clinical causality for classic AHS rests on POLG, not an independently established POLGARF mechanism. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)

Variant classes and consequences

Pathogenic variants include missense, nonsense, frameshift, splice-site, and small insertion/deletion alleles across the exonuclease, linker, and polymerase domains. They are constitutional/germline, usually compound heterozygous or homozygous—not somatic. Functional consequences are predominantly loss or severe impairment of polymerase fidelity/processivity, proofreading, DNA binding, or interaction with the accessory subunit, producing mtDNA copy-number loss and respiratory-chain dysfunction. (hikmat2017theclinicalspectrum pages 4-6, anagnostou2016epilepsydueto pages 11-12, saneto2013alpershuttenlochersyndrome. pages 1-2)

Frequently reported variants include:

NM_002693.3:c.1399G>A, p.(Ala467Thr) — linker-region missense; recurrent pathogenic allele.
c.2243G>C, p.(Trp748Ser) — recurrent missense, often occurring on a haplotype with p.Glu1143Gly; pathogenicity must be interpreted in phase.
c.2542G>A, p.(Gly848Ser) — recurrent polymerase-domain missense.
c.1766C>T, p.(Pro589Leu) — used with A467T in the 2024 Alpers organoid model. (anagnostou2016epilepsydueto pages 11-12, hong2024thenad+precursor pages 1-4)

A knowledge-base implementation should store ClinVar accession, review status, ACMG classification, phase, transcript, ancestry-specific gnomAD frequency, and functional evidence separately for every allele. No large chromosomal abnormality, repeat expansion, or acquired somatic mechanism is characteristic of AHS.

5. Environmental, lifestyle, and infectious information

No reproducible environmental, behavioral, infectious, radiation, smoking, alcohol, or occupational cause is known. Pediatric age is a feature of classic phenotypic expression rather than an exposure. Sex-linked risk is not expected because POLG is autosomal. Family history may be absent because parents are usually unaffected carriers.

Clinically relevant precipitating factors are valproate, intercurrent illness, fasting/catabolism, and sustained seizure activity. Their effects are superimposed on genetically reduced mitochondrial reserve. A viral prodrome has occasionally preceded seizure onset, but no specific pathogen or immune-mediated etiology is established. (rahman2019polgrelateddisordersand pages 3-4, rotig2024distinctclinicalcourses pages 1-2)

6. Mechanism and pathophysiology

Causal chain

Biallelic POLG dysfunction (upstream) → defective mtDNA replication/repair → tissue-specific mtDNA depletion and occasionally deletions → insufficient synthesis of mtDNA-encoded oxidative-phosphorylation subunits → respiratory-chain deficiency, especially complex I and less consistently complex IV → impaired ATP production, abnormal NADH/NAD+ metabolism, ROS excess, mitophagy/senescence and reduced energetic reserve → selective failure and death of high-energy neurons and hepatocytes → occipital epilepsy, status epilepticus, regression, ataxia, and hepatic failure. Seizures further increase energetic demand and can drive a feed-forward cycle of acute focal necrosis and stroke-like injury. (hayhurst2019dissectingtheneuronal pages 1-4, hayhurst2019dissectingtheneuronal pages 13-15, hayhurst2019dissectingtheneuronal pages 10-13, saneto2013alpershuttenlochersyndrome. pages 1-2)

Human pathology: examination of 13 postmortem brains showed severe complex I and lesser complex IV deficiencies in occipital-cortical GABAergic interneurons and pyramidal neurons and cerebellar Purkinje cells, with reduced neuronal densities. Loss of inhibitory neurons plausibly shifts excitation–inhibition balance toward seizures; Purkinje-cell loss contributes to ataxia. (hayhurst2019dissectingtheneuronal pages 1-4, hayhurst2019dissectingtheneuronal pages 13-15)

GO suggestions: mitochondrial DNA replication (GO:0006264); mitochondrial genome maintenance (GO:0000002); mitochondrial electron transport, NADH to ubiquinone (GO:0006120); oxidative phosphorylation (GO:0006119); ATP metabolic process (GO:0046034); cellular response to oxidative stress (GO:0034599); mitophagy (GO:0000423); neuron apoptotic process (GO:0051402).

Cell Ontology suggestions: neuron (CL:0000540), GABAergic neuron (CL:0000617), glutamatergic neuron (CL:0000679), cerebellar Purkinje cell (CL:0000121), astrocyte (CL:0000127), hepatocyte (CL:0000182).

Pathology and biochemical abnormalities

Brain pathology includes occipital-predominant cortical atrophy, spongiosis/microvacuolation, laminar neuronal loss, astrocytosis, and focal necrosis, with involvement of thalamus, basal ganglia, and cerebellum. Liver pathology includes microvesicular steatosis, bile-ductular proliferation, hepatocyte dropout/necrosis, architectural disorganization, bridging fibrosis, and cirrhosis. (rahman2019polgrelateddisordersand pages 8-10, hayhurst2019dissectingtheneuronal pages 13-15)

Supportive biochemical findings include elevated lactate, alanine, transaminases, bilirubin, ammonia, prolonged INR, low albumin, respiratory-chain enzyme defects, and tissue mtDNA depletion. FGF21 may be elevated but is not specific or independently diagnostic. Cerebral folate deficiency has been described. (rahman2019polgrelateddisordersand pages 8-10, hikmat2017theclinicalspectrum pages 4-6)

Molecular profiling and advanced technologies

In 2024, patient-derived A467T/P589L iPSC cortical organoids reproduced neuronal loss, mtDNA depletion, complex I loss, ROS excess, and NADH-pathway dysregulation. Transcriptomic profiling identified altered electron-transport, ATP-synthase, mitophagy, synaptic, and neuroinflammatory programs. Nicotinamide riboside shifted expression toward control profiles and improved mitochondrial and neuronal readouts; this is in-vitro proof of concept, not clinical efficacy. (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)

Another 2024 cerebral-organoid study reported neurodegeneration, mtDNA depletion, complex I deficiency, dysregulated neuronal-development pathways, and increased NOTCH/JAK–STAT signaling; metformin improved several mitochondrial and cell-death measures but did not rescue all vulnerable neuronal populations. Again, this remains preclinical and should not justify off-label treatment.

No validated AHS single-cell atlas, spatial-transcriptomic diagnostic signature, clinical proteomic panel, lipidomic biomarker, or CRISPR therapy was identified as of the requested 2023–2024 window.

7. Anatomical structures affected

Primary organs: brain and liver.
Brain regions: bilateral cerebral cortex with strong occipital/calcarine and parieto-occipital predilection; thalamus, basal ganglia, hippocampal regions, and cerebellar cortex may be involved. Lesions may be multifocal/asymmetric during stroke-like episodes but the disorder is systemic rather than a fixed unilateral disease. (hayhurst2019dissectingtheneuronal pages 1-4, rahman2019polgrelateddisordersand pages 8-10)
Peripheral/autonomic nervous system: peripheral nerves, nerve roots, enteric nervous system, and autonomic pathways can be affected in broader childhood POLG disease. (rotig2024distinctclinicalcourses pages 1-2)
Tissues/cells: cortical gray matter, inhibitory interneurons, pyramidal neurons, Purkinje cells, astroglia, hepatocytes and biliary/ductular compartments.
Subcellular compartment: mitochondrion (GO:0005739), mitochondrial nucleoid (GO:0042645), mitochondrial matrix (GO:0005759), respiratory-chain complex I (GO:0005747).

UBERON suggestions: brain (UBERON:0000955), cerebral cortex (UBERON:0000956), occipital lobe (UBERON:0002021), thalamus (UBERON:0001897), cerebellum (UBERON:0002037), liver (UBERON:0002107), peripheral nerve (UBERON:0001021).

8. Temporal development

Classic onset is pediatric, usually 6 months–3 years, and often insidious until explosive focal seizures or status epilepticus. Early stages may include hypotonia, developmental delay, poor growth, vomiting, or mild liver-test abnormalities. Intermediate disease includes recurrent focal/generalized seizures, EPC, regression, ataxia, visual loss, stroke-like lesions, and progressive hepatopathy. Advanced disease features refractory/super-refractory SE, severe encephalopathy, feeding and respiratory failure, coagulopathy, cirrhosis or acute liver failure, sepsis, and death. (rahman2019polgrelateddisordersand pages 3-4, rahman2020mitochondrialdiseasein pages 5-6, hikmat2024statusepilepticusin pages 1-2)

The course is progressive with stepwise declines after seizures or metabolic stress, not relapsing-remitting. Temporary seizure control is not neurologic remission. Critical intervention windows are before valproate exposure and early in escalating seizure activity, when prompt aggressive management may limit the seizure–energy-failure feedback loop.

9. Inheritance and population

Inheritance is autosomal recessive. For two confirmed heterozygous parents, each pregnancy carries a 25% probability of an affected child, 50% probability of an unaffected carrier, and 25% probability of inheriting neither familial allele. Penetrance of two severe pathogenic alleles appears high, but age at onset and expressivity vary substantially across the POLG spectrum. Anticipation is not expected. Germline mosaicism is not a recognized major mechanism, although standard residual-risk counseling applies.

Reliable AHS-specific incidence/prevalence estimates were not identified; Orphanet classifies it as rare. POLG-spectrum frequency estimates cannot be substituted for classic AHS. AHS reportedly represents about 70% of pediatric POLG presentations in a multinational context, but this is a referral-cohort proportion, not population prevalence. (rahman2019polgrelateddisordersand pages 3-4)

Founder or enriched POLG alleles include A467T and W748S in some European populations, but variant geography does not restrict disease to any ethnicity. Consanguinity increases the probability of homozygous recessive alleles. No consistent sex bias is expected or established.

10. Diagnostics

Clinical suspicion and criteria

AHS should be suspected in a previously normal or mildly delayed infant/child with new focal—especially occipital—seizures, EPC/status epilepticus, rapid regression, ataxia, visual symptoms, unexplained hepatopathy, or unexpected deterioration after valproate. In the Columbia natural-history protocol, molecularly confirmed AHS required biallelic POLG variants plus epilepsy and either regression or hepatopathy. Without molecular confirmation, refractory seizures, regression, hepatopathy, and supportive imaging/biochemical/pathology findings were required. (NCT03034512 chunk 1)

Testing strategy

Immediately avoid valproate while evaluating a compatible phenotype.
Obtain CBC, glucose, electrolytes, lactate/pyruvate, plasma amino acids, ammonia, AST/ALT, GGT, bilirubin, albumin, INR/PT/PTT, and renal indices. Normal lactate or normal muscle mtDNA does not exclude AHS. (pronicka2011drugresistantepilepsiaand pages 6-7)
EEG: look for occipital/occipitotemporal epileptiform activity, high-voltage polyspike–slow waves, and RHADS. Continuous EEG is appropriate in encephalopathy or suspected nonconvulsive SE. (rahman2019polgrelateddisordersand pages 8-10, hikmat2017theclinicalspectrum pages 4-6)
MRI brain with diffusion and spectroscopy: cortical edema/restricted diffusion and stroke-like lesions, commonly occipital; thalamic lesions, cortical atrophy, reduced N-acetylaspartate, or lactate peaks may support the diagnosis. One pediatric cohort reported lesions in 82% at onset and 88% during follow-up. (hikmat2017theclinicalspectrum pages 4-6)
Molecular confirmation: sequence and deletion/duplication analysis of POLG, preferably on a rapid mitochondrial epilepsy/hepatocerebral panel. Trio WES/WGS is appropriate if panel testing is negative, phenotype is atypical, or an Alpers-like gene is suspected. Confirm phase of two variants through parental testing.
Tissue studies: liver or muscle mtDNA copy number and respiratory-chain assays can support unresolved cases, but depletion is tissue-specific. Biopsy is now secondary to rapid molecular testing and should be performed only if results will change management. Histology may show the characteristic liver lesions described above. (hikmat2017theclinicalspectrum pages 1-2, hikmat2017theclinicalspectrum pages 4-6)

CMA, karyotyping, FISH, repeat-expansion testing, and primary mtDNA sequencing alone have low first-line yield for classic AHS unless another diagnosis is suspected. RNA sequencing may clarify splice variants; untargeted metabolomics/proteomics remain research adjuncts.

Differential diagnosis

Important alternatives include mitochondrial hepatocerebral depletion syndromes due to DGUOK, MPV17, C10orf2/TWNK, FBXL4, mitochondrial aminoacyl-tRNA synthetase disorders (FARS2, NARS2, PARS2), Leigh syndrome, MELAS/MERRF-spectrum disease, pyruvate dehydrogenase deficiency, urea-cycle and organic-acidemia disorders, CDG, Wilson disease in older children, viral/autoimmune encephalitis, FIRES, structural epilepsy, and drug-induced liver injury. The combination of occipital epilepsy/EPC, regression, characteristic liver disease, and biallelic POLG variants is strongly discriminating. (pronicka2011drugresistantepilepsiaand pages 6-7, hikmat2017theclinicalspectrum pages 6-7, rahman2020mitochondrialdiseasein pages 5-6)

There is no population newborn screen. Cascade testing of relatives and targeted carrier testing are appropriate after familial variants are established.

11. Outcome and prognosis

Prognosis in classic childhood AHS is very poor. In the 2017 pediatric cohort, overall mortality was 85% (22/26); median age at death was 15.8 months, median survival from onset 4.9 months, and liver failure caused 13/22 deaths. In the Alpers subgroup, seizures and liver dysfunction each occurred in 100%, with median survival of approximately four months from onset. (hikmat2017theclinicalspectrum pages 6-7)

In the 2024 French cohort of 40 children with biallelic POLG disease, only 6/40 survived; ages at death ranged from 3 months to 10 years. Hepatic presentations began earliest and had the shortest survival. (rotig2024distinctclinicalcourses pages 1-2)

Across the broader 2024 POLG cohort, seizure presence predicted higher mortality; after status-epilepticus onset, median time to death was five months. (hikmat2024statusepilepticusin pages 1-2)

Major complications are refractory SE, acute/chronic liver failure, coagulopathy, hyperammonemia, aspiration, respiratory failure, malnutrition, infections/sepsis, immobility, and profound neurologic disability. Durable neurologic recovery is unusual once regression and recurrent SE are established. No validated molecular prognostic biomarker is available; early hepatic presentation, SE, liver dysfunction, and valproate exposure are adverse clinical indicators.

12. Treatment and real-world implementation

Current strategy

There is no approved curative or disease-modifying therapy. Care should be coordinated by mitochondrial medicine, pediatric neurology/epileptology, hepatology, intensive care, nutrition, rehabilitation, genetics, and palliative-care teams. (rahman2019polgrelateddisordersand pages 11-13, saneto2013alpershuttenlochersyndrome. pages 11-13)

Seizures: levetiracetam, benzodiazepines such as clobazam, lamotrigine, topiramate, or selected sodium-channel agents are used, often in combination. No antiseizure medicine has demonstrated disease-specific superiority. Refractory SE may require ICU anesthetic therapy; ketamine, magnesium, and rarely focal surgery/hemispherectomy have been described in case reports. These interventions control seizures but do not correct POLG deficiency. (rahman2019polgrelateddisordersand pages 11-13, rahman2019polgrelateddisordersand pages 19-20)

Absolute safety point: valproic acid/divalproex is contraindicated in known or suspected POLG disease because it can precipitate fatal liver failure. POLG testing should be considered before valproate in children or adolescents with unexplained epilepsy plus regression, occipital features, or liver abnormalities. (rahman2019polgrelateddisordersand pages 11-13, rotig2024distinctclinicalcourses pages 1-2)

Supportive care: enteral nutrition/gastrostomy, avoidance of fasting, treatment of hypoglycemia/acidosis/hyperammonemia, respiratory support, infection treatment, physical/occupational/speech therapy, management of spasticity/dystonia, visual support, psychosocial care, and early goals-of-care discussions. Folinic acid may be considered only with documented cerebral folate deficiency. Carnitine, coenzyme Q10, riboflavin, thiamine, and antioxidant “mitochondrial cocktails” are used empirically, but controlled evidence of benefit is absent. (saneto2013alpershuttenlochersyndrome. pages 13-14, saneto2013alpershuttenlochersyndrome. pages 11-13, lee2007liverdiseasein pages 9-10)

Liver transplantation: isolated transplantation is generally unsuitable for classic childhood AHS because neurologic disease continues. Historic series show predominantly poor neurologic outcomes; one 2011 series had median post-transplant survival of 2.8 months with no long-term survivors among 17 cases, although selected older POLG patients without advanced neurologic disease have survived for years. Decisions require individualized multidisciplinary assessment and should not generalize adult POLG outcomes to classic AHS. (rahman2019polgrelateddisordersand pages 11-13, rahman2019polgrelateddisordersand pages 29-30)

Suggested NCIt intervention concepts: Anticonvulsant Therapy, Benzodiazepine, Levetiracetam, Lamotrigine, Topiramate, Enteral Nutrition, Gastrostomy, Mechanical Ventilation, Physical Therapy, Occupational Therapy, Speech Therapy, Genetic Counseling, Palliative Care, Liver Transplantation. Exact NCIt codes should be resolved against the current NCIt release.

Trials and emerging therapies

NCT03034512, Alpers Huttenlocher Natural History Study: observational, terminated after enrollment of two participants because of changed research focus. (NCT03034512 chunk 1)
NCT04378075, vatiquinone for mitochondrial disease with refractory epilepsy: phase 2/3, terminated; broader mitochondrial population rather than proven AHS efficacy.
NCT05218655, vatiquinone safety extension: phase 3, completed; not evidence of AHS-specific benefit.

Nicotinamide riboside and metformin have improved mitochondrial or neuronal readouts in patient-derived organoids, but neither has demonstrated clinical efficacy or safety for AHS. Gene replacement/editing, RNA therapy, cell therapy, and mitochondrial transplantation remain conceptual or preclinical for POLG-AHS. (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)

13. Prevention

Because AHS is genetic, lifestyle modification cannot prevent disease in an affected genotype.

Primary prevention: carrier identification in relatives; genetic counseling; IVF with PGT-M for known familial variants; prenatal diagnosis by CVS/amniocentesis; use of donor gametes where desired.
Secondary prevention: rapid diagnosis in at-risk siblings or children with compatible epilepsy; cascade testing; strict avoidance of valproate; early seizure and metabolic-stress management.
Tertiary prevention: avoid fasting and mitochondrially hazardous medicines, maintain nutrition/hydration, promptly treat infection and seizures, monitor liver function/coagulation/ammonia, prevent aspiration and pressure injury, and provide rehabilitation.

No vaccine, public-health environmental intervention, chemoprophylaxis, or population newborn-screening program is applicable. Prenatal and preimplantation testing should target the nuclear POLG variants; mitochondrial replacement therapy is not the standard solution for this autosomal nuclear-gene disorder.

14. Other species and natural disease

No well-established naturally occurring veterinary disease equivalent to human POLG-AHS was identified. POLG orthologs are evolutionarily conserved in mammals and other eukaryotes, preserving mitochondrial DNA replication, but cross-species conservation does not establish a naturally occurring syndrome. There is no infectious transmission or zoonotic potential.

Suggested taxonomy identifiers for experimental work include Homo sapiens NCBI Taxon 9606, Mus musculus 10090, Danio rerio 7955, Drosophila melanogaster 7227, and Saccharomyces cerevisiae 4932. Species-specific POLG/POLG-like gene IDs should be drawn directly from current NCBI Gene/Alliance releases.

15. Model organisms and experimental systems

Traditional POLG mouse models—including mutator, proofreading-deficient, knockout, and tissue-specific models—are valuable for mtDNA mutagenesis, depletion, aging, and bioenergetics but often fail to reproduce the complete human AHS combination of explosive childhood occipital epilepsy, selective neuronal injury, and hepatopathy. This limits their predictive value for therapeutic screening.

The most disease-relevant current models are:

Patient fibroblasts and neural stem cells: demonstrate mtDNA/complex-I loss, ROS excess, altered NAD+ metabolism, senescence, and BNIP3-associated mitophagy.
Patient-derived iPSC neurons: permit analysis of genotype-specific neuronal vulnerability.
Cortical/cerebral organoids: reproduce neuronal loss, astrogliosis, mtDNA depletion and complex-I deficiency and permit transcriptomic and drug-response analysis.
Isogenic CRISPR-corrected or knock-in controls: desirable for separating variant effects from genetic-background effects, although they remain in-vitro systems without whole-body hepatic–neurologic interactions.

The 2024 NR organoid study is the strongest recent AHS-specific model evidence, but it derived from a very small number of patient lines and lacks pharmacokinetics, liver toxicity, immune interactions, and clinical endpoints. (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)

Evidence gaps and expert interpretation

Precise population incidence, prevalence, sex ratio, ancestry-specific risk, penetrance, and carrier frequency for classic AHS remain undefined.
Most treatment evidence consists of retrospective cohorts, case series, or expert practice; no therapy has shown AHS-specific benefit in a randomized trial.
Genotype alone cannot reliably predict the childhood neurologic, hepatic, or gastrointestinal course. (rotig2024distinctclinicalcourses pages 1-2)
AHS-specific quality-of-life instruments, longitudinal biomarkers, single-cell human tissue atlases, and prospective natural-history cohorts are lacking.
The most actionable evidence is preventive: recognize the phenotype early, obtain rapid molecular testing, aggressively manage seizures and metabolic stress, and never administer valproate when POLG disease is known or strongly suspected. (rahman2019polgrelateddisordersand pages 11-13, rotig2024distinctclinicalcourses pages 1-2)

Key recent and authoritative sources

Rötig A, et al. Distinct Clinical Courses and Shortened Lifespans in Childhood-Onset DNA Polymerase Gamma Deficiency. Neurology Genetics. Published August 2024. DOI: https://doi.org/10.1212/NXG.0000000000200167. (rotig2024distinctclinicalcourses pages 1-2)
Hikmat O, et al. Status epilepticus in POLG disease: a large multinational study. Journal of Neurology. Published June 2024;271:5156–5164. DOI: https://doi.org/10.1007/s00415-024-12463-5. (hikmat2024statusepilepticusin pages 1-2)
Hong Y, et al. The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC-Derived Cortical Organoid of Alpers’ Disease. International Journal of Biological Sciences. Published July 2024;20:1194–1217. DOI/preprint record: https://doi.org/10.1101/2023.07.02.547346. (hong2024thenad+precursor pages 10-12, hong2024thenad+precursor pages 1-4)
Hayhurst H, et al. Dissecting the neuronal vulnerability underpinning Alpers’ syndrome. Brain Pathology. Published October 2019;29:97–113. DOI: https://doi.org/10.1111/bpa.12640. (hayhurst2019dissectingtheneuronal pages 1-4)
Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nature Reviews Neurology. 2019;15:40–52. DOI: https://doi.org/10.1038/s41582-018-0101-0. (rahman2019polgrelateddisordersand pages 3-4, rahman2019polgrelateddisordersand pages 11-13)
Hikmat O, et al. The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. Genetics in Medicine. Published November 2017;19:1217–1225. DOI: https://doi.org/10.1038/gim.2017.35. (hikmat2017theclinicalspectrum pages 1-2, hikmat2017theclinicalspectrum pages 6-7)

PMID-linked foundational POLG–AHS literature identified through Open Targets: PMID 12707443, 15534189, 17846414, 18828154, 20142534, 22000311, 22237560, 23545419, 25129007, and 27604308; links follow the pattern https://pubmed.ncbi.nlm.nih.gov/12707443/. These records should be individually matched to claims during database curation rather than treated as interchangeable evidence. (OpenTargets Search: Alpers-Huttenlocher syndrome-POLG)

References

(rahman2019polgrelateddisordersand pages 3-4): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.
(rahman2020mitochondrialdiseasein pages 5-6): S. Rahman. Mitochondrial disease in children. Journal of Internal Medicine, 287:609-633, Apr 2020. URL: https://doi.org/10.1111/joim.13054, doi:10.1111/joim.13054. This article has 235 citations and is from a domain leading peer-reviewed journal.
(hayhurst2019dissectingtheneuronal pages 1-4): Hannah Hayhurst, Maria‐Eleni Anagnostou, Helen J. Bogle, John P. Grady, Robert W. Taylor, Laurence A. Bindoff, Robert McFarland, Doug M. Turnbull, and Nichola Z. Lax. Dissecting the neuronal vulnerability underpinning alpers’ syndrome: a clinical and neuropathological study. Brain Pathology, 29:97-113, Oct 2019. URL: https://doi.org/10.1111/bpa.12640, doi:10.1111/bpa.12640. This article has 31 citations and is from a domain leading peer-reviewed journal.
(rotig2024distinctclinicalcourses pages 1-2): Agnès Rötig, Pauline Gaignard, Giulia Barcia, Zahra Assouline, Claire-Marine Berat, Magalie Barth, Léna Damaj, Nolwenn Laborde, Marie-Thérèse Abi-Warde, Brigitte Chabrol, Pascale De Lonlay, Isabelle Desguerre, Alice Goldenberg, Emmanuel Gonzales, Emmanuel Jacquemin, Patrizia Amati -Bonneau, Dominique Bonneau, Véronique Abadie, Chrystèle Bonnemains, Pierre Broue, Anne De Saint-Martin, Philippe Durand, Alain Fouilhoux, Bertrand Isidor, Marianne Jaroussie, Guillaume Jedraszak, Hélène Maurey, Karine Mention, Sylvie S. Odent, Laurent Pasquier, Christelle Rougeot-Jung, Cyril Gitiaux, Charles-Joris Roux, Nathalie Boddaert, Arnold Munnich, and Manuel Schiff. Distinct clinical courses and shortened lifespans in childhood-onset dna polymerase gamma deficiency. Aug 2024. URL: https://doi.org/10.1212/nxg.0000000000200167, doi:10.1212/nxg.0000000000200167. This article has 12 citations.
(hikmat2024statusepilepticusin pages 1-2): Omar Hikmat, Karin Naess, Martin Engvall, Claus Klingenberg, Magnhild Rasmussen, Eylert Brodtkorb, Elsebet Ostergaard, Irenaeus de Coo, Leticia Pias-Peleteiro, Pirjo Isohanni, Johanna Uusimaa, Kari Majamaa, Mikko Kärppä, Juan Dario Ortigoza-Escobar, Trine Tangeraas, Siren Berland, Emma Harrison, Heather Biggs, Rita Horvath, Niklas Darin, Shamima Rahman, and Laurence A. Bindoff. Status epilepticus in polg disease: a large multinational study. Journal of Neurology, 271:5156-5164, Jun 2024. URL: https://doi.org/10.1007/s00415-024-12463-5, doi:10.1007/s00415-024-12463-5. This article has 21 citations and is from a domain leading peer-reviewed journal.
(hikmat2017theclinicalspectrum pages 6-7): Omar Hikmat, Charalampos Tzoulis, Wui K Chong, Latifa Chentouf, Claus Klingenberg, Carl Fratter, Lucinda J Carr, Prab Prabhakar, Nandhini Kumaraguru, Paul Gissen, J Helen Cross, Thomas S Jacques, Jan-Willem Taanman, Laurence A Bindoff, and Shamima Rahman. The clinical spectrum and natural history of early-onset diseases due to dna polymerase gamma mutations. Genetics in Medicine, 19:1217-1225, Nov 2017. URL: https://doi.org/10.1038/gim.2017.35, doi:10.1038/gim.2017.35. This article has 87 citations and is from a highest quality peer-reviewed journal.
(hikmat2017theclinicalspectrum pages 4-6): Omar Hikmat, Charalampos Tzoulis, Wui K Chong, Latifa Chentouf, Claus Klingenberg, Carl Fratter, Lucinda J Carr, Prab Prabhakar, Nandhini Kumaraguru, Paul Gissen, J Helen Cross, Thomas S Jacques, Jan-Willem Taanman, Laurence A Bindoff, and Shamima Rahman. The clinical spectrum and natural history of early-onset diseases due to dna polymerase gamma mutations. Genetics in Medicine, 19:1217-1225, Nov 2017. URL: https://doi.org/10.1038/gim.2017.35, doi:10.1038/gim.2017.35. This article has 87 citations and is from a highest quality peer-reviewed journal.
(hayhurst2019dissectingtheneuronal pages 13-15): Hannah Hayhurst, Maria‐Eleni Anagnostou, Helen J. Bogle, John P. Grady, Robert W. Taylor, Laurence A. Bindoff, Robert McFarland, Doug M. Turnbull, and Nichola Z. Lax. Dissecting the neuronal vulnerability underpinning alpers’ syndrome: a clinical and neuropathological study. Brain Pathology, 29:97-113, Oct 2019. URL: https://doi.org/10.1111/bpa.12640, doi:10.1111/bpa.12640. This article has 31 citations and is from a domain leading peer-reviewed journal.
(hayhurst2019dissectingtheneuronal pages 10-13): Hannah Hayhurst, Maria‐Eleni Anagnostou, Helen J. Bogle, John P. Grady, Robert W. Taylor, Laurence A. Bindoff, Robert McFarland, Doug M. Turnbull, and Nichola Z. Lax. Dissecting the neuronal vulnerability underpinning alpers’ syndrome: a clinical and neuropathological study. Brain Pathology, 29:97-113, Oct 2019. URL: https://doi.org/10.1111/bpa.12640, doi:10.1111/bpa.12640. This article has 31 citations and is from a domain leading peer-reviewed journal.
(anagnostou2016epilepsydueto pages 11-12): Maria‐Eleni Anagnostou, Yi Shiau Ng, Robert W. Taylor, and Robert McFarland. Epilepsy due to mutations in the mitochondrial polymerase gamma (polg) gene: a clinical and molecular genetic review. Epilepsia, 57:1531-1545, Aug 2016. URL: https://doi.org/10.1111/epi.13508, doi:10.1111/epi.13508. This article has 111 citations and is from a domain leading peer-reviewed journal.
(saneto2013alpershuttenlochersyndrome. pages 1-2): Russell P. Saneto, Bruce H. Cohen, William C. Copeland, and Robert K. Naviaux. Alpers-huttenlocher syndrome. Pediatric neurology, 48 3:167-78, Mar 2013. URL: https://doi.org/10.1016/j.pediatrneurol.2012.09.014, doi:10.1016/j.pediatrneurol.2012.09.014. This article has 158 citations and is from a peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 8-10): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.
(hong2024thenad+precursor pages 10-12): Yu Hong, Zhuoyuan Zhang, Tsering Yangzom, Anbin Chen, Bjørn Christian Lundberg, Evandro Fei Fang, Gareth John Sullivan, Charalampos Tzoulis, Laurence A. Bindoff, and Kristina Xiao Liang. The nad+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in ipsc derived cortical organoid of alpers' disease. International Journal of Biological Sciences, 20:1194-1217, Jul 2024. URL: https://doi.org/10.1101/2023.07.02.547346, doi:10.1101/2023.07.02.547346. This article has 11 citations and is from a peer-reviewed journal.
(hong2024thenad+precursor pages 1-4): Yu Hong, Zhuoyuan Zhang, Tsering Yangzom, Anbin Chen, Bjørn Christian Lundberg, Evandro Fei Fang, Gareth John Sullivan, Charalampos Tzoulis, Laurence A. Bindoff, and Kristina Xiao Liang. The nad+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in ipsc derived cortical organoid of alpers' disease. International Journal of Biological Sciences, 20:1194-1217, Jul 2024. URL: https://doi.org/10.1101/2023.07.02.547346, doi:10.1101/2023.07.02.547346. This article has 11 citations and is from a peer-reviewed journal.
(OpenTargets Search: Alpers-Huttenlocher syndrome-POLG): Open Targets Query (Alpers-Huttenlocher syndrome-POLG, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(NCT03034512 chunk 1): Michio Hirano, MD. Alpers Huttenlocher Natural History Study. Columbia University. 2014. ClinicalTrials.gov Identifier: NCT03034512
(pronicka2011drugresistantepilepsiaand pages 6-7): Ewa Pronicka, Anna Weglewska-Jurkiewicz, Maciej Pronicki, Jolanta Sykut-Cegielska, Pawel Kowalski, Magdalena Pajdowska, Irena Jankowska, Katarzyna Kotulska, Piotr Kalicinski, Joanna Jakobkiewicz-Banecka, and Grzegorz Wegrzyn. Drug-resistant epilepsia and fulminant valproate liver toxicity. alpers-huttenlocher syndrome in two children confirmed post mortem by identification of p.w748s mutation in polg gene. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 17:CR203-CR209, Apr 2011. URL: https://doi.org/10.12659/msm.881716, doi:10.12659/msm.881716. This article has 51 citations.
(hikmat2017theclinicalspectrum pages 1-2): Omar Hikmat, Charalampos Tzoulis, Wui K Chong, Latifa Chentouf, Claus Klingenberg, Carl Fratter, Lucinda J Carr, Prab Prabhakar, Nandhini Kumaraguru, Paul Gissen, J Helen Cross, Thomas S Jacques, Jan-Willem Taanman, Laurence A Bindoff, and Shamima Rahman. The clinical spectrum and natural history of early-onset diseases due to dna polymerase gamma mutations. Genetics in Medicine, 19:1217-1225, Nov 2017. URL: https://doi.org/10.1038/gim.2017.35, doi:10.1038/gim.2017.35. This article has 87 citations and is from a highest quality peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 11-13): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.
(saneto2013alpershuttenlochersyndrome. pages 11-13): Russell P. Saneto, Bruce H. Cohen, William C. Copeland, and Robert K. Naviaux. Alpers-huttenlocher syndrome. Pediatric neurology, 48 3:167-78, Mar 2013. URL: https://doi.org/10.1016/j.pediatrneurol.2012.09.014, doi:10.1016/j.pediatrneurol.2012.09.014. This article has 158 citations and is from a peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 19-20): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.
(saneto2013alpershuttenlochersyndrome. pages 13-14): Russell P. Saneto, Bruce H. Cohen, William C. Copeland, and Robert K. Naviaux. Alpers-huttenlocher syndrome. Pediatric neurology, 48 3:167-78, Mar 2013. URL: https://doi.org/10.1016/j.pediatrneurol.2012.09.014, doi:10.1016/j.pediatrneurol.2012.09.014. This article has 158 citations and is from a peer-reviewed journal.
(lee2007liverdiseasein pages 9-10): Way Lee and Ronald Sokol. Liver disease in mitochondrial disorders. Seminars in liver disease, 27 3:259-73, Aug 2007. URL: https://doi.org/10.1055/s-2007-985071, doi:10.1055/s-2007-985071. This article has 135 citations and is from a peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 29-30): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 507 citations and is from a highest quality peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Progression

Differential Diagnoses

Related Datasets

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Alpers–Huttenlocher Syndrome: Disease-Characteristics Research Report

Executive summary

1. Disease information

Definition and classification

Identifiers and synonyms

2. Etiology and risk/protective factors

Causal factors

Genetic risk and modifiers

Environmental and gene–environment interactions

3. Phenotypes

4. Genetic and molecular information

Causal gene

Variant classes and consequences

5. Environmental, lifestyle, and infectious information

6. Mechanism and pathophysiology

Causal chain

Pathology and biochemical abnormalities

Molecular profiling and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical suspicion and criteria

Testing strategy

Differential diagnosis

11. Outcome and prognosis

12. Treatment and real-world implementation

Current strategy

Trials and emerging therapies

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Evidence gaps and expert interpretation

Key recent and authoritative sources

Artifacts